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Prostate cancer is the most commonly diagnosed form of cancer among 
male in Europe and the United States (1, 2). In the Netherlands prostate 
cancer was found in 21% of the total number of new cancer cases 
(Fig. 1) (3). Prostate cancer is not only frequently diagnosed it is also an 
important cause of death. In the Netherlands, prostate cancer is with 2535 
men the second leading cause of death among men who die from cancer 
(11% of the total number of cancer deaths). In comparison, in the same year 
3161 woman died from breast cancer (4). 
Current diagnosis of prostate cancer
In patients with an elevated prostate specific antigen (PSA) and/or abnormal 
digital rectal examination (DRE), random systematic transrectal ultrasound 
(TRUS)-guided biopsy is the standard of practice for prostate cancer diagnosis. 
However, this diagnostic pathway has limitations, because the PSA-test is highly 
sensitive but an unspecific marker and DRE and TRUS-guided biopsy are rather 
insensitive examinations for prostate cancer detection (5, 6). 
With TRUS-guided biopsy an ultrasound probe is inserted in the rectum of the 
patient for biopsy guidance and 10 to 12 samples are obtained from the prostate 
according to a standardized scheme from the posterior peripheral zone. Due to 
sampling error more than 20% of the cancers are not detected in the first TRUS-
guided biopsy session (7). With repeat TRUS-guided biopsies, prostate cancer 
detection rates decrease from 22% to 4% in four subsequent TRUS-guided biopsy 
sessions (7). Cancer detection rates of extensive saturation biopsy in men with 1, 
2, and ≥3 prior negative TRUS biopsies were 56%, 42%, and 34%, respectively (8). 
Thus, a large number of patients with a persistently elevated or increasing PSA 
and one or more negative TRUS-guided biopsy sessions are subject to diagnostic 
insufficiency and uncertainty. 
1.0 CHAPTER 1.0  InTROducTIOn
Figure 1: Incidence of most frequently diagnosed cancer locations in the Netherlands in 2013. 
With 10,897 new cases prostate cancer is the most frequently diagnosed cancer among men. 
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Besides the fact that, clinically significant tumours are missed with the current 
TRUS-guided biopsy protocol, clinically insignificant tumours are identified by 
chance. These tumours often remain dormant and clinically unimportant for 
decades. Consequently, early detection of prostate cancer, with the intent to 
diagnose this disease in a curable state, currently leads to over-diagnosis which 
in turn can result in over-treatment (9).
Furthermore, there is undergrading of tumour aggressiveness (represented by the 
Gleason score) when the less aggressive part of a tumour is sampled or the clinically 
significant lesion is missed. With the current clinical evaluation of PSA, DRE, and 
TRUS-guided biopsy it is not possible to accurately determine tumour characteristics 
and location since understaging (36%) and undergrading of the Gleason score 
(34-38%) is commonly seen (10-13). Understanding these limitations (Fig. 2) is of 
clinical importance because with these parameters, together with preference of 
the patient and physician, a decision is made for tailored treatment. 
Furthermore, minimally invasive therapies are increasingly being investigated in 
localized prostate cancer (14-16). An important aspect is patient selection which 
relies on accurate tumour localization and risk stratification (17). Therefore, with 
the introduction of focal therapy the need for an adequate diagnostic tool has 
become even more important. 
MR-guided prostate biopsy 
With multi-parametric magnetic resonance imaging (MRI) techniques it is possible 
to obtain anatomical and functional information from prostatic tissue to identify 
cancerous lesions (18). Anatomical information can be obtained from T2-weighted 
MR imaging. However, T2-weighted imaging alone is sensitive but not specific 
for prostate cancer and should therefore be combined with functional imaging 
techniques (19). T1-weighted dynamic contrast enhanced (DCE) MRI following the 
administration of gadolinium-based contrast medium is the most common imaging 
method for evaluating tumour perfusion. Diffusion weighted imaging (DWI) is 
a measure for the mobility of water molecules. Differences in restricted diffusion 
are seen in tissues with a high cell density, such as prostate cancer. Apparent 
diffusion coefficient (ADC)-values derived from DWI are related to prostate cancer 
aggressiveness (20). Functional MRI increases prostate cancer localization accuracy 
when added to anatomic T2-weighted MRI in a multi-parametric MRI exam (21, 22). 
Using the localization ability of multi-parametric MRI, it has recently become possible 
to target biopsies from cancer suspicious lesions with MR-guided biopsy rather than 
systematically sampling of the prostate with TRUS-guided biopsy. Besides the fact 
that less sampling cores are needed for diagnosis, this technique predominantly (44-
87%) detects clinically significant prostate cancers in biopsy-naïve males and men 
with prior negative biopsies (18). Furthermore, the high negative predictive value (63 
- 98%) of multi-parametric MRI can be used to rule out significant disease (18). These 
properties are promising regarding the current diagnostic dilemma since diagnosing 
insignificant tumours may cause unnecessary treatment of men who probably will 
not have clinical symptoms during their life (9). In this context it is important to keep 
in mind that most men will die with prostate cancer rather than die from it (23). 
Furthermore, multi-parametric MRI will play an important role in minimal invasive 
focal therapy regarding patient selection, treatment planning and monitoring and 
follow-up (14, 16, 24). 
The question “which direction?” seems to be answered with MR-guided biopsy 
since it becomes possible to obtain biopsies from the most aggressive part of 
cancer suspicious lesions within the prostate seen on multi-parametric MRI. 
However, we are not there yet. Currently the only commercially available 
transrectal MR-guided prostate biopsy device is a manually adjustable device 
for needle guide positioning (25). After inserting a needle guide into the rectum 
(Fig. 3), MR images are acquired. Based on these MR images, the needle guide is 
manually positioned in the direction of the cancer suspicious lesion (Fig. 3). 
Figure 2: With the current TRUS-guided biopsy protocol clinically significant tumours are 
missed (A), furthermore clinically insignificant tumours are identified by chance (B), and there 
is undergrading of tumour aggressiveness (represented by the Gleason score ) when the less 
aggressive part of a tumour is sampled (C) or the significant lesion is missed (D).
1.0 
Figure 3: The patient is positioned in prone position with the needle guide inside the rectum 
(left image). The needle guide can be directed towards the cancer suspicious lesion by 
adjusting the biopsy device based on the acquired MR images (right image).
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In order to manipulate needle guide direction the patient has to be moved out 
of the scanner bore and moved into the bore again for imaging. This is repeated 
many times until the needle is in the right position. Consequently, the physician 
needs to walk each time up and down between scanner room and control room 
to adjust needle guided direction and interpret needle guide direction on the 
MR-images. This procedure is unpleasant for the patient, time consuming and 
operator dependent. Furthermore, this increases the uncertainty of the exact 
needle position, due to potential movement of the patient during the procedure. 
In this thesis, we took the first step to solve these problems with the development 
of an MR-compatible robotic manipulator for real-time image guided positioning, 
which can be controlled at the operation console. In this way the patient does not 
need to be moved in and out of the magnet bore during needle guide positioning.
The magnetic field used in MRI makes it a technically challenging area for 
robotics since metal and electricity cannot be applied within the scanner room. 
Specifically iron will be attracted by the magnetic field and other metals could 
disturb the homogeneity. Furthermore, radio frequency (RF) pulses required to 
create the MR signal can cause excessive heating in conducting materials by 
concentration of electrical currents (26). 
Aim and outline of this thesis
In my thesis the symbiosis of imaging and robotics in MR-guided biopsy 
is investigated with the aim to improve prostate cancer diagnosis. 
The approach is described in the flowing chapters:
Chapter 2 reports on the detection rate of prostate cancer detected with MR-
guided prostate biopsy in patients with an elevated PSA, one or more negative 
TRUS-guided biopsy sessions, and cancer suspicious lesions on 3T multi-
parametric MRI. The aim is to proof the need for MR-guided biopsy. Chapters 3 
and 4 describe the location of prostate cancer in patients with repeated negative 
TRUS-guided biopsy sessions and biopsy naive patients respectively. Identifying 
prostate cancer locations and aggressiveness found with TRUS-guided biopsy 
and multi-parametric MRI followed by MR-guided biopsy provides insight in the 
diagnostic limitations of both techniques. In chapter 5 we investigated whether 
it is possible to discriminate between prostatitis and prostate cancer based on 
apparent diffusion coefficient (ADC)-values derived from DWI. This imaging 
modality may help to reduce the number of false positive findings at prostate 
cancer MR imaging. Consequently, DWI may improve patient selection for MR-
guided biopsy and therapy. Chapter 6 is a phantom study where the feasibility of the 
in-house developed pneumatically actuated MR-compatible robotic manipulator 
is evaluated. Furthermore, safety aspects for patient care are evaluated. Chapter 
7 evaluates the accuracy and speed of the novel robotic technique compared to 
the manual biopsy method in patients. In chapter 8 the feasibility of a real-time 
tracking sequence is demonstrated that can automatically align the image plane 
trough the needle guide. This sequence has the potential to improve real-time 
imaging of the needle guide during manipulation with the robotic technique. 
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Abstract
Background: Patients with elevated prostate-specific antigen (PSA) and one or 
more previous negative transrectal ultrasound (TRUS)-guided biopsy sessions 
are subject to diagnostic uncertainty due to TRUS-guided biopsy undersampling. 
Magnetic resonance (MR)-guided biopsy has shown high prostate cancer detection 
rates in studies with limited patient numbers.
Objective: Determine the detection rate of (clinically significant) prostate cancer 
for MR-guided biopsy of cancer suspicious lesions (CSLs) on 3T multi-parametric 
MR imaging in patients with elevated PSA and one or more negative TRUS-guided 
biopsy sessions.
Design, setting, and participants: Of 844 patients who underwent 3T multi-
parametric MRI in our referral centre between March 2008 and February 2011, 
438 consecutive patients with a PSA >4.0 ng/mL and one negative TRUS-guided 
biopsy session or more were included. MR-guided biopsy was performed in 265 
patients. Exclusion criteria were existent prostate cancer, endorectal coil use, and 
multi-parametric MRI for indications other than cancer detection.
Intervention: Patients underwent MR-guided biopsy of multi-parametric MRI CSLs.
Measurements: (Clinically significant) MR-guided biopsy cancer-detection rates 
were determined. Clinically significant cancer was defined by accepted (i.e. 
Epstein and d’Amico) criteria based on PSA, Gleason score, stage, and tumour 
volume. Follow-up PSA and histopathology were collected. Sensitivity analysis was 
performed for patients with multi-parametric MRI CSLs without MR-guided biopsy.
Results and limitations: In a total of 117 patients, cancer was detected with MR-
guided biopsy (n=108) or after negative MR-guided biopsy (n=9). Prostate cancer 
was detected in 108 of 438 patients (25%) and in 41% (108 of 265) of MR-guided 
biopsy patients. The majority of detected cancers (87%) were clinically significant. 
Clinically significant cancers were detected in seven of nine (78%) negative MR-
guided biopsy patients in whom prostate cancer was detected during follow-up. 
Sensitivity analysis resulted in increased cancer detection (47-56%). Complications 
occurred in 0.2% of patients (5 of 265). 
Conclusions: In patients with elevated PSA and one or more negative TRUS-guided 
biopsy sessions, MR-guided biopsy of multi-parametric MRI CSLs had a prostate 
cancer detection rate of 41%. The majority of detected cancers were clinically 
significant (87%).
CHAPTER 2.0  
ThRee-TeSLA MAgneTIc 
ReSOnAnce (MR)-guIded 
PROSTATe bIOPSy In 
Men wITh IncReASed 
PROSTATe SPecIFIc 
AnTIgen And RePeATed, 
negATIVe, RAndOM, 
SySTeMATIc, TRAnSRecTAL 
uLTRA SOund bIOPSIeS: 
deTecTIOn OF cLInIcALLy 
SIgnIFIcAnT PROSTATe 
cAnceRS
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Introduction
Prostate cancer is a major health care problem with 899 000 new cases and 
258 000 deaths per year in Europe (1). In patients with elevated prostate-
specific antigen (PSA) and/or abnormal digital rectal examination (DRE), random 
systematic transrectal ultrasound (TRUS)-guided biopsy is the most commonly 
used technique to further evaluate prostate cancer diagnosis. However, like 
PSA, which is an unspecific marker (specificity: 36%), and DRE, which is a rather 
insensitive examination (sensitivity: 37%) for prostate cancer detection, TRUS-
guided biopsy also has its shortcomings (2, 3). Due to sampling error, >20% of 
cancers are not detected in the first TRUS-guided biopsy session (4). With repeat 
TRUS-guided biopsies, prostate cancer detection rates decreased from 22% to 4% 
in four subsequent TRUS-guided biopsy sessions (4). As a result of the mentioned 
issues, a large number of patients with a persistently elevated or increasing PSA 
and one or more negative TRUS-guided biopsy sessions are subject to diagnostic 
uncertainty. 
Magnetic resonance (MR)-guided prostate biopsy of a detected cancer-suspicious 
lesion (CSL) on MR imaging (MRI) is a feasible diagnostic technique: prostate cancer 
detection rates with this method range from 37% to 59% (5-10). Moreover, the 
implementation of MR-guided biopsy has resulted in detection of predominantly 
(93%) clinically significant prostate cancer (8).
Functional MRI techniques increased prostate cancer localization accuracy (area 
under the curve (AUC): 0.84-0.91) when added to anatomic T2-weighted MRI (AUC: 
0.69-0.81) in a multi-parametric MRI exam (11, 12). Using its localization strength, 
multi-parametric MRI of the prostate has increased opportunities for image-guided 
techniques like MR-guided biopsy. However, most MR-guided biopsy studies were 
performed with a low number of patients at a lower field strength of 1.5T. 
Therefore, we aimed to determine the detection rate of (clinically significant) 
prostate cancer for MR-guided biopsy of CSLs detected on 3T multi-parametric 
MRI in patients with an elevated PSA and at least one previous negative TRUS-
guided biopsy session in a large population. 
Materials and methods
Patients
The need for informed consent for this retrospective study was waived by our 
institutional review board. 
Between March 2008 and February 2011, 844 consecutive patients underwent 
multi-parametric MRI in our referral centre. Of these, 438 patients with PSA >4 
ng/mL and at least one previous negative TRUS-guided biopsy session who 
had undergone multi-parametric MRI and/or MR-guided biopsy were included. 
Exclusion criteria were existent prostate cancer, use of an endorectal coil, and 
multi-parametric MRI for other indications than cancer detection. Patient selection 
is shown in a flow diagram in Figure 1. 
Figure 1: Study flow diagram. MRI = magnetic resonance imaging, PSA = prostate specific 
antigen, TRUS = transrectal ultrasound
2.0 
p 20 p 21MRI-guIded PROSTATe bIOPSy: whIch dIRecTIOn?
Magnetic resonance imaging 
Multi-parametric MRI and MR-guided biopsy were performed on two comparable 
3T MR scanners (MAGNETOM Trio and MAGNETOM Skyra; Siemens Medical 
Solutions, Erlangen, Germany) using a combined spinal and pelvic-phased array 
coil. MRI parameters are presented in Table 1. 
Magnetic resonance imaging interpretation 
Two radiologists with 9 yr and 18 yr of experience in prostate MRI, respectively, 
evaluated the multi-parametric MRI examinations using in-house developed 
software (13). CSLs were defined on T2-weighted images in combination with 
diffusion-weighted MRI (DWI) and dynamic contrast-enhanced MRI as described 
earlier (14). In addition to apparent diffusion coefficient (ADC) maps, DWI-
calculated b1400 images were used to determine CSLs. A lesion was defined as 
a CSL on DWI in cases of focal restriction on the ADC map combined with an 
iso- to hypersignal intensity on the calculated b1400 image. Clinical data of all 
patients were available at MRI reading. 
Table 1: Imaging parameters. T2WI = T2-weighted MR imaging, DWI = diffusion weighted 
MR imaging, DCE-MRI = dynamic contrast enhanced MR imaging, SSFP = steady state free 
procession, TR = repetition time, TE = echo time, TSE = turbo spin echo, SSEPI = steady state 
echo planar imaging, GE = gradient echo, EPI = echo-planar imaging. 
Protocol Sequence TR  
(ms)
TE  
(ms)
Flip angle 
(degrees)
Slice thickness 
(mm)
Field of view  
(mm x mm)
Matrix size Voxel size  
(mm x mm x mm)
b-values  
(s/mm2)
Temporal 
resolution (s)
Multi-parametric MRI of the prostate (MAgneTOM Trio)
T2wI axial and coronal 
TSE
4480 103 120 3.0 180 x 180 320 x 320 0. x 0.6 x 3.0 NA NA
T2wI Sagittal 4950 110 120 3.0 180 x 180 320 x 320 0.6 x 0.6 x 3.0 NA NA
dwI SSEPI axial 2500 64 NA 4.0 256 x 256 128 x 128 2.0 x 2.0 x 4.0 0/50/500/800 NA
dce-MRI GE axial 3D 800 1.47 8 4.0 230 x 230 180 x 180 1.8 x 1.8 x 4.0 NA NA
dce-MRI Spoiled GE axial 3D 32 1.47 10 4.0 230 x 230 128 x 128 1.8 x 1.8 x 4.0 NA 2.5
Multi-parametric MRI of the prostate (MAgneTOM Skyra)
T2wI axial (TSE) 5180 101 160 3.0 192 x 192 320 x 320 0.6 x 0.6 x 3 NA NA
T2wI coronal (TSE) 4320 101 160 3.0 192 x 192 320 x 320 0.6 x 0.6 x 3 NA NA
T2wI sagittal (TSE) 4000 101 160 3.0 180 x 180 320 x 320 0.56 x 0.56 x 3 NA NA
dwI SSEPI axial 3000 64 NA 4.0 256 x 256 128 x 128 2 x 2 x 4 0/50/100/1200 NA
dce-MRI GE axial 800 1.53 14 3.0 192 x 192 128 x 128 1.5 x 1.5 x 3 NA NA
dce-MRI GE axial 36 1.41 14 3.0 192 x 192 128 x 128 1.5 x 1.5 x 3 NA 3.5
MR-guided biopsy (MAgneTOM Trio)
T2wI TSE axial 3620 103 120 4.0 256 x 256 320 x 320 0.8 x 0.8 x4.0 NA NA
dwI EPI axial 3300 60 NA 3.6 260 x 211 160 x 120 2.2 x 1.6 x 3.6 0/100/400/800 NA
SSFP GE axial and 
sagittal
4.48 2.24 70 3.0 280 x 280 256 x 256 1.1 x 1.1 x 3.0 NA NA
MR-guided biopsy (MAgneTOM Skyra)
T2wI TSE axial 3560 104 120 120 256 x 256 320 x 320 0.8 x 0.8 x 4 NA NA
dwI EPI axial 3000 64 NA 4.0 256 x 212 128 x 128 2.0 x 2.0 x 4.0 50/100/1600 NA
balanced 
SSFP
GE axial and 
sagittal
4.56 2.28 70 3.0 280 x 280 256 x 256 1.1 x 1.1 x 3.0 NA NA
2.0 
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Magnetic resonance-guided prostate biopsy
MR-guided biopsy was performed in a separate session and every CSL was 
targeted. Two radiologists with 2 yr and two radiologists with 1 yr of MR-guided 
biopsy experience performed transrectal prostate MR-guided biopsy as described 
earlier (14). Axial T2-weighted images and DWI were acquired as baseline images 
for targeting.
Histopathology
Biopsy specimens were immediately fixed in formalin and subsequently 
underwent routine histopathologic evaluation by a urogenital histo pathologist 
who had 18 yr of experience.
Prostate cancer: clinical significance
When prostatectomy was not performed, clinical significance of MR-guided 
biopsy detected prostate cancer was defined by: (1) a PSA >10 ng/mL and a PSA 
density >0.15 ng/mL per mL; (2) clinical stage ≥T2b; (3) a Gleason grade (GG) 4 
or 5 within the biopsy specimen; or (4) a total cancer-core length (TCCL) ≥10mm, 
where TCCL is the total cancer length in all MR-guided biopsy cores from one 
CSL (15-18). This definition was based on Epstein and d’Amico criteria (15, 18). 
In case of performed prostatectomy, prostate cancer was considered clinically 
significant when prostate cancer volume was ≥0.5 mL or a stage ≥pT3 or a GG 4 
or 5 (19, 20) was present.
Follow-up
Post MR-guided biopsy PSA measurements and histopathology results were 
collected until July 22, 2011, for all MR-guided biopsy patients.
Statistical analysis
Parametric continuous variables were reported as mean plus or minus the 
standard deviation; nonparametric continuous variables were reported as median 
and the interquartile range (IQR). The Pearson chi-square test was used to test 
for differences in proportions. In a multivariable logistic regression analysis, PSA, 
PSA density, and prostate volume were assessed as predictors for MR-guided 
biopsy prostate cancer detection. We used sensitivity analyses in which we 
assumed that, in all patients with visible MRI lesions, prostate cancer would have 
been detected if MR-guided biopsy would have been performed. A significance 
level of <0.05 was used for all analyses.
Results 
Inclusion criteria were met in 438 of 844 consecutive men. MR-guided biopsy was 
performed in 265 of these 438 men (Fig. 1). MR-guided biopsy was not performed 
due to lack of visible lesions (n=80); advice for follow-up multi-parametric MRI 
in lesions suspicious for prostatitis, benign prostatic hyperplasia, or low-grade 
cancer (n=64); or despite MR-guided biopsy advice (n=29). Patient characteristics 
are presented in Table 2. The last TRUS-guided biopsy had a median of nine cores 
(IQR: 9-10, available in 123 of 265 MR-guided biopsy patients) with transition zone 
(TZ) sampling in protocols of eight or more cores. The median MR-guided biopsy 
duration was 44 min (IQR: 35-51 min).
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Table 2: patients characteristics. MRI = magnetic resonance imaging, IQR = interquartile range, 
PSA = prostate-specific antigen, TRUS = transrectal ultrasound, CSL = cancer suspicious lesion, 
NA = not applicable.
1  p-values were calculated using an independent t-test and a Mann-Whitney U test for   
 nonparametric variables.
2  Mann-Whitney U test.
3  p <0.05 was considered statistically significant.
Characteristic All patients 
(n=438)
Patients with 
detected 
prostate cancer 
on MR-guided 
biopsy (n=108)
Patients without 
detected 
prostate cancer 
on MR-guided 
biopsy (n=156)
p-value1 for 
patients with vs 
patients without 
detected 
prostate cancer
Median age in 
years (IQR)
66 (61-69) 65 (62-70) 64 (61-69) 0.29
PSA level in  
ng/mL (IQR) 
11.4 (8.6-18.3) 18.0 (10.0-27.9) 12.0 (9.1-17.1) < 0.0012,3
Median prostate 
volume in mL 
(IQR) 
67 (50-93) 53 (36-68) 70 (51-89) < 0.0012,3
Median number 
of previous 
negative TRUS 
biopsy sessions 
(IQR)
2 (2-3) 3 (2-3) 2 (2-3) NA
Median interval 
between last 
TRUS biopsy 
and MR-guided 
biopsy in 
months (IQR)
12 (5-20) 13 (6-21) 11 (5-20) 0.16
Median interval 
between MR 
imaging and 
MR-guided 
biopsy in 
months (IQR)
2 (1-2) 1 (1-2) 2 (1-2) 0.0023
Median number 
of biopsied CSL 
(IQR)
1 (1-2) 1 (1-2) 2 (1-2) NA
Median number 
of MR-guided 
biopsy cores for 
one CSL (IQR)
2 (2-3) 2 (2-3) 2 (2-3) NA
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In a total of 117 patients, prostate cancer was detected with MR-guided biopsy 
(n=108) or during follow-up after negative MR-guided biopsy (n=9). Prostate 
cancer detection rates were 25% (108 of 438; 95% confidence interval (CI), 
21-29%) in included patients and 41% (108 of 265; CI, 35-47%) in patients who 
underwent both multi-parametric MRI and MR-guided biopsy. The majority of 
detected cancers were clinically significant: a total of 87% (94 of 108) met the 
clinical criteria and 93% (26 of 28) met radical prostatectomy-specimen criteria. 
A total of 368 CRSs were indicated in the 265 MR-guided biopsy patients. With 
a median of two cores per CSL, prostate cancer was detected in 33% of CSLs 
(123 of 368; CI, 29-38%). The majority of CSLs (63% (78 of 123); CI, 55-71%) were 
detected in the TZ. Thirty-three percent (40 of 123; CI, 25-41%) of detected 
cancer CSLs were located in the peripheral zone (PZ). The remaining 4% (5 of 
123; CI, 2-9%) were situated on the TZ-PZ border or in the seminal vesicles. Other 
predominant CSL diagnoses are shown in Table 3. 
Significantly more prostate cancer was detected in patients with a prostate 
volume ≤50 mL (60%) versus >50 mL (36%; p <0.0001) and in patients with PSA 
density >0.15 ng/mL per mL (52%) versus ≤0.15 ng/mL per mL (24%; p <0.0001). 
Upon multivariable logistic regression analysis, PSA was not a predictor of MR-
guided biopsy prostate cancer detection. After correction for PSA, only prostate 
volume ≤50 mL (p = 0.008) and PSA density >0.15 ng/mL per mL (p <0.0001) were 
predictors of MR-guided biopsy prostate cancer detection in a final multivariable 
logistic regression model. These results are presented in Table 4. 
Histology in MR-guided biopsy cores of CSLs Percentage of CSLs1 
Prostate cancer 33 (123/368)
Prostatitis 30 (109/368)
Healthy intra-prostatic tissue 23 (85/368)
Atrophia 8 (31/368)
Material not representative for prostate tissue 5 (18/368)
HGPIN 4 (16/368)
Reactive atypia 2 (9/368)
AAH 2 (8/368)
Fibrosis 0.003 (1/368)
Total CSLs 100 (368/368)
Table 3: MR-guided biopsy histopathology results for cancer suspicious lesions. CSLs = cancer 
suspicious lesions, HGPIN = high-grade intraprostatic neoplasia; AAH = atypical adenomatous 
hyperplasia. 
1  Because some CSLs had more than one diagnosis, the sum of percentages is higher than  
 100%.
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Table 4: Univariable and multivariable analysis of dichotomized PSA, prostate volume and PSA 
density related to MR-guided prostate cancer detection in patients with initial positive MR-guided 
biopsy and initial negative MR-guided biopsy results1. CI = 95% confidence interval, PSA = prostate-
specific antigen, MRGB+ = patients with prostate cancer on initial MR-guided biopsy, MRGB- = 
patients without prostate cancer on initial MR-guided biopsy, , DR = detection rate, OR = odds ratio, 
Chi-square = Pearson Chi-squared test, NA = not applicable.
1  The final multivariable logistic regression model consisted of two independent variables  
 (PSA density and prostate volume (as dichotomized categorical covariates)) and one  
 dependent variable (prostate cancer detection on MR-guided biopsy).
2  Statistically significant difference at a threshold of p <0.05.
3  One patient with initial negative MR-guided biopsy had prostate cancer detected upon 
 TRUS biopsy. This patient is not added to the totals in the fourth column.
Percentage 
of patients 
with prostate 
cancer
CI Total  
percentage 
of patients 
with prostate 
cancer upon 
MR-guided 
biopsy3
Univariable 
analysis 
Chi-square 
test
Multi - 
variable 
logistic 
regression 
analysis, 
initial 
model OR
Multi- 
variable 
logistic 
regression 
analysis,  
final 
model OR
MRGB+
MRGB-
100 (108/108)
6 (9/156)
96-100
3-11
44 (117/264), 
CI: 38-50
NA NA NA
PSA ≤ 10 
ng/mL 
  MRGB+
  MRGB-
100 (28/28)
5 (3/57)
86-100
1-15
36 (30/84),
CI: 26-46
0.09
(PSA >10/ 
≤10 ng/
ml)
OR = 1.13
CI: 
0.53-2.40
p = 0.75
NA
PSA > 10 
ng/mL 
  MRGB+
  MRGB-
100 (80/80)
6 (6/99)
95-100
3-13
48 (86/179),
CI: 41-55
Prostate 
volume  
≤ 50 mL 
  MRGB+
  MRGB-
100 (47/47)
13 (6/40)
96-100
7-29
60 (52/86),
CI:50-70
<0.00012
Prostate 
volume 
≤ 50 / 
> 50 mL
OR = 2.28
CI:1.23-4.21
p=0.0092
Prostate 
volume 
≤ 50 / 
> 50 mL
OR = 2.21
CI:1.23-
3.97
p=0.0082
Prostate 
volume 
>50 mL 
  MRGB+
  MRGB-
100 (61/61)
3 (3/116)
93-100
1-8
36 (64/177),
CI:29-43
PSA 
density  
≤ 0.15 ng 
/mL/mL
  MRGB+
  MRGB-
100 (15/15)
5 (3/57)
76-100
1-15
24 (17/71),
CI: 15-35
<0.00012
PSA 
density 
> 0.15 / 
≤ 0.15 
OR=3.50
CI: 1.52-
8.05
P=0.0032
PSA 
density 
> 0.15 / 
≤ 0.15 
OR=3.76
CI: 1.84-
7.68
p<0.00012
PSA 
density > 
0.15 ng 
/mL/mL
  MRGB+
  MRGB-
100 (93/93)
6 (6/99)
95-100
3-13
52 (99/192),
CI: 45-59
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In sensitivity analysis, prostate cancer detection rates would have increased to 
47% (137 of 294; CI, 41-52%) if MR-guided biopsy would have been performed and 
prostate cancer would have been detected in patients with a multi-parametric 
MRI CSL who were advised to undergo MR-guided biopsy (n=29). Detection 
rates would have increased even further to 56% (201 of 358; CI, 51-56%) if MR-
guided biopsy would have been performed and prostate cancer would also have 
been detected in patients with an multi-parametric MRI suspicious for prostatitis, 
benign prostatic hyperplasia, or low-grade cancer, and in whom repeat multi-
parametric MRI was advised (n=64). A patient example of multi-parametric MRI 
and MR-guided biopsy is shown in Figure 2.
Follow-up
Reported MR-guided biopsy complications were sepsis with hospitalization in 
one patient and a vasovagal reaction in four other patients. 
Only in 51 of 156 negative MR-guided biopsy patients was a follow-up of 5 months, 
including two PSA measurements or histopathology, available. 
In 6% (9 of 156; CI, 3-6%) of negative- MR-guided biopsy patients, prostate 
Figure 2: A 76-yr-old patient with a prostate-specific antigen level of 32 ng/mL and density 
of 0.46 ng/mL per mL, clinical stage T1C, and one previous negative TRUS-guided biopsy 
session underwent multi-parametric MRI for a clinical indication of prostate cancer detection. 
(A) A ventral transition zone cancer is visible (demarcated regions). A focal lenticular-shaped 
homogeneous low-signal intensity (blue demarcation) in the ventral prostate is visible on (iii) 
sagittal and (v) axial T2-weighted MRI. A focal (ii) low apparent diffusion-coefficient value 
(blue demarcation) and (iv) high signal intensity (blue demarcation) on the calculated b1600 
image are visible in the same area on diffusion-weighted MRI. The Ktrans overlay on T2-weighted 
images can be appreciated (i). Dynamic contrast-enhanced MRI shows asymmetric increased 
enhancement (black demarcation) matching the other functional images and T2-weighted (i). 
Benign prostate hyperplasia nodules are also enhanced (orange arrows). (B) Sagittal and (C) 
transverse balanced gradient echo images were made to confirm the needle positions. Needle 
artefacts (orange lines) and needle guiders (blue lines with white-dotted top) are visible. In this 
magnetic resonance-guided biopsy specimen, a Gleason score 4 + 5 prostate cancer was found 
in the ventral transition zone. 
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cancer was detected during this mean follow-up of 5 months. Detected cancers 
were clinically significant in 78% (seven of nine patients) based on clinical criteria 
and in 100% (four of four) based on radical prostatectomy-specimen criteria. 
Follow-up results of patients who underwent multi-parametric MRI for suspicion 
of prostate cancer are presented in Figure 3.
Figure 3: Follow-up histopathology results in patients with multi-parametric MRI: (A) 
excluded patients with multi-parametric MRI, (B) included multi-parametric MRI patients 
without MR-guided biopsy, (C) patients with multi-parametric MRI and MR-guided biopsy.
GG = Gleason grade, MRGB = magnetic resonance-guided prostate biopsy, TRUS-Bx biopsy = 
transrectal ultrasound-guided biopsy.
A b c
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Discussion
In patients with one or more negative TRUS-guided biopsy sessions, MR-guided 
biopsy of 3T multi-parametric MRI-detected CSLs resulted in a prostate cancer 
detection rate of 41%. In our study, MR-guided biopsy detected more cancers 
than repeated TRUS-guided biopsy (≤18%) (21, 22). Furthermore, our number of 
detected clinically significant cancers (87%) is high compared to an estimated 
56% of clinically significant cancers for repeat TRUS-guided biopsy in screening 
(23). We detected more clinically significant cancers because our referred patient 
population probably contained more cancers of higher Gleason score than a 
screening population. Another reason for detecting many clinically significant 
cancers may be higher MRI detection rates for higher Gleason score cancers (24). 
Furthermore, MR-guided biopsy has higher GG concordance with prostatectomy 
specimens compared to systematic TRUS-guided biopsy and, therefore, less 
undergrading may have occurred (25). 
Our detection rate of 41% is in agreement with some MR-guided biopsy 
publications (37-39%) (6, 10). However, our detection rate is lower compared to 
other MR-guided biopsy studies (52-59%) (5, 8, 9). This may be explained by the 
fact that in our study, as opposed to these last studies, not all patients underwent 
MR-guided biopsy. Finally, for clinically significant cancers, our detection rate 
(87%) approaches that of Hambrock et al. (93%) (25). The detection rate of 
clinically significant cancers of Roethke et al. was lower than ours (81%) (5). This 
may be explained by the fact that they did not add multi-parametric MRI to T2-
weighted images in the first 52 of their 100 patients. 
Our relatively high detection rates of prostate cancer in the TZ (63%) agree with 
results of Hambrock et al. (57% in TZ) (8). However, in other reports, TZ cancer-
detection rates (47% and 35%, respectively) were lower than PZ cancer-detection 
rates (respectively, 53% and 64%) (5, 6). Heterogeneity of patient populations 
due to differences in the number of previous TRUS-guided biopsy sessions, 
the TRUS-guided biopsy protocol, and in the number of cores in TRUS-guided 
biopsies makes it difficult to compare results of reported predominant prostate 
cancer locations.
Clinical alternatives to MR-guided biopsy are limited to saturation biopsy 
protocols (including transperineal template biopsies). Saturation biopsies have 
the disadvantages of possibly requiring anaesthesia and a high number of cores. 
Detection rates of protocols including 20-38 cores ranged from 14% to 41% without 
significantly increasing the likelihood of detecting clinically significant cancers 
(26). In MR-guided biopsy, only a limited number of cores (median two cores 
per CSL) are needed to detect a high percentage (86%) of clinically significant 
cancers. Furthermore, in MR-guided biopsy, no general anaesthesia is required. 
Clinical use of MR-guided biopsy is currently restricted by its limited availability 
and its rather long procedure times (median: 44min). However, application of 
MR-ultrasound fusion techniques (using registration), needle-guide tracking 
sequences, and implementation of robotics may improve these drawbacks in the 
near future (27-29). When these issues are solved, multi-parametric MRI and MR-
guided biopsy could be applied on a larger scale for prostate cancer detection 
in patients with an elevated PSA and one or more negative TRUS-guided biopsy 
sessions. However, prostate cancer detection rates for random systematic TRUS-
guided biopsy versus targeted MR-guided biopsy should be prospectively 
compared in patients stratified for previously performed similar TRUS-guided 
guided biopsy protocols. 
Our study has several limitations. First, our follow-up is limited to two or fewer 
PSA measurements within 1 yr without histopathology examinations in most 
patients. Inferring conclusions from false-negative MR-guided biopsy results 
remains difficult based on this limited follow-up. However, regardless of follow-
up duration, differentiation of a patient with small-volume cancer missed by 
MR-guided biopsy from a patient without prostate cancer remains problematic 
without availability of radical prostatectomy specimens directly after MR-guided 
biopsy. Second, as our work was performed in a referral centre, interpatient 
variation in the number and the protocols of previous negative TRUS-guided 
biopsy sessions is present. Furthermore, intrapatient variation exists due to time 
differences between protocols of different TRUS-guided biopsy sessions in a 
single patient. Furthermore, in some patients, bias may have been caused by the 
relatively low number of TRUS-guided biopsy cores for the sampled prostate-
cancer volume. Third, MR-guided biopsy was performed by four radiologists 
who did not perform consensus image reading. Possible differences in image 
interpretation between reading radiologists and MR-guided biopsy radiologists 
may have biased our results. Finally, a TCCL ≥10 mm, recently defined to predict a 
radical prostatectomy specimen tumour volume ≥0.5 mL using TRUS-guided (5 
mm grid) template biopsy simulations (17), was used as a criterion for clinically 
significant prostate cancer in MR-guided biopsy specimens. As MR-guided 
biopsy is targeted precisely to a lesion and is not taken every 5 mm according to 
a grid, our TCCL criterion may have overestimated MR-guided biopsy results for 
clinically significant cancers. However, as no results on MR-guided biopsy TCCL 
for prediction of tumour volume exist currently, we incorporated this ultrasound 
criterion for estimation of tumour volume based on MR-guided biopsy specimens.
In conclusion, in patients with an elevated PSA level and one or more previous 
negative TRUS-guided guided prostate biopsy sessions MR-guided biopsy of 3T 
multi-parametric MRI detected CSLs has a detection rate of 41% for predominantly 
clinically significant prostate cancer (87%).
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Abstract
Objective: The purpose of this article is to identify histopathologically proven prostate 
cancer locations using MRI followed by MR-guided biopsy in patients with elevated 
prostate-specific antigen (PSA) levels and at least one negative transrectal ultrasound 
(TRUS)-guided biopsy session. Our hypothesis is that in this patient group most 
cancers are located in the anterior portion of the prostate. This may have implications 
for the biopsy strategy regarding the location of sampling. 
Materials and methods: This retrospective study consisted of 872 consecutive men 
who had undergone MR-guided prostate biopsy. Inclusion criteria were PSA level 
greater than or equal to 4 ng/mL, one or more negative TRUS-guided biopsy session, 
the presence of suspicious lesions on previous multi-parametric MRI, and prostate 
cancer histopathologically proven by MR-guided biopsy. Thereafter, the location of 
intermediate- or high-risk cancers and cancers with a maximum cancer core length of 
6 mm or longer were determined. The proportion of cancer locations was compared 
using a chi-square test. One-way ANOVA analyses were performed to compare patient 
characteristics.
Results: Results were presented on both a patient and lesion basis because a single 
patient can have multiple lesions. In total, 176 of 872 patients met the inclusion criteria. 
Prostate cancer was detected in 202 of 277 (73%) suspicious lesions. In total, 76% of 
patients had cancer of the transition zone and anterior fibromuscular stroma. Peripheral 
zone cancers were found in 30% of the patients, and 6% had cancers in both zones. In 
70% of cases (141/202; 95% CI; 63-76%), lesions were located anteriorly; this included 
75% (132/176; 95% CI; 69-81%) of patients. Intermediate- or high-risk prostate cancer 
was found in 93% (128/138; 95% CI; 88-96%) of patients. Of these patients, 73% (94/128; 
95% CI; 66-81%) had anterior involvement. Cancers with a maximum cancer core length 
of 6 mm or more were more likely to be located in the anterior part of the prostate 
than were cancers with a core length of less than 6 mm (66% vs 6%). Most cancers 
58% (102/176; 95% CI; 51-65%) were found in the mid prostate. Anterior involvement of 
prostate cancer detected by MR-guided biopsy was statistically significantly (p = 0.04) 
higher in patients with two or more negative TRUS-guided biopsy sessions (79%) than 
in those with one negative TRUS-guided biopsy session (55%). 
Conclusion: Anterior involvement was high (75%) in patients with an elevated PSA 
level and one or more negative TRUS-guided biopsy session, and the majority of these 
cancers (93%) were intermediate or high risk.
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Introduction 
Transrectal ultrasound (TRUS)-guided biopsy protocols primarily sample the 
peripheral zone (PZ), because most prostate cancers are located in this zone at 
initial biopsy (1). In routine autopsy studies, most cancer foci (83-85%) were found 
in the PZ (2, 3). 
In patients who underwent cystoprostatectomy for bladder cancer treatment, 75% 
of the prostate cancers were located in the PZ (4). In patients with increasing 
prostate-specific antigen (PSA) levels and repeated negative TRUS-guided biopsy 
sessions, the diagnosis of intermediate- or high-risk cancers is often delayed (1). 
With repeated TRUS-guided biopsies, prostate cancer detection rates decreased 
from 22% to 4% in four subsequent TRUS-guided biopsy sessions (5). Transperineal 
saturation biopsies are considered as a good alternative for patients with repeated 
negative TRUS-guided biopsy sessions, because higher cancer detection rates (37-
53%) are reported (6-8). With the use of this technique, 37-54% of patients with 
one or more negative TRUS-guided biopsy sessions had cancers in the PZ (8, 9) 
and 18-77% had transition zone (TZ) involvement. Anterior involvement (i.e., the 
anterolateral horn of the PZ, anterior fibromuscular stroma, and TZ) was seen in 
44-83% of patients (6, 8-12). 
The use of MR-guided prostate biopsy increased prostate cancer detection rates 
(38-52%) in patients with an elevated PSA level and one or more negative TRUS-
guided biopsy sessions. Furthermore, the TZ was the predominant location of 
these detected cancers, which is similar to the findings of saturation biopsies (13-
16). Therefore, identifying the location of prostate cancer found with MR-guided 
biopsy may provide insight to cancers missed with standard TRUS-guided biopsy 
schemes. This may have implications for the biopsy strategy regarding the location 
of sampling in this particular patient group. The purpose of our study was to identify 
the location of prostate cancer diagnosed with MR-guided biopsy in patients with 
an elevated PSA level and at least one negative TRUS-guided biopsy session.
Materials and methods
Patient selection
This retrospective study consisted of a cohort of 872 consecutive men who had 
undergone MR-guided prostate biopsy between March 2008 and March 2012 in 
our referral center. Inclusion criteria were PSA level 4 ng/mL or higher, one or 
more negative TRUS-guided biopsy session, the presence of suspicious lesions 
on previous multi-parametric MRI, and prostate cancer histopathologically proven 
by MR-guided biopsy. Exclusion criteria were an unknown number of previous 
TRUS-guided biopsy sessions, interval between last TRUS-guided biopsy and 
MR-guided biopsy longer than 2 years, and previous prostate cancer diagnosis, 
including a suspicion of recurrent prostate cancer or seminal vesicle involvement. 
The flowchart in Figure 1 describes reasons for inclusion and exclusion.
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Figure 1: Flowchart describing patient selection and reasons for exclusion. In total, 176 patients 
were included; 277 suspicious lesions were biopsied, and cancer was detected in 202 (73%) 
of them. *Other category included patients with unknown number of previous negative 
transrectal ultrasound (TRUS)-guided biopsies, unknown prostate-specific antigen (PSA) level 
or pathologic findings, and seminal vesicle involvement. In total, 696 patients were excluded.
Diagnostic MRI Protocol
Multi-parametric prostate MRI and MR-guided biopsy were performed on a 3T MRI 
scanner (Magnetom Trio and Magnetom Skyra, both from Siemens Healthcare) 
using a spinal and pelvic phased-array coil. The image parameters were applied 
according to the European Society of Urogenital Radiology guidelines (14, 17). 
Two radiologists with 9 and 18 years of experience in reading prostate MRI 
examinations evaluated the multi-parametric MRI data using in-house developed 
software (18). Lesions suspicious for cancer were defined on T2-weighted imaging 
in combination with diffusion-weighted imaging and dynamic contrast-enhanced 
MRI (19). Clinical data of all patients were available during MR image interpretation. 
Prostate volume (mL) was estimated on the MR images using an ellipsoid formula: 
length x width x height x 1/6 x π.
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MR-guided biopsy
Transrectal MR-guided prostate biopsy was performed in a separate session with 
the same MRI systems used for the diagnostic images (19). Axial T2-weighted 
images and diffusion-weighted images were acquired to relocate the suspicious 
lesion described on the diagnostic multi-parametric MRI. During the MR-guided 
biopsy procedure, two confirmation scans (each in a different plane, with the 
needle left in situ) were acquired to verify the location of the biopsy needle. In 
this study, a fully automatic 18-gauge titanium double shot biopsy gun with needle 
length of 175 mm and tissue core sampling length of 17 mm was used. 
Location of prostate cancer
Two readers with 2 and 4 years of experience in MR-guided prostate biopsy 
determined in consensus the location of histopathologically proven prostate 
cancer according to the position of the needle on the MRI confirmation scans. The 
biopsy location was determined using biplanar MRI confirmation scans (sagittal 
and transversal) with the needle left in situ (Fig. 2). The location was reported 
according to an adapted scheme as described by Dickinson et al. (20). In this 
adapted scheme, the prostate was divided into 36 different segments (Fig. 3). 
One segment was assigned to each lesion, even when the cancer involved more 
segments on the multi-parametric MRI. When the sampling core was located in 
two segments, the segment with the lowest apparent diffusion coefficient value on 
the MR images was chosen, because a low apparent diffusion coefficient value is 
associated with more aggressive prostate cancer (21). Furthermore, 5 mm or more 
of the sampling core had to be located in the assigned segment. 
In our study, the anterior portion of the prostate was defined as the area 17 
mm anterior from the posterior prostatic surface irrespective of prostate size. 
This definition was chosen because during a standard TRUS-guided biopsy the 
physician obtains samples from the prostate by firing a needle with a 17 mm notch 
from the posterior prostate surface (20). 
In some patients, more than one cancer-positive lesion was detected. Therefore, 
the results were presented in two ways: on a lesion basis and on a patient basis.
Intermediate- or high-risk cancer and maximum cancer core length
Intermediate- or high-risk prostate cancer lesion was defined as follows: a Gleason 
grade component of 4 or 5 within the biopsy specimen, or a maximum cancer 
core length in one MR-guided biopsy core 6 mm or longer, for which the longest 
maximum cancer core length (cancer volume percentage x length of biopsy core) 
was taken for every patient. With a maximum cancer core length 6 mm or longer, 
cancer volumes of 0.5 mL or greater can be predicted with a sensitivity of 95% or 
greater (22). Both aggression and maximum cancer core length were correlated 
with prostate cancer location.
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Figure 2: Axial (left) and sagittal (middle) balanced gradient-echo images of prostate with 
biopsy needle (dashed line) and biopsy core (thick solid line) inserted (needle guide is also 
delineated with solid line). Corresponding segment was annotated (right) as right medial 
peripheral zone in mid prostate (dark gray segment, middle).
Figure 3: Schematic axial and sagittal views of prostate. Diagrams show all cancer locations 
(A) and intermediate- or high-risk cancer locations (B). Horizontal dashed lines (17 mm) in 
axial views (left) separate anterior and posterior part of prostate. Peripheral zone (light gray), 
transition zone (dark gray), and anterior fibromuscular stroma (white) are shown on right (R) 
and left (L) sides. Numbers shown in axial view are numbers of histologically proven prostate 
cancer lesions found in MR-guided biopsy specimen for that specific segment. Segments 
with more than five positive lesions are colored red. In total, 202 (138 intermediate- or 
high-risk) lesions with prostate cancer were detected in 176 (128 intermediate- or high-risk) 
patients. In schematic sagittal views of prostate (right), distribution of histopathologically 
proven prostate cancer locations after MR-guided biopsy is shown as percentage of all 
lesions (A) and intermediate- or high-risk lesions (B). Adapted with permission from 
Dickinson et al. (20).
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Statistical analysis
The proportion of patients with cancer in each prostate location was compared 
using a chi-square test. The corresponding 95% CIs were calculated using the 
modified Wald method. One-way ANOVA analyses were performed to compare the 
means of age, PSA level, prostate volume, and PSA density between the different 
negative TRUS-guided biopsy session groups. All analyses were performed with 
SPSS software (version 20.0, IBM).
3.0 
Results
Patient selection and suspicious lesions
In total, 176 of the 872 patients were included; reasons for exclusion are described 
in Figure 1. In these patients, 277 suspicious lesions were biopsied, and cancer was 
detected in 202 lesions (73%). Patient characteristics are shown in Table 1. The 
median time between the last TRUS-guided biopsy and MR-guided biopsy was 8 
months (range, 0-23 months).
Table 1: Patient Char-
acteristics and Zonal 
Distribution Stratified 
by the Number of Neg-
ative Transrectal Ultra-
sound (TRUS) Biopsy 
Sessions. 
Note: Patients with an 
anterior or peripheral 
zone prostate cancer 
can have a posterior, 
transition zone, or an-
terior fibromuscular 
stroma cancer as well. 
The p-values shown are 
the results for the one-
way ANOVA analyses 
(age, prostate-specific 
antigen (PSA) level, 
prostate volume, and 
PSA density) and the 
chi-square analyses to 
compare proportions 
of patients with certain 
prostate cancer (PCa) 
locations for different 
parameters including 
the number of previous 
negative TRUS-guided 
biopsy sessions.
All patients 
Number of previous nega-
tive TRUS biopsy sessions
1 2 3 ≥4 Total p
Mean age (years) 63 64 66 66 65 0.09
Mean PSA (ng/mL) 11 21 23 29 22 <0.01
Mean prostate volume (mL) 51 50 52 56 52 0.66
Mean PSA density (ng/mL/cc) 0.3 0.5 0.5 0.6 0.5 0.06
Median number of cores 
during last biopsy session 
10 10 10 10 10
Patients with PCa (%(n)) 17.6 (31) 28.4 (50) 28.9 (51) 25.0 (44) 176
Lesions with PCa 16.8 (34) 27.7 (56) 28.2 (57) 26.1 (55) 202
gleason score 
5 2 1 4 4 11
6 18 21 15 21 75
7 9 28 24 16 77
8 4 5 11 10 30
9 0 1 3 3 7
10 1 0 0 1 2
≥8 5 6 14 14 39
Patients with involvement of (% (n))
Transition zone or anterior 
fibromuscular stroma
61.3 (19) 74.0 (37) 84.3 (43) 79.5 (35) 76.1 (134) 0.11
Peripheral zone 38.7 (12) 34.0 (17) 21.6 (11) 27.3 (12) 29.5 (52) 0.34
Anterior portion 54.8 (17) 78.0 (39) 82.4 (42) 77.3 (34) 75.0 (132) 0.04
Posterior portion 48.4 (15) 26.0 (13) 21.6 (11) 29.5 (13) 29.5 (52) 0.07
Base 29.0 (9) 12.0 (6) 25.5 (13) 31.8 (14) 23.9 (42) 0.12
Mid 45.2 (14) 60.0 (30) 58.8 (30) 63.6 (28) 58.0 (102) 0.43
Apex 29.0 (9) 30.0 (15) 25.5 (13) 22.7 (10) 26.7 (47) 0.86
Patients with significant PCa
1 2 3 ≥4 Total p
64 65 66 68 66 0.08
12 21 25 33 24 0.01
42 49 53 57 51 0.19
0.4 0.6 0.5 0.6 0.5 0,40
10 10 10 10 10
14.1 (18) 29.7 (38) 30.5 (39) 25.8 (33) 128
13.8 (19) 30.4 (42) 29.7 (41) 26.1 (36) 138
0 1 1 4 6
7 8 5 10 30
9 28 24 16 77
4 5 11 10 30
0 1 3 3 7
1 0 0 1 2
5 6 14 14 39
55.6 (10) 71.1 (27) 84.6 (33) 78.8 (26) 75.0 (96) 0.11
44.4 (8) 36.8 (14) 20.5 (8) 30.3 (10) 31.3 (40) 0.25
50.0 (9) 76.3 (29) 79.5 (31) 75.8 (25) 73.4 (94) 0.11
55.6 (10) 26.3 (10) 25.6 (10) 33.3 (11) 32.0 (41) 0.12
27.8 (5) 7.9 (3) 25.6 (10) 30.3 (10) 21.9 (28) 0.09
38.9 (7) 65.8 (25) 64.1 (25) 69.7 (23) 62.5 (80) 0.16
38.9 (7) 28.9 (11) 23.1 (9) 24.2 (8) 27.3 (35) 0.62
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Prostate cancer locations detected with MR-guided biopsy
Lesion basis: The distribution of lesions with histologically proven prostate cancer 
for each segment is shown in Figure 3. Lesions were located anteriorly in 70% of 
cases (141/202; 95% CI, 63-76%). 
Patient basis: In 75% (132/176; 95% CI,69-81%) of patients, there was involvement 
of the anterior part of the prostate. Anterior involvement of prostate cancer 
detected by MR-guided biopsy was statistically significantly (p = 0.04) higher in 
patients with two or more negative TRUS-guided biopsy sessions 79% (115/145; 
95% CI, 74-85%) compared with those with one negative TRUS-guided biopsy 
session 55% (17/31; 95% CI, 39-71%) (Fig. 4). 
In total, 76% (134/176; 95% CI, 70-83%) of the patients had cancer involvement of 
the TZ and anterior fibromuscular stroma. PZ cancers were found in 30% (52/176; 
95% CI, 23-37%), and 6% of patients (11/176; 95% CI, 3-10%) had cancer in both 
zones. In 60% (123/202; 95% CI, 54-67%) of cases, cancer was detected in the TZ 
and anterior fibromuscular stroma only. The same numbers were found for solitary 
anterior cancers. Most cancers were found in the mid prostate 58% (102/176; 
95% CI, 51-65%) followed by the apex 27% (47/176; 95% CI, 21-34%) and base 
24% (42/176; 95% CI, 18-30%). No statistically significant differences were found 
among the base, mid, or apex and the number of negative TRUS-guided biopsy 
sessions (Table 1). 
In patients with a high PSA level or high PSA density, more cancers were located 
anteriorly compared with patients with a lower PSA or lower PSA density 
(p < 0.0001). Most cancers with a Gleason score of 5 were found in the anterior 
part of the prostate (Fig. 4). However, anterior involvement was not statistically 
significantly different (p = 0.30) between different Gleason scores. 
Prostate cancer location of intermediate- or high-risk cancers
Lesion basis: For 115 of 202 lesions (57%), the maximum cancer core length could be 
obtained from the pathology report. Most (66%; 76/115) had a maximum cancer core 
length greater than or equal to 6 mm. The relationship between maximum cancer 
core length and the location of prostate cancer is shown in Table 2. In 66% of cases 
(50/76; 95% CI, 55-76%), lesions with a maximum cancer core length of greater than 
or equal to 6 mm were located in the anterior portion, whereas 56% (22/39; 95% CI, 
41-72%) of lesions with a maximum cancer core length less than 6 mm were located 
in the anterior portion; the difference was not statistically significant. 
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Figure 4: Percentage of anterior prostate cancers (A–E). Graphs show percentage of anterior 
prostate cancers with respect to number of negative transrectal ultrasound (TRUS)-guided 
biopsy sessions (A), prostate-specific antigen (PSA) level (B), prostate volume (C), PSA density 
(D), and Gleason score (E). In patients with higher PSA level, higher PSA density, and larger 
prostate volume, more cancers were located anteriorly compared with patients with lower 
PSA level, PSA density (p < 0.0001). There were no statistically significant differences between 
Gleason score and cancer location (p = 0.30). Data in A–D are presented on per-patient basis 
and those in E are presented on per-lesion basis. Patients with anterior or peripheral zone 
cancer can have posterior and transition zone cancer as well.
Table 2: Correlation between maximum cancer core length (MCCL) and location of prostate 
cancer per lesion. The MCCL could be determined from the pathology report from 115 lesions. 
Data are number (%) of lesions [95% CI].
MCCL <6 mm (n=39) MCCL ≥6 mm (n=76)
Anterior 22 (56.4) [41-72] 50 (65.8) [55-76]
Peripheral zone 16 (41.0) [26-56] 25 (32.9) [22-43]
Transition zone and anterior 
fibromuscular stroma
23 (59.0) [44-74] 51 (67.1) [57-78]
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Patient basis: For 138 patients it was possible to determine whether intermediate- 
or high-risk prostate cancer was present; in 38 patients with a highest Gleason 
grade of 3, the maximum cancer core length was not described in the pathology 
report. Intermediate- or high-risk prostate cancer was found in 93% of patients 
(128/138; 95% CI, 88-96%). Of these patients, 73% (94/128; 95% CI, 66-81%) had 
anterior involvement. Among all patients with cancer, 65% (114/176; 95% CI, 58-
72%) had a Gleason grade of 4 or higher.
Discussion 
In patients with prostate cancer initially missed with TRUS-guided biopsy, multi-
parametric MRI followed by MR-guided biopsy detected cancer in the anterior 
part in 75% of cases. In particular, patients with repeated negative TRUS-guided 
biopsy sessions more often received a diagnosis of anterior prostate cancer 
(79%). Intermediate- or high-risk prostate cancer was found in 93% of cases. Of 
these patients, 73% had anterior involvement. In 66% of cases, the lesions with 
a maximum cancer core length of greater than or equal to 6 mm were located 
in the anterior portion, which was a higher proportion than the lesions with a 
maximum cancer core length less than 6 mm (56%). These results confirm our 
hypothesis that in patients with an elevated PSA level and one or more negative 
TRUS-guided biopsy session, more cancers are located in the anterior portion of 
the prostate. This is most likely the result of undersampling of the anterior part 
using standardized TRUS-guided biopsy schemes. 
Comparison with other biopsy strategies
Another method to sample the prostate in cases of negative TRUS-guided biopsies 
and elevated PSA levels is transperineal saturation biopsies. In the literature, 
higher detection rates were reported for this method in this patient group when 
compared with standard TRUS-guided biopsy schemes. Furthermore, most of 
these patients also had anterior involvement (77%); TZ and PZ involvement was 
seen in 45-77% and 37-54% of patients, respectively (6, 8-10). The higher PZ 
involvement found with transperineal template TRUS-guided biopsy compared 
with MR-guided biopsy may be explained by the fact that it is difficult to target 
and determine the exact needle location with transperineal biopsy. With MR-
guided biopsy, a biplanar confirmation scan was made with the needle left in situ. 
In these images, the TZ and PZ can easily be discriminated. This is not possible 
on TRUS images because no confirmation scans are made with the needle left 
in situ. 
Intermediate- or high-risk prostate cancer was found in 93% of patients, which is 
higher than the detection rate with transperineal template TRUS-guided biopsy 
(60-89%) (6, 7, 23). However, the criteria for intermediate-or high-risk prostate 
cancer differ (i.e., maximum cancer core length, total cancer core length, and 
number of positive cores) among studies. Furthermore, the criteria used for 
template TRUS-guided biopsy are not applicable to MR-guided biopsy because 
these criteria also use the number of positive cores. Among the patients in our 
study who received a diagnosis of cancer, 65% had a Gleason grade of 4 or higher, 
which is comparable to the results found in transperineal template TRUS-guided 
biopsy studies (34-72%) (6, 10, 24). 
Although systematic transperineal template TRUS-guided biopsy improves the 
detection rate of prostate cancer, the procedure is more expensive and invasive 
than standard TRUS-guided biopsy (25). Extended TRUS-biopsy schemes have 
been investigated in which TZ sampling was added to the standard PZ biopsies 
in patients with previous negative TRUS-guided biopsy sessions and persistently 
elevated PSA level. Solitary TZ cancers were found in 8-31% of the patients 
(26,27). In our study, 60% of the patients had a solitary TZ cancer. This is of 
important clinical value because these cancers were missed with TRUS-guided 
biopsy. Nevertheless, the detection rate of TRUS-guided biopsy with additional 
TZ biopsies is lower (17-28%) than that of transperineal template TRUS-guided 
biopsy (27-30). 
MR-guided biopsy is a relatively new technique in the detection of prostate 
cancer and has shown superior results compared with TRUS-guided biopsy 
(17). The fusion of MR images with TRUS images is another new technique that 
combines the localization strength of MRI and real-time ultrasound imaging. Only 
a limited number of studies are available in patients with an elevated PSA level 
and at least one negative TRUS-guided biopsy session. Those studies found an 
increase in the detection rate and more intermediate- or high-risk cancers were 
found compared with standard TRUS-guided biopsy schemes (31-33). Studies 
that compare MR-guided biopsy and fusion of MR images with TRUS images 
regarding detection rate, number of intermediate- or high-risk prostate cancers, 
and prostate cancer location and cancer size are necessary to determine which 
technique is beneficial in which patient (28). 
The high number of lesions with prostate cancer found in the TZ (69%) is 
comparable to earlier published results in small patient populations who 
underwent MR-guided biopsy (63-70%) and saturation biopsy (45-77%) (13-15). 
To our knowledge, this is the first study to describe the location of prostate cancer 
detected with MR-guided biopsy in relation to the number of negative TRUS-
guided biopsies in a large population. This is of clinical importance because it will 
help both radiologists and urologists to focus on areas with targeted biopsy areas 
where cancers are most likely to be. Furthermore, these results have implications 
for diagnosis because physicians might pay extra attention to locations that are 
likely to contain prostate cancer.
Limitations
Some limitations of our study should be discussed. First, only patients with positive 
biopsy results were included. Similar to systematic transperineal template TRUS-
guided biopsy, prostate cancer may be missed with multi-parametric MRI and 
MR-guided biopsy. Inevitably, this introduced a patient selection bias because we 
have currently no information about the patients with negative findings. Thus far, 
there is no reference standard in this patient group. 
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Second, in this study, the anterior portion was defined as the area ventral to 
a fixed distance of 17 mm from the posterior prostatic surface. Therefore, the 
fraction between anterior and posterior volume was not equal in all prostates 
and depended on prostate volume. However, in this study, the number of anterior 
lesions did not increase with larger prostate volumes, which is in agreement 
with the hypothesis that the posterior 17 mm of the prostate is sampled with 
TRUS-guided biopsy. Furthermore, in patients with a small prostate, an anteriorly 
located lesion could be classified as a posterior lesion because the whole prostate 
was within the 17 mm line. 
Third, only one segment was assigned to each lesion to prevent a large cancer 
on MRI accounting for two lesions. When the sampling core was located in two 
segments, the segment with the highest suspicion for prostate cancer (i.e., the 
lowest apparent diffusion coefficient value) on the MRI was chosen. Therefore, 
cancers may extend beyond the assigned segment. 
Fourth, our study had a retrospective design without randomization and 
comparison with other biopsy approaches; therefore, it may inherently contain 
another bias regarding patient selection. However, this is a well-defined series of 
consecutive patients, which strengthens its applicability in daily clinical practice. 
Fifth, the maximum cancer core length could be obtained in 57% of the lesions 
because the cancer volume percentage or biopsy core length could not be 
obtained from the pathology report. With the defined criteria for intermediate- or 
high-risk prostate cancer, it was possible to determine in only 138 of the patients 
whether intermediate- or high-risk prostate cancer was present because in 38 
patients with a highest Gleason grade of 3, the maximum cancer core length was 
unknown. 
Conclusion
The aim of this study was to identify the location of histopathologically proven 
prostate cancer using multi-parametric MRI followed by MR-guided biopsy. The 
results presented in this article confirm our hypothesis that anterior involvement 
is high (75%) in patients with an elevated PSA level and at least one negative 
TRUS-guided biopsy session. Furthermore, most (93%) of these cancers are 
intermediate- or high-risk.
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Abstract
Background: Knowledge of significant prostate cancer locations being missed with 
magnetic resonance (MR)- and transrectal ultrasound (TRUS)-guided biopsy may 
help to improve these techniques.
Objective: To identify the location of significant prostate cancer lesions being missed 
with MR- and TRUS-guided biopsy.
Design, Setting, and Participants: In a referral center 223 consecutive biopsy-naive 
men with elevated prostate specific antigen level and/or abnormal digital rectal 
examination were included. Histopathologically proven cancer locations, Gleason 
score and tumor length were determined.
Intervention: All subjects underwent multi-parametric MRI and 12-core systematic 
TRUS-guided biopsy. MR-guided biopsy was performed in all patients with suspicion 
of prostate cancer on multi-parametric MRI (n=142).
Outcome Measurements and Statistical Analysis: Cancer locations were compared 
between MR- and TRUS-guided biopsy. Proportions were expressed as percentages, 
and the corresponding 95% CIs were calculated. 
Results and limitations: In total 191 lesions were found in 108 patients with significant 
prostate cancer. From these lesion 74% (141/191) were defined as significant prostate 
cancer on either MR- or TRUS-guided biopsy. MR-guided biopsy detected 74% 
(105/141) of these lesions, this was 61% (86/141) with TRUS-guided biopsy. TRUS-
guided biopsy detected more lesions compared to MR-guided biopsy (140 vs 109). 
However, these lesions were often low-risk (39%). Significant lesions missed with 
MR-guided biopsy had most often involvement of dorsolateral (58%) and apical 
(37%) segments and missed segments with TRUS-guided biopsy were located 
anteriorly (79%), anterior mid prostate (50%) and anterior apex (23%).
Conclusions: Both techniques have difficulties in detecting apical lesions. MR-guided 
biopsy most often missed cancer with involvement of the dorsolateral part (58%) 
and TRUS-guided biopsy with involvement of the anterior part (79%).
Patient summary: Both biopsy techniques do miss cancer in specific locations within 
the prostate. Identification of these lesions may help to improve these techniques. 
Martijn G. Schouten, Marloes van der Leest, Morgan R. Pokorny, 
Martijn Hoogenboom, Jelle O. Barentsz, Les C. Thompson,  
Jurgen J. Fütterer
European Urology 2017  Jun;71(6):896-903
CHAPTER 4.0  
why And wheRe dO 
we MISS SIgnIFIcAnT 
PROSTATe cAnceR wITh 
MuLTI-PARAMeTRIc MRI 
FOLLOwed by MR-guIded 
And TRuS-guIded bIOPSy 
In bIOPSy nAïVe Men?
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Introduction
Early detection of prostate cancer, with the intent to diagnose this disease in a 
curable state, currently leads to over-diagnosis which in turn can result in over-
treatment (1). Over-diagnosis is the main disadvantage of the present clinical 
standard where men with elevated serum prostate specific antigen (PSA) levels 
and/or abnormal digital rectal examination (DRE) undergo random systematic 10 
to 12-core prostate transrectal ultrasound (TRUS)-guided biopsy. Other limitations 
of TRUS-guided biopsy are under-detection and under-grading of clinically 
significant prostate cancer (2). The number of cores and location for systematic 
sampling is a topic of debate (2-4). In biopsy naïve patients, generally accepted 
schemes for systematic sampling with TRUS-guided biopsy are limited to the 
posterior peripheral zone since most cancers are located in this region (2, 4). In the 
repeat biopsy setting most cancers are located in the anterior apex of the prostate 
(2, 4, 5). 
Multi-parametric MRI can be used to reduce over-diagnosis and subsequent over-
treatment (6). multi-parametric MRI is able to detect significant prostate cancer 
(44-87%) in biopsy-naïve males and men with prior negative biopsies. Furthermore, 
the high negative predictive value (63-98%) of multi-parametric MRI can be used 
to rule out significant prostate cancer (7-9). 
Although multi-parametric MRI is a promising technique, significant prostate cancer 
may be missed (10). The interpretation of multi-parametric MRI can sometimes 
be difficult (11, 12). Current research has not focused on the location of cancers 
missed with multi-parametric MRI followed by MR-guided biopsy. Knowledge of 
lesions being missed with MR- and TRUS-guided biopsy is of clinical importance 
for diagnosis and treatment. 
The purpose of this study is to identify the location of significant prostate cancer 
lesions being missed with MR-guided biopsy and systematic TRUS-guided biopsy 
in biopsy naïve patients at risk for prostate cancer. 
Materials and methods
Patient selection and imaging
This study was a retrospective analysis of stored MR-images of biopsy-naïve 
consecutive subjects with an elevated PSA level and/or abnormal DRE. Al subject 
enrolled by referral from urologists from July 2012 through January 2013 and 
were included in a previous prospectively study. However, no detailed data were 
published on the location of prostate cancer (13). 
All subjects underwent multi-parametric MRI performed at 3T (Magnetom Skyra, 
Siemens) according to the ESUR prostate MR-guidelines (14). multi-parametric MRI 
scans were scored independently by three readers (1, 1, and 19 years of experience, 
respectively) using the Prostate Imaging Reporting and Data System version 1.0 (PI-
RADS): from 1 (low) to 5 (high) according to the likelihood of significant prostate 
cancer being present (14). Disagreements in PI-RADS were resolved by consensus.
Prostate biopsy 
Both MR- and TRUS-guided biopsy were performed in a second visit Figure 1. 
The standard diagnostic pathway consisted of systematic TRUS-guided biopsy only 
for men who had a PI-RADS 1 or 2 reported on multi-parametric MRI. MR-guided 
biopsy was performed in all patients with a PI-RADS 3-5 lesion on multi-parametric 
MRI, followed by systematic TRUS-guided biopsy as well (15). Each PI-RADS 3-5 
lesions on multi-parametric MRI was biopsied using two to three cores. Seminal 
vesicles were sampled if suspicious for tumor invasion.
During the MR-guided biopsy session an axial diffusion weighted image (DWI) 
was acquired to relocate the cancer suspicious lesions (CSL) described on the 
diagnostic multi-parametric MRI. After needle insertion with MR-guided biopsy 
two confirmation scans were acquired to verify the biopsy location. TRUS-guided 
biopsy was performed within 30 minutes after MR-guided biopsy by an urologist 
blinded to the multi-parametric MRI and MR-guided biopsy procedure. Any lesions 
seen on TRUS were targeted using the core for the relevant prostate zone.
4.0 
Figure 1: Flowchart describing the diagnostic pathways. All patients underwent both multi-
parametric MRI and TRUS-guided biopsy. Patients with a PI-RADS ≥3 on multi-parametric MRI 
received MR-guided biopsy in addition to TRUS-guided biopsy. 
PI-RADS = Prostate Imaging Reporting and Data System
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Histopathology and risk stratification
All biopsy specimens underwent evaluation by a urogenital-histopathologist blinded 
to the biopsy strategy. Low-risk prostate cancer was defined as either low- volumes 
Gleason score (GS) 3+3 or 3+4 (9). significant prostate cancer (=intermediate- and/
or high-risk prostate cancer) on MR- and TRUS-guided biopsy was defined as a GS 
≥4+3 or GS 3+4 (>4mm, or >1 positive core), or a GS 3+3 with a core length >6mm. 
Furthermore, a GS 3+3 was defined as significant prostate cancer when more than 
1 or 2 cores were positive on MR- and TRUS-guided biopsy, respectively (13). Thus, 
for lesions with a GS 3+3 the number of cores was modality specific. 
Biopsy outcome
Results were described on a segment, lesion and patient level. 
1. Segment: Cancer locations were reported according to an adapted scheme 
as described by Barentsz et al. (16) (Fig. 2). Two readers (MS and ML), 
both with 2 years of experience in multi-parametric MRI of the prostate, 
determined in consensus the involved segments of the earlier defined CSL 
on multi-parametric MRI. Segments with suspicion on multi-parametric MRI 
(PI-RADS 3-5) were labeled as cancer when histopathologically proven 
with MR-guided biopsy. With TRUS-guided biopsy, 6 lateral and 6 medial 
samples from the posterior base, mid and apex were obtained according to 
a standard scheme for initial biopsy (2). A positive biopsy core was assigned 
to the corresponding segment(s). Segments of significant prostate cancer 
lesions (defined below) that were cancer positive on only one modality were 
considered as locations missed with the other modality. It should be noted 
that “missed with MR-guided biopsy” can be the results of not identifying a 
CSL on multi-parametric MRI, or incorrect needle positioning during the MR-
guided biopsy procedure. 
2. Lesion:  
a TRUS-guided biopsy: All cancer positive segments (Fig. 2) that had a  
 direct connection (neighbouring segments in the anterior-posterior,  
 left-right or superior-inferior direction) were labelled as a single lesion.  
b  MR-guided biopsy: All cancer suspicious segments seen on the   
 diagnostic multi-parametric MRI that had a direct connection were  
 labelled as a single lesion when cancer was proven in at least one of  
 these segments with MR-guided biopsy. Lesions with ≥1 matching  
 segment on MR- and TRUS-guided biopsy were defined as the same  
 lesion. To determine whether a lesions contained significant prostate  
 cancer each lesion was evaluated separately by using the same criteria  
 applied on a patient level. The maximum cancer core length (MCCL)  
 and total cancer core length (TCCL) were determined to evaluate  
 tumour volume.
3. Patient: Three groups were defined: patients with significant prostate 
cancer detected with MR-guided biopsy alone (group 1) or TRUS-guided 
biopsy alone (group 2) and with both techniques (group 3).
The highest GS was determined on a patient and lesions level by combining 
histopathology from MR- and TRUS-guided biopsy.
Statistics
One-way ANOVA was performed to determine significant differences in age, PSA 
or prostate volume. The proportions of cancer positive segments were expressed 
as percentages, and the corresponding 95%CIs were calculated. The Fisher’s 
exact test was performed to determine significant differences between groups. 
The Wilcoxon-signed rank test was used to determine significant differences 
between the MCCL and TCCL found with MR- and TRUS-guided biopsy. Since 
patients served as their own control we used the McNemar’s test to detect a 
significant difference between the association of MR- and MR-guided biopsy and 
outcome. A significant difference was considered when the p-value was <0.05. 
The Standards for Reporting of Diagnostic Accuracy Studies (STARD) guidelines 
were followed to report the results. All analyses were performed with SPSS 
software (version 20.0, IBM). 
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Figure 2: Distribution maps of cancer positive segments in patients with significant prostate 
cancer on MR-guided biopsy (left) and TRUS-guided biopsy (right). The anterior portion 
of the prostate was defined by a hypothetical line drawn 17mm anterior from the posterior 
prostatic surface irrespective of prostate size, which represents the core length commonly 
used during TRUS-guided biopsy (17).
SV = seminal vesicles.
Cancer positive on MR-guided biopsy Cancer positive on TRUS-guided biopsy
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Results
Patient characteristics and histopathological outcome of the 223 included patients 
are shown in Tables 1 and 2 and reported before (13). 
Patient basis
Combined histopathology from MR- and TRUS-guided biopsy revealed prostate 
cancer in 64% of the patients (142/223, 95% CI; 57-70%) and 48% (108/223, 95% 
CI; 42-55%) of the cases showed significant prostate cancer. MR- and TRUS-guided 
biopsy detected significant prostate cancer in 42% (93/223) and 35% (79/223) of 
the patients, respectively and this was statistically significant different (p<0.0001). 
Low-risk cancer was significantly (p<0.0001) more often detected with TRUS-
guided biopsy (21%, 47/223) compared to MR-guided biopsy (3%, 6/223). In 
patients diagnosed with significant prostate cancer on MR- and TRUS-guided 
biopsy upgrading of the GS was seen in 32% (35/108) with MR-guided biopsy and 
in 22% (24/108) with MR-guided biopsy, this was statistically significant different 
(p<0.001). 
In 15 patients significant prostate cancer was detected with TRUS-guided biopsy 
only (3 PI-RADS 3, 7 PI-RADS 4-5, and in 5 patients no CSLs were seen on multi-
parametric MRI). Retrospectively, in 6/10 patients with a PI-RADS ≥3 the MR-
guided biopsy needle was not in the correct position and in 1 patient the images 
of the MR-guided biopsy were not stored and thus not available for re-evaluation.
Anterior tumor involvement was seen in 41% (44/108, 95% CI; 31-50%) of the 
patients with significant prostate cancer.
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All patients Significant PCa detected with:
Included 
patients
negative 
on MR- 
and TRuS-
guided 
biopsy
MR-
guided 
biopsy 
only 
(group 1)
TRuS-
guided 
biopsy 
only 
(group 2)
both 
modalities 
positive 
(group 3)
p-value
Number 
of patients 
(%)
223 (100) 81 (36.3) 29 (13.0) 15 (6.7) 64 (28.7) NA
Mean age 
(SD) years 62.4 (7.4) 59.6 (7.2) 63.5 (7.0) 62.7 (5.8) 65.5 (6.7) 0.2
Mean PSA 
(SD) ng/
ml
5.9 (3.1) 5.1 (2.2) 6.7 (4.5) 4.9 (1.0) 7.1 (3.5) 0.1
Mean 
prostate 
volume 
(SD) cc
46.8 (22.6) 56.2 (24.4) 40.0 (17.1) 40.0 (10.1) 39.0 (19.9) 1.0
Table 1: Patient characteristics of all included patients in whom cancer was not detected, and 
patients in which prostate cancer was detected with MR-guided biopsy only (group 1), TRUS-
guided biopsy only (group 2) and both modalities (group 3). The p-value of one way ANOVA is 
given for the comparison between groups 1-3.
PSA = Prostate specific antigen. PCa = prostate cancer. SD = standard deviation
TRUS-guided biopsy
no 
cancer
Low-risk Pca Significant Pca
Gleason 
3+3 low 
volume
Gleason 
3+4 low 
volume
Gleason 
3+3 
high 
volume
Gleason 
3+4 
High 
volume
Gleason 
≥ 4+3
totals
M
R
-g
u
id
ed
 b
io
p
sy
no cancer 81 23 8 3 4 5 124
Low-risk
Pca 
Gleason 
3+3 low 
volume
0 1 1 1 1 1 5
Gleason 
3+4 low 
volume
0 1 0 0 0 0 1
Signifi -
cant 
Pca
Gleason 
3+3 high 
volume
3 2 2 1 2 0 10
Gleason 
3+4 
High 
volume
8 4 3 2 16 7 40
Gleason 
≥ 4+3
5 0 2 0 4 32 43
totals 97 31 16 7 27 45 223
Table 2: Histopathological biopsy outcome on a per patient level for MR- and TRUS-guided 
biopsy for the total cohort of 223 men. Green shading indicates patients where MR-guided 
biopsy upgraded the Gleason score in relation to TRUS-guided biopsy. Analogous blue shading 
indicates patients where TRUS-guided biopsy upgraded the Gleason score in relation to MR-
guided biopsy. A dark color represents a larger discrepancy between the two modalities.
PCa = prostate cancer.
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Lesion basis 
In total 191 lesions were found in 108 patients with significant prostate cancer 
(Table 3). From these lesions 74% (141/191, 95% CI; 68-80%) were defined as 
significant prostate cancer on either MR- or TRUS-guided biopsy. MR-guided 
biopsy detected 74% (105/141) of these lesions, and this was 61% (86/141) with 
TRUS-guided biopsy (13% difference, 95% CI; 8-19%). In 37% (64/175, 95% CI; 30-
44%) of the CSLs seen on multi-parametric MRI no prostate cancer was found with 
MR-guided biopsy. Reasons for failure of MRI to identify cancer lesions are shown 
in table 4.
In 15 patients in which significant prostate cancer was detected with TRUS-
guided biopsy only, 26 lesions were detected of which 50% (13/26, 95% CI; 31-
69%) contained significant prostate cancer. In retrospect (with knowledge of the 
cancer locations from MR-guided biopsy) 8 lesions could be defined as significant 
on multi-parametric MRI. In 3 of these significant prostate cancer lesions, low-risk 
cancer was diagnosed with MR-guided biopsy and 5 significant prostate cancer 
lesions were not seen on the initial detection MRI. 
TRUS-guided biopsy detected more lesions (73%, 140/191) compared to MR-guided 
biopsy (57%, 109/191) (16% difference, 95% CI; 12-21%). However, more lesions were 
low-risk prostate cancer (28%, 54/191) compared to MR-guided biopsy (2%, 4/191) 
(26% difference, 95% CI; 20-32%). 
The MCCL and TCCL of lesions solitary detected with TRUS-guided biopsy were 
significantly (p<0.0001) smaller than MR-guided biopsy lesions (Table 5 - page 58). 
In patients diagnosed with significant prostate cancer on MR- and/or TRUS-guided 
biopsy upgrading of the GS was seen in 41% (58/141) with MR-guided biopsy and in 
35% (49/141) with TRUS-guided biopsy (6% difference, 95% CI; 3-11%). 
Anterior tumor involvement was seen in 31% (44/140, 95% CI; 24-39%) of the 
significant prostate cancer.
Segment basis
MR- and TRUS-guided biopsy identified 277 and 347 cancer positive segments 
respectively in patients with significant prostate cancer. The distribution of these 
segments is shown in Figure 2. With MR- and TRUS-guided biopsy, most cancer 
positive segments were located in the mid prostate; 53% (147/277, 95% CI; 47-
59%) and 37% (128/347, 95% CI; 32-42%) respectively. In total, 39% (109/277, 95% 
CI; 34-45%) of MR-guided positive segments were located in the anterior part of 
the prostate.
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TRUS-guided biopsy
no 
cancer
Low-risk Pca Significant Pca
Gleason 
3+3 low 
volume
Gleason 
3+4 low 
volume
Gleason 
3+3 
high 
volume
Gleason 
3+4 
High 
volume
Gleason 
≥ 4+3
totals
M
R
-g
u
id
ed
 b
io
p
sy
no cancer  36 12 5 14 15 82
Low-risk
Pca 
Gleason 
3+3 low 
volume
1 0 0 1 0 1 3
Gleason 
3+4 low 
volume
1 0 0 0 0 0 1
Signifi -
cant 
Pca
Gleason 
3+3 high 
volume
7 1 1 0 4 0 13
Gleason 
3+4 
High 
volume
24 3 1 1 9 9 47
Gleason 
≥ 4+3
18 0 0 0 2 25 45
totals 51 40 14 7 29 50 191
Table 3: Highest Gleason score for all lesions (n=191) detected with MR- and TRUS-guided 
biopsy in patients with significant cancer (n=108). Green shading indicates patients where MR-
guided biopsy upgraded the Gleason score in relation to TRUS-guided biopsy. Analogous blue 
shading indicates patients where TRUS-guided biopsy upgraded the Gleason score in relation 
to MR-guided biopsy. A dark color represents a larger discrepancy between the two modalities. 
PCa = prostate cancer. 
Table 4: Reasons for failure of MRI to identify cancer lesions. 
PCa = prostate cancer. 
Situation Low-risk Significant PCa All lesions
Lesions detected with TRUS-
guided biopsy in all patients
93 86 179
Lesions detected with MR-
guided biopsy in all patients
10 105 115
Negative multi-parametric 
MRI but positive TRUS-guided 
biopsy (likely reading failure)
81 33 114
Positive multi-parametric MRI 
but negative MR-guided biopsy 
and negative TRUS-guided 
biopsy (likely reading failure)
0 0 56
Positive multi-parametric MRI 
and positive TRUS-guided 
biopsy but negative MR-guided 
biopsy (likely sampling failure)
5 3 8
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significant prostate cancer is associated with increased age, PSA level and a 
small prostate volume (22). Although not statistically significant the patient 
characteristics in our study (Table 1) confirm these relations, but the PSA levels 
in patients with significant prostate cancer detected with TRUS-guided biopsy 
(group 2) did not confirm this relation. 
Multi-parametric MRI evaluation can be difficult in the apex given the small size 
of this region and its location at the margin of the prostate (12). Also, some focal 
lesions might be unnoticed on standard DWI protocols due to signal received from 
surrounding benign prostatic tissue which overshadows the lesion (11). This may 
be overcome by using high b-values (1400-2000 s/mm2) (11, 16). In our diagnostic 
protocol we used a calculated b-value of 1400 s/mm2 which may not be sufficient. 
Furthermore, from the 67 lesions seen on multi-parametric MRI which were negative 
on MR-guided biopsy only 3 lesions contained significant prostate cancer on TRUS-
guided biopsy, which suggests these CSLs were false-positive on multi-parametric 
MRI rather than being missed with MR-guided biopsy. 
The relatively high involvement of dorsolateral segments in significant prostate 
cancer lesions missed with MR-guided biopsy might be explained by subcapsular 
tumours (12). Critical evaluation of small areas with abnormal signal intensity on DWI 
and dynamic contrast enhanced (DCE) images in the absence of a readily apparent 
mass abutting the capsule is recommended (12). Furthermore, since the exact needle 
location is not known with TRUS-guided biopsy some lateral biopsy samples can be 
false-positive. This may occur in case the biopsy core was located in both the medial 
and lateral segments but the tumor is confined within the medial segment.
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In lesions with significant prostate cancer, MR- and TRUS-guided biopsy missed 
97 and 111 segments respectively (Fig. 3). Lesions missed with MR-guided biopsy, 
which had significant prostate cancer detected with TRUS-guided biopsy, appear 
to be located in the apex (37%, 36/97, 95% CI; 28-47%) and dorsolateral segments 
(58%, 56/97, 95% CI; 47-67%). Missed significant prostate cancer lesions on TRUS-
guided biopsy had most often involvement of anterior segments (79%, 88/111, 95% 
CI; 71-86%). Specifically: anterior mid prostate (50%, 56/111, 95% CI; 41-60%) and 
anterior apex (23%, 25/111, 95% CI; 15-31%). 
Discussion
This paper extrapolates on a previously published study, but focuses on lesions 
missed with MR- and TRUS-guided biopsy. Significant prostate cancer lesions 
missed with MR-guided biopsy most often had involvement of the dorsolateral 
(58%) and apical (37%) segments. With TRUS-guided biopsy, missed significant 
prostate cancer lesions had involvement of segments located anteriorly (79%), 
anterior mid prostate (50%) and anterior apex (23%). Anterior tumor involvement 
was seen in 41% of the patients, which is consistent with the literature (18). Lesions 
localized in the apical region were difficult to detect with both modalities, which 
is also concordant with the literature (18-21). 
Figure 3: Distribution maps of the segments of significant prostate cancer lesions that were 
missed with MR-guided biopsy (left) and TRUS-guided biopsy (right). 
SV = seminal vesicles.
Missed segments with MR-guided biopsy Missed segments with TRUS-guided biopsy
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Table 5: Differences between mean maximum cancer core length (MCCL) and total cancer 
core length (TCCL) in patients with significant cancer. The p-value of the Wilcoxon-signed 
rank test is provided. 
Situation MR-guided 
biopsy
TRUS-guided 
biopsy
p-value  
(MR-guided 
biopsy vs TRUS-
guided biopsy)
All lesions 109 140 NA
Number of missed lesions 82 51 NA
Number of missed significant 
lesions
34 49 NA
Mean MCCL (mm) of lesions 
detected with both modalities 
(SD):
10.0 (4.6) 9.5 (4.7) 0.64
Mean TCCL (mm) of lesions 
detected with both modalities 
(SD):
19.6 (12.3) 24.2 (21.1) 0.17
Mean MCCL (mm) of missed 
lesions and thus solitary 
detected with the other 
modality (SD):
3.4 (3.4) 8.6 (4.2) <0.0001
Mean TCCL (mm) of missed 
lesions and thus solitary 
detected with the other 
modality (SD)
6.6 (8.6) 16.9 (10.2) <0.0001
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Ukimura et al. recommends sampling according to a medial sextant pattern with ≥4 
cores from the lateral peripheral zone. Furthermore, this review advises obtaining 
samples from the anterior apex, anterior lateral horn and anterior transition zone 
in the repeat biopsy setting (2). The results found in our study confirm these 
recommendations. 
To our knowledge this is the first study which describes the differences between 
MR- and TRUS-guided biopsy regarding cancer location in biopsy naïve men at 
risk for prostate cancer. The results have clinical implications for both radiologists 
and urologists. For example, to optimize biopsy sites for TRUS-guided biopsy 
and systematic sampling with MRI targeted TRUS-biopsy (23). Based on our 
observation it is reasonable to obtain additional samples at initial TRUS-guided 
biopsy from the anterior apex and anterior mid prostate since these are the most 
common sites where cancer is missed. Adding cores in the extreme anterior apex 
has been shown to be beneficial (24). Similarly, it might be reasonable to obtain 
additional random biopsies from dorsolateral and apical regions during multi-
parametric MRI targeted TRUS-guided biopsy to improve detection of significant 
prostate cancer without the need for systematic 12-core biopsy (25). 
Regarding costs and patients comfort TRUS-MRI fusion is an interesting alternative 
for MR-guided biopsy (26). Although there is no study comparing multi-parametric 
MRI targeted TRUS-guided biopsy and in-bore MR-guided biopsy, the visual 
feedback regarding the accuracy of needle placement makes the in-bore MR-
guided biopsy, to our opinion, more accurate. 
In our study only 18% of the patients with a PI-RADS 3 lesion on multi-parametric 
MRI had significant prostate cancer. This figure was 89% in patients with a PI-RADS 
4,5 lesion. Although considerable efforts have been undertaken to determine 
the optimal threshold for biopsy, this is still a topic of debate (27). Based on the 
findings from our study it might be interesting to investigate a region-dependent 
threshold for biopsy. For example, a threshold of PI-RADS 3 for lesions in the apical 
and dorsolateral regions and a threshold of PI-RADS 4,5 for lesions elsewhere in 
the prostate. 
Some limitations of this study should be addressed. Firstly, there is no universally 
accepted and validated definition for significant prostate cancer (28). The 
modality-specific definition used in our study make the results difficult to compare 
with other studies. Furthermore, in the case in which a patient has multiple low-
risk lesions, this definition can diagnose a patient as having significant prostate 
cancer without having a discrete significant prostate cancer lesion. However, this 
definition was created to allow comparison of two to four MR-guided biopsy cores 
with 12-cores obtained with TRUS-guided biopsy.
Secondly, whole mount prostatectomy would be the most reliable tool for 
histopathologic evaluation but is ethically impossible in patients with no proven 
cancer on biopsy. An alternative approach is to use 5mm transperineal template 
prostate mapping (4). The need for general anesthesia and increased complication 
rate makes this a highly invasive technique and presents challenges in recruiting 
patients for clinical trials when less invasive alternatives are available (4). 
Third, a sub-analysis of patients who underwent prostatectomy would provide an 
excellent reference standard, however this may have introduced selection bias. By 
comparing the biopsy results between MR- and TRUS-guided biopsy we were able 
to directly compare differences between these modalities in a large patient group. 
Conclusions
Both MR- and TRUS-guided biopsy have difficulties in detecting apical lesions. MR-
guided biopsy most often missed cancer with involvement of the dorsolateral part 
(58%) and TRUS-guided biopsy missed lesions with involvement of the anterior 
part (79%).
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Abstract
Purpose: To determine if prostatitis and prostate cancer can be distinguished 
by using apparent diffusion coefficients (ADCs) on magnetic resonance 
(MR) images, with specimens obtained at MR-guided biopsy as the standard 
of reference. 
Materials and Methods: The need for institutional review board approval and 
informed consent was waived. MR-guided biopsies were performed in 130 
consecutive patients with cancer-suspicious regions (CSLs) on multi-parametric 
MR images obtained at 3T. In this retrospective study, 88 patients met the inclusion 
criteria. During the biopsy procedure, an axial diffusion-weighted sequence was 
performed and ADC maps were generated (repetition time ms/echo time ms, 
2000/67; section thickness, 4 mm; in-plane resolution, 1.8 x 1.8 mm; and b-values 
of 0, 100, 500, and 800 s/mm2). Subsequently, a confirmation image with the 
needle left in situ was acquired and projected on the ADC map. The corresponding 
ADCs at the biopsy location were compared with the histopathologic outcomes 
of the biopsy specimens. Linear mixed-model regression analyses were used to 
test for ADC differences between the histopathologic groups. 
Results: The study included 116 biopsy specimens. Median ADCs of 
normal prostate tissue, prostatitis, low-grade prostate cancer (Gleason 
grade components 2 or 3), and high-grade prostate cancer (Gleason 
grade components 4 or 5) were 1.22 x 10−3 mm2/s (standard deviation, 
± 0.21), 1.08 x 10−3 mm2/s (± 0.18), 0.88 x 10−3 mm2/s (± 0.15), and 0.88 x 10−3 mm2/s 
(± 0.13), respectively. Although the median ADCs of biopsy specimens with 
prostatitis were significantly higher compared with low- and high-grade prostate 
cancer (P <0.001), there is a considerable overlap between the tissue types. 
Conclusion: Diffusion-weighted imaging is a non invasive technique that shows 
differences between prostatitis and prostate cancer in both the peripheral zone 
and central gland, although its usability in clinical practice is limited as a result of 
significant overlap in ADC values. 
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Introduction
Urologists often face the dilemma of treating a patient in whom there is a high 
suspicion for prostate cancer based on an elevated prostate-specific antigen 
(PSA) level (1-3). Benign prostatic hyperplasia can also lead to elevated PSA levels 
and is not always associated with clinical symptoms. Therefore, differentiation 
between prostate cancer and benign prostatic hyperplasia in the central gland 
(CG) is a major challenge for the urologist and also for the radiologist. Prostatitis 
is normally a diffuse disease, whereas benign prostatic hyperplasia and tumour 
normally present as focal disease. Prostatitis can be a cause of an elevated PSA 
level; however, this is clinically a difficult diagnosis. As a consequence, prostatitis 
patients will undergo transrectal ultrasonography (TRUS)-guided biopsy 
sessions. Moreover, prostate cancer can still be present in patients with biopsy-
proved prostatitis. This illustrates the need for a non invasive diagnostic test that 
can be used to differentiate between prostate cancer and prostatitis (4). 
Magnetic resonance (MR) imaging of the prostate is the imaging modality of 
choice in prostate cancer detection, localization, and staging (5-8). The diagnostic 
value of anatomic T2-weighted MR imaging in discriminating prostate cancer 
from benign prostate tissue is limited. The interpretation of these images can be 
affected by false-positive findings such as prostatitis, post biopsy haemorrhage, 
and fibrosis (9-11). To improve the diagnostic accuracy of prostate MR imaging, 
functional imaging techniques have been applied, such as dynamic contrast-
enhanced MR imaging (12-14), proton MR spectroscopic imaging (15-17), and 
diffusion-weighted (DW) MR imaging (18-21), with limited success to date. 
DW imaging has been shown to aid in distinguishing between malignant and 
benign prostate tissue based on relatively lower apparent diffusion coefficients 
(ADCs) of cancer tissue (22-35). The correlation between the ADC and tissue 
is usually done by using TRUS-guided biopsy and step-section specimens after 
prostatectomy as a standard of reference (31-35). Even using improved correlation 
methods (35) there is still an uncertainty whether the correct tissue is sampled 
and correlated with imaging. 
MR-guided biopsy may overcome the latter limitations. A confirmation MR image 
can be acquired with the needle left in situ. This allows for an accurate verification 
of the biopsy location in the cancer suspicious lesion (CSL) and correlation with 
the ADC map. Therefore, the purpose of our study was to determine if prostatitis 
and prostate cancer can be distinguished by using ADCs on MR images, with 
specimens obtained at MR-guided biopsy as the standard of reference. 
Materials and methods 
Patients
Institutional review board approval was not required, and the need for informed 
consent was waived.
Between October 2008 and March 2010, 130 consecutive patients underwent 
MR-guided prostate biopsy of CSLs seen on previous diagnostic 3T MR prostate 
images and were eligible for inclusion this retrospective study. MR-guided biopsy 
was performed in male patients with (a) an elevated PSA level (>4 ng/mL), (b) 
family history of prostate cancer, (c) suspicion for prostate cancer based on 
diagnostic MR examination of the pelvis, and (d) at least one negative TRUS-
guided biopsy. Inclusion criterion for this study was that a DW sequence was 
performed at both the diagnostic MR examination and the MR-guided biopsy 
examination (Fig. 1). Exclusion criteria for this study were patients with suspicion 
of recurrent prostate cancer after therapy (prostatectomy, radiation therapy, 
chemotherapy, cryosurgery, or high-intensity focused ultrasound therapy), 
and biopsy specimens that could not be categorized within the following 
histopathologic groups: normal prostate tissue, prostatitis, low-grade prostate 
cancer (Gleason grade components 2 or 3) and high-grade prostate cancer 
(Gleason grade components 4 or 5). Eighty-eight patients met the inclusion 
criteria and were included for further analysis.
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Diagnostic MR imaging
Before the biopsy procedure, a diagnostic MR examination was performed 
with a 3T MR imager (Trio Tim; Siemens, Erlangen, Germany). This multi-
parametric detection and localization examination consisted of T2-weighted 
imaging, DW imaging, and dynamic contrast-enhanced MR imaging (36). 
Peristalsis was suppressed with an intramuscular administration of 20 mg 
butylscopolaminebromide (Buscopan; Boehringer-Ingelheim, Ingelheim, 
Germany) and 1 mg of glucagon (Glucagen; Nordisk, Gentofte, Denmark). 
The imaging protocol included the following sequences (Table 1): First, a T2-
weighted turbo spin-echo sequence was performed in three planes. Second, 
a single-shot echo-planar imaging sequence with diffusion modules and fat 
suppression pulses was performed. The imager software automatically calculated 
ADC maps. Third, three-dimensional T1-weighted spoiled gradient-echo 
images were acquired during an intravenous bolus injection of a paramagnetic 
gadolinium chelate, 0.1 mmol of gadopentetate dimeglumine (Dotarem; Guerbet, 
Paris, France) per kilogram of body weight, which was administered with a power 
injector (Spectris Medrad, Warrendale) at 2.5 mL/s and followed by a 15 mL saline 
flush. With this sequence, a three-dimensional volume covering the entire prostate 
was acquired every 2.5 s during 210 s, with the same positioning angle and centre 
as the transverse T2-weighted sequence. Before contrast material injection, the 
same transverse three-dimensional T1-weighted gradient-echo sequence (with 
the exception of repetition time ms/echo time ms, 800/1.6, and flip angle of 8°) 
was used to obtain proton-density images, with identical positioning to allow 
calculation of the relative gadolinium chelate concentration curves.
Diagnostic MR image interpretation
The diagnostic MR images were analyzed with an in-house developed analytical 
software workstation that calculated the dynamic contrast-enhanced MR 
imaging parameters and projected these parameters as colour overlay maps 
over the T2-weighted images (37, 38). Images of all patients were read by two 
radiologists in consensus with 15 years (J.O.B.) and 7 years (J.J.F.) of experience 
in prostate MR imaging. The high-spatial-resolution, axial T2-weighted images 
were used as basis for evaluation of the prostate, and all other functional imaging 
modalities were interpreted in relation to these. On T2-weighted images, the 
generally known prostate cancer detection criteria were used to determine CSLs. 
These included low-signal-intensity areas in the peripheral zone (PZ) and/or a 
homogeneous low T2 signal intensity area with ill-defined margins or a lenticular 
shape within the CG (39). After identification of CSLs on T2-weighted images, 
the ADC maps and multi-parametric dynamic contrast-enhanced MR imaging 
colour maps transfer constant (Ktrans), extravascular extracellular volume (ve), rate 
constant (Kep), and washout were analyzed in a colour overlay mode on the T2-
weighted images. The generally known features of prostate cancer on dynamic 
contrast-enhanced MR images (13, 40) (high ve, K
trans, Kep, and negative washout) 
and areas of restriction on ADC maps (especially in the PZ and CG) were used 
to identify CSLs qualitatively (38). Additionally, after the functional data from 
DW and dynamic contrast-enhanced MR imaging were evaluated in relation to 
the CSL findings on the T2-weigthed images, the DW and dynamic contrast-
enhanced MR images were viewed separately and in combination to determine 
additional CSLs not evident on T2-weighted images. Finally, the information from 
all the imaging modalities were combined and used to determine the CSLs within 
the PZ and CG of the prostate (38). 
MR-guided biopsy protocol
In a second session, prostate biopsies were performed in the same MR imager 
with a dedicated MR-compatible biopsy device (Invivo, Schwerin, Germany) (38, 
41-43). As previously described, the patient was placed in a prone position and 
the rectally inserted needle sleeve was attached to the arm of the MR-compatible 
biopsy device. A pelvic phased-array coil was used for signal reception (36, 38). 
Identification of the CSL, determined during the initial MR examination, was 
achieved by using the following MR sequences (Table 1): First, an axial T2-
weighted turbo spin-echo sequence was performed. Second, an axial DW 
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Imaging 
Protocol
Sequence Repe- 
titions  
time 
(ms)
Echo 
time 
(ms)
Flip 
angle 
(degree)
Voxel 
size 
(mm3)
b-values 
(s/mm2)
Temporal 
resolu- 
tion (s)
diagnostic MR imaging session 
T2WI Axial turbo 
spin-echo
3620 116 180 0.4 x 
0.4 x 
3.0
NA NA
DW Single-shot 
echo-planar 
with diffusion 
modules and 
fat suppression 
pulses
2500 91 1.5 x 1.5 
x3 3.0
0, 50, 
500, 
and 
800
NA
DCE 3D T1-weighted 
spoiled 
gradient echo
34 1.6 14 1.5 x 1.5 
x 4.0
NA 2.5
Proton 
density
3D T1-weighted 
spoiled 
gradient echo
800 1.6 8 1.5 x 1.5 
x 4.0
NA NA
MR-guided biopsy session 
True 
FISP
True FISP 4.48 2.24 70 1.1 x 1.1 x 
3.0
NA NA
DW Single-shot 
echo-planar 
with diffusion 
modules and 
fat suppression 
pulses
2000 67 1.8 x 1.8 x 
4.0
0, 100, 
500, 
and 
800
NA
T2WI Axial turbo spin-
echo
3620 104 120 0.8 x 0.8 
x 4.0
NA NA
Table 1: Imaging parameters. DCE = dynamic contrast enhanced, NA = not applicable, 3D = 
three dimensional, T2-weighted MR imaging
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sequence was performed with a single-shot echo-planar imaging sequence with 
diffusion modules and fat suppression pulses. Water diffusion in three directions 
was measured by using four b-values. Finally, the imager software calculated 
ADC maps automatically (Fig. 2).
After identification of the CSLs, adjustments were applied to the biopsy device 
to move the needle sleeve exactly toward a CSL (41, 42). To control needle sleeve 
direction, T2-weighted true fast imaging with steady precession (FISP) images 
were acquired in the axial and sagittal direction. Biopsy was performed in all 
determined CSLs on the diagnostic MR images, even if they were not visible on 
the T2-weighted anatomic MR images obtained at the time of biopsy. In these 
cases, the DW MR images were used to move the needle sleeve toward the CSL. 
After fixation of the needle sleeve in the correct position, one or more tissue 
samples were taken at the region with lowest ADCs in each CSL with an 18-gauge, 
fully automatic, core needle, double-shot biopsy gun (Invivo) with a needle length 
of 150 or 175 mm and tissue sampling core length of 17 mm. After obtaining 
a biopsy specimen, fast T2-weighted axial and sagittal true-FISP images were 
obtained with the needle left in situ. 
MR image correlation
During the biopsy session, at least one biopsy specimen was obtained from each 
CSL. The biopsy specimen that was located in the most diffusion-restricted area 
of each CSL was selected for image analysis. This was performed by using the 
true-FISP confirmation image and the corresponding ADC map obtained during 
the biopsy session. Some patients had multiple CSLs. The CSLs of all patients 
were analyzed without knowledge of the histopathologic outcomes. MR images 
of the biopsy specimens were analyzed with an in-house developed analytical 
software workstation (37). The calculated ADC maps were projected on the post 
biopsy T2-weighted true-FISP images (confirmation image with the needle left in 
situ) to determine the biopsy location. By using this location, a region of interest 
was drawn manually with the size and extent of the most diffusion-restricted 
region on the ADC map, representing the biopsied CSL (Fig. 3). In case of the 
absence of restricted diffusion on the ADC maps, a low-signal-intensity area 
on T2-weighted images was used to draw the region of interest. All regions of 
interest were annotated in consensus by two radiologists (T.H., J.J.F.). Of each 
region of interest, the median and standard deviation of the ADC values were 
calculated (median size, 51; range 8-335 voxels). Multiple regions of interest were 
obtained in case a patient had multiple CSLs.
Histopathologic evaluation
Biopsy specimens were processed by means of a routine fixation in formaldehyde, 
embedded in paraffin, and stained with hematoxylin-eosin before being evaluated 
by a pathologist for the presence of prostate cancer or other benign pathologic 
lesions. Biopsy specimens with prostate cancer were graded according to the 
2005 ISUP Modified Gleason Grading System (44). 
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Figure 3: Images obtained in a 66-year-old man (PSA = 21.6 ng/mL) with a CSL in the PZ. Biopsy 
revealed a Gleason grade 3 + 3 prostate cancer. (A) The CSL (red circle) at pre biopsy MR imag-
ing is visible on the ADC map, calculated from an axial single-shot echo-planar DW image by 
using three orthogonal diffusion gradients (2000/67; b = 0, 100, 500, and 800 s/mm2). (B) Con-
trol T2-weighted true-FISP image (4.48/2.24) obtained during biopsy in axial and sagittal plane 
shows the position of the biopsy needle (dashed blue line) with a sampling core length of 17 mm 
(green line). (C) After projection of the ADC map on the true-FISP image, (D) a region of interest 
was drawn manually with the size and extent of the restricted diffusion region on the ADC map.
Figure 2: ADC maps calculated from a single-shot echo-planar DW image in three orthogonal 
diffusion gradients (2000/67; b = 0, 100, 500, and 800 s/mm2) in the axial plane in two men 
with a CSL in the CG. (A) Image in a 72-year-old man (PSA = 22.1 ng/mL) shows a CSL (red 
circle) with a median ADC of 0.97 x 10−3 mm2/s. Histopathologic examination of the correspond-
ing biopsy specimens revealed prostatitis. (B) Image in a 65-year-old man (PSA = 30.0 ng/mL) 
shows a suspicious region (red circle) with a median ADC of 0.83 x 10−3 mm2/s. Histopathologic 
examination of this biopsy specimen revealed low-grade prostate cancer (Gleason grade 3 + 3).
A
A
c
b
b
d
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Statistical Analysis
A Mann-Whitney U test was performed to determine how ADC operates as a 
discriminatory test between prostatitis and CSLs. We have studied data summaries 
by region in addition to histopathologic grouping. The analyses were conducted 
by using linear mixed-effects regression models without autoregressive time-
component, because in some patient multiple regions of interest were drawn. 
The significance level was set at a P value of less than 0.05. All analyses were 
performed with statistical software (SPSS, version 18.0.0; SPSS, Chicago, Ill). 
Results 
In our study, 88 of the 130 consecutive patients with CSLs on diagnostic MR 
images met the inclusion criteria and were included in our study (Table 2). 
These patients had one (n=62), two (n=24) or three CSLs (n=2). A total of 136 
MR-guided prostate biopsy specimens were obtained. Twenty biopsy specimens 
could not be categorized within the defined histopathologic groups (Table 2) and 
were excluded from further analysis. Consequently, 116 biopsy specimens were 
included and divided in four histopathologic classified groups: normal prostate 
tissue (32), prostatitis (42), low-grade prostate cancer (25), and high-grade 
prostate cancer (17). The 42 cancer-positive biopsy specimens were obtained 
from 39 patients. Patient and biopsy characteristics of these groups are shown 
in Table 3. In six cases, the determined CSLs on the initial diagnostic MR images 
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Table 2: Biopsy findings excluded from analysis. Data are numbers of patients excluded or 
numbers of biopsy specimens excluded (among included patients). HIFU = high-intensity fo-
cused ultrasound, PIN = prostate intraepithelial neoplasia.
Reason for exclusion Number excluded
Excluded patients 42
Prostate treatment (prostatectomy, radiation therapy, 
chemotherapy, cryosurgery, or HIFU therapy)
32
Deviating biopsy specimens 10
Atrophic tissue 4
Atypical adenomatous 1
High-grade PIN 3
Nonprostate tissue 2
Excluded biopsy specimens of included patients 20
Atrophic tissue 3
Atypical adenomatous hyperplasia 4
High-grade PIN 4
Nonprostate tissue 9
Characteristic All 
patients
Normal 
tissue
Prosta- 
titis
Low-
grade 
PCa
High-
grade 
PCa
Exclu-
ded 
tissue
No. of included patients 88
No. of included biopsy 
specimens
116 32 42 25 17
No. of excluded biopsy 
specimens
20 20
Median no. of previous negative 
TRUS-guided biopsy sessions
2 (0-6) 2 (0-6) 2 (1-5) 2 (0-5) 3 (1-4)
Mean age (y) 63 (44-
76)
62 (52-
76)
63 (50-
73)
63 (44-
72)
67 (56-
73)
Median PSA  
(ng/mL)
11.0 
(0.1-
58.0)
11.1 
(0.8-
36.0)
10.9 
(0.1-
30.2)
10.0 
(1.2-
51.0)
15.0 
(18.0-
51.0)
Median prostate volume (mL) 49 (18-
263)
79 (20-
108)
55 (30-
263)
40 (18-
107)
42 (25-
98)
Median time between MR-
guided biopsy and initial 
diagnostic MR examination (wk)
8.9 
(0.0-
31.7)
8.7 
(2.3-
21.0)
8.7 
(0.0-
31.7)
10.0 
(2.1-
31.4)
8.3 
(3.1-
16.4)
Location of cSLs
PZ 69 23 27 14 5
CG 47 9 15 11 12
no. of excluded biopsy specimens among the included patients
Atrophic tissue 3
Atypical adenomatous 
hyperplasia 
4
High-grade PIN 4
Nonprostate tissue 9
Low-grade Pca gleason score
2+3 2
3+2 1
3+3 22
high-grade Pca gleason score
3+4 12
3+5 1
4+3 3
4+5 1
Table 3: Patient and biopsy characteristics. Data are numbers of patients or biopsy specimens, and 
numbers in parentheses are the range. PIN = prostate intraepithelial neoplasia, PCa = prostate cancer
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were not visible on the MR images obtained at biopsy (hereafter, the “biopsy MR 
images”). Although not visible, the suspected area was biopsied. Furthermore, 
no new CSLs were seen on the biopsy MR images. Therefore, the numbers of 
CSLs on the diagnostic and biopsy MR images were equal. During the image 
analysis, 12 CSLs showed a low-signal-intensity area on T2-weigthed images and 
no restricted diffusion on the ADC maps, and 15 CSLs had an area of restricted 
diffusion without abnormality on the T2-weighted images. Discrepancies 
between the CSLs on the diagnostic MR images and the corresponding CSLs 
on the biopsy MR images were found in 5% (six of 116) of the biopsy specimens.
Biopsy specimens with normal prostate tissue, prostatitis, low-grade prostate 
cancer, and high-grade prostate cancer had a mean ADC of 1.22 x 10−3 mm2/s ± 0.21 
(standard deviation), 1.08 x 10−3 mm2/s ± 0.18, 0.88 x 10−3 mm2/s ± 0.15, and 0.88 x 
10−3 mm2/s ± 0.13, respectively (Fig. 4, Table 4). The linear mixed-model analyses 
revealed significant differences between mean ADCs of the groups with normal 
prostate tissue and prostatitis (P = 0.002), the groups with prostatitis and low-
grade prostate cancer (P <0.001), and the groups with prostatitis and high-grade 
prostate cancer (P <0.001). The difference between the mean ADCs of the groups 
with low-grade and high-grade prostate cancer was not significant (P = 0.76).
Also, differences in mean ADCs between the three classified groups were analyzed 
for the PZ and CG. A total of 69 and 47 biopsy specimens were obtained from the 
PZ and CG, respectively. Median ADCs of the classified groups and regions are 
shown in Table 4. The linear mixed-model analyses showed a significant difference 
between the mean ADCs of the biopsy specimens with normal prostate tissue 
and prostatitis in the PZ (P = 0.012). This statistical analysis was not performed 
for the CG, because the number of biopsy specimens with normal prostate tissue 
in the CG was too low (n=9). In both PZ and CG, however, significant differences 
in mean ADCs were found between the groups with prostatitis and low-grade 
prostate cancer (PZ: P = 0.01, CG: P <.001). Furthermore, a significant difference 
was revealed between the groups with prostatitis and high-grade prostate cancer 
in the PZ (P = 0.016). The difference between the mean ADCs of the groups 
with low-grade prostate cancer and high-grade prostate cancer in PZ was not 
significant (P = 0.84). Again, the numbers in the group with high-grade prostate 
cancer in the CG was too low (n=5) to use for statistical analyses. 
Discussion
In our study cohort, we found differences between mean ADCs of biopsy specimens 
with prostatitis and low- and high-grade prostate cancer (P <0.001), even though 
there was a high degree of overlap. It is questionable whether differences in 
mean ADCs of 0.14 x 10−3 mm2/s between the groups with prostate cancer and 
prostatitis, although statistically significant, are also clinically useful. The overlap of 
ADCs between these two histopathologic groups hinders a reliable differentiation 
between prostatitis and prostate cancer in routine clinical practice. Nevertheless, a 
CSL with a mean ADC of less than 0.75 x 10−3 mm2/s appears suspicious for prostate 
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Table 4: Mean ADCs of the histopathologic groups
1 unit of measure is 10-3 mm2/s. 
2 Mean in this histopathologic group is significantly different from that of the reference group, 
prostatitis (P <0.05). 
3 Number of biopsy specimens of this group is too low for reliable statistical analysis.
PCa = prostate cancer, PZ = peripheral zone, CG = central gland, ADC = apparent diffusion 
coefficient. 
PZ CG
group Mean Adc 
± standard 
deviation1
no. of 
specimens
Mean Adc 
± standard 
deviation1
no. of 
specimens 
Normal tissue 1.28 ± 0.222 23 1.03 ± 0.153 9
Prostatitis 1.13 ± 0.20 27 1.02 ± 0.13 15
Low-grade PCa 0.94 ± 0.132 14 0.78 ± 0.152 11
High-grade PCa 0.90 ± 0.133 5 0.86 ± 0.132 12
Figure 4: Box-and-whisker plots for the DW imaging of the suspicious areas according to his-
tologic diagnosis of normal prostate, prostatitis, and low- and high-grade prostate cancer in 
the PZ, CG, and combined PZ and CG. Centre horizontal line = median, bottom and top edges 
of box = 25th and 75th percentiles, vertical line = range of data. 
PZ = peripheral zone, CG = central gland
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cancer (Fig. 4) and a biopsy procedure might be recommended. Future studies will 
be needed that focus on the combined approach of functional imaging techniques 
to reduce the diagnostic overlap between prostatitis and prostate cancer. 
In recent years, several studies have demonstrated significant differences between 
the ADCs of malignant and benign prostate tissue by using TRUS-guided biopsy 
(22-27) or step-section specimens after prostatectomy as reference standard (31-
34). In these previously described studies, mean ADCs for malignant and benign 
prostate tissue varied over a relatively broad range from 0.93 x 10−3 mm2/s to 1.38 
x 10−3 mm2/s and from 1.34 x 10−3 mm2/s to 1.96 x 10−3 mm2/s, respectively. However, 
in our study, mean ADCs were lower for both malignant (range, 0.78 to 0.90 x 
10−3 mm2/s) and benign (range, 0.99 to 1.13 x 10−3 mm2/s) biopsy specimens. This 
may be explained by the fact that the biopsy specimens with normal prostate 
tissue were CSLs based on multi-parametric MR imaging. The regions of interest of 
the previously described studies were annotated without abnormalities on multi-
parametric MR images. This could have resulted in relatively higher ADCs compared 
with our study. 
The prostate cancer detection rate of our study (44%) is lower compared with 
previous reports (52%-59%) (41, 43, 45). This could be explained by inclusion of one 
patient with a low PSA level (0.1 ng/mL) and patients with a positive family history 
of prostate cancer. 
A limited number of studies have assessed the histopathologic findings of CSLs on 
ADC maps with step-section specimens after prostatectomy (31-34). It is difficult to 
correlate the ADC maps with the corresponding histologic slices, since deformation 
and shrinkage of the prostate may occur after prostatectomy. Furthermore, all 
these studies have annotated the CSLs on ADC maps according to step-section 
specimens of the prostate. 
In our study, the time interval between the initial diagnostic MR examination and the 
biopsy session ranged from 0 to 32 weeks. Discrepancies between the CSLs on the 
diagnostic MR images and the corresponding CSLs on the biopsy MR images were 
found in 5% (six of 116) of the biopsy specimens. However, all determined CSLs on 
the diagnostic MR images underwent biopsy, even if they were not visible on the 
biopsy MR images. The image analyses were not negatively affected by large time 
intervals, because the biopsy MR images were used to determine the ADCs of the 
CSLs, instead of the diagnostic MR images. These biopsy MR images were obtained 
on the same day of the biopsy session. Therefore, growth or shrinkage of the CSL 
was minimized. 
Our study had a number of limitations. First, during manipulation of the needle sleeve, 
the prostate may have moved (i.e. due to patient motion, peristaltic movement, and/
or bladder filling). It is therefore imaginable that the ADC map, obtained before the 
needle sleeve manipulation, does not exactly match with the confirmation image on 
which the needle is left in situ. During the image analyses, these movements were 
corrected manually by using anatomic landmarks such as cysts, calcifications, and 
femoral head and pelvic bones around the prostate. Advanced registration software 
using anatomic landmarks may help to overcome these discrepancies (46). 
Second, the spatial resolution of DW imaging was limited (1.8 x 1.8 mm). 
This may result in missing CSLs with a diameter smaller than approximately 4-5 
mm. Conversely, the diameter of an 18-gauge biopsy needle, and the corresponding 
biopsy specimen, was approximately 1.0 mm. However, this titanium needle causes 
image artefacts on post biopsy true-FISP images with a diameter of approximately 
6 mm. Even if the spatial resolution of DW imaging can be improved in future, the 
accuracy of the determination of the position of the biopsy needle will likely remain 
limited due to these needle artefacts. In the future these may be overcome by using 
novel material for needle manufacture. 
In biopsy specimens obtained in patients with prostate cancer, the entire specimen 
may not contain prostate cancer. In our study, we did not include tumour biopsy 
volumetry. Because the histopathologic reports did not describe the localization 
of the cancerous components in the biopsy specimen, we have disregarded the 
volume percentage. However, this limitation could have influenced the accuracy of 
the measurements. The change in the diagnostic MR imaging protocol during the 
study period and the differences between the diagnostic and biopsy protocol may 
have influenced lesion detection. 
In conclusion, DW imaging is a non invasive technique that demonstrates a difference 
in mean ADC between prostatitis and prostate cancer by using MR-guided biopsy 
specimens as standard of reference, although its usability in clinical practice is 
limited due to a high degree of overlap.
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Abstract
Purpose: To introduce a new in-house developed pneumatically controlled 
magnetic field compatible manipulator as an aid to perform magnetic resonance 
(MR)-guided biopsies of the prostate. 
Methods: A pneumatic controlled manipulator with five degrees of freedom 
constructed of plastic to achieve magnetic field compatibility was developed to 
guide biopsies. A risk analysis, mechanical tests, and RF safety tests with respect 
to needle tip heating were performed to assure future patient safety and to meet 
standard safety requirements for the use in a medical environment. The accuracy 
of needle positioning with the needle guide manipulator to sample a predefined 
target was measured in agar phantoms on a 3T whole body MR system. The in-
plane error was used to evaluate the accuracy, which is defined as the orthogonal 
distance between target and biopsy needle. The time for each step in the biopsy 
procedure was recorded to evaluate the procedure time. The influence of the 
insertion angle with respect to the static field of the MR scanner on the needle 
artefact was investigated.
Results: The risk analyses met patient safety requirements. No RF induced 
local heating around the needle tip was observed. The average in-plane 
error in 19 measurements was 3.0 mm (range 0-5.6 mm). The average 
time needed for manipulation to place the needle guide in the desired 
position was 5 min (range 3-8 min). Total procedure time was 30 min. 
The needle artefact size increases with the insertion angle with respect to the 
static field of the MR scanner. 
Conclusions: The new MR compatible manipulator can be used safely for patient 
care. It showed a high accuracy and short total procedure time, demonstrating 
great potential to improve the transrectal prostate biopsy procedure.
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Introduction
The recent symbiosis between robotics and medical science has made a rapid 
development, particularly in imaging and interventions. Different imaging 
modalities provide feedback to interventional devices which are crucial in 
precise positioning tasks such as needle insertion, biopsy interventions, and 
catheter placement (1). In the detection of prostate cancer, the most frequently 
diagnosed form of noncutaneous cancer in men (2), this fusion may help to 
improve detection rate. The detection rate for transrectal ultrasound (TRUS)-
guided biopsies is low (3) Despite the low detection rate and high false negative 
biopsy rate, TRUS-guided biopsy is still the standard procedure (4) Magnetic 
resonance (MR) imaging can be used as a diagnostic tool to detect, localize, 
and stage prostate cancer (5) The detection rate is improved in patients with 
elevated prostate specific antigen and repetitive negative TRUS-guided biopsies 
using MR-guided prostate biopsies (6-9) 
MR imaging has the reputation of being expensive. This seems to be conceivable 
when comparing a MR-guided biopsy session with a conventional TRUS-guided 
biopsy session in the detection of prostate cancer. Nevertheless, it should 
be noted that the detection rate of prostate cancer in patients after the first 
negative TRUS-guided biopsy session is 22% and 14% for the third biopsy session. 
Generally, multiple TRUS-guided biopsy sessions are needed. The detection rate 
of MR-guided biopsies after two or greater negative TRUS-guided biopsy session 
is 59% (10). These numbers showed the potential of MR-guided biopsies. 
In literature, both manually and mechanically actuated experimental 
MR compatible biopsy devices are described (11-17). Most of these devices 
have a needle entrance pathway (transgluteal and transperineal) where local 
anaesthesia is needed, which is more invasive in comparison with the clinically 
most commonly used transrectal pathway, where no anaesthesia is needed. 
Furthermore, the transperineal pathway has a longer trajectory to the prostate 
with more critical structures compared to the transrectal pathway. So far, the 
only commercially available transrectal MR-guided prostate biopsy device is a 
manually adjustable standard for needle guide positioning (6, 18, 19) This device 
cannot be controlled from distance, as opposed to the experimental devices that 
are mechanically actuated from outside the magnet room. A needle guide filled 
with gadolinium-doped water is inserted in the rectum of the patient. Based on 
the acquired MR images, the needle guide is manually positioned in the direction 
of the region of interest. This procedure is unpleasant for the patient, operator 
dependent, and time consuming. For these reasons an in-house MR-compatible 
robotic manipulator is developed with which the needle guide direction can be 
controlled outside the magnet room with real-time MR guidance. Consequently 
the patient does not need to be moved in and out of the magnet bore during 
needle guide repositioning. It is therefore conceivable that this robotic manipulator 
may improve procedure time, enhance patient comfort, and improve needle 
guide positioning. 
To our knowledge, this is the first pneumatically actuated and magnetic field 
compatible manipulator for needle guide positioning under real-time MR-
guidance, to perform transrectal prostate biopsies. The purpose of our phantom 
study was therefore to assess the accuracy and safety of the new transrectal MR 
compatible manipulator for guidance of prostate biopsies.
Materials and methods
 
System
The system consists of the robotic manipulator and its controller unit. The controller 
unit includes a computer, motion control elements, and electropneumatic and 
electronic interfaces which are located outside the MR cage of Faraday. Plastic 
tubes connect the manipulator to the control unit (Fig. 1). The entire manipulator 
consists of plastic to achieve magnetic field compatibility, for assuring patient 
safety and prevention of any signal artefacts. The manipulator is designed to 
interact with the patient within any standard clinical closed-bore MR system. In 
this study a closed-bore 3T (gradient strength of 40 mT/m)system was used 
(Magnetom Trio, Siemens Medical Solutions, Erlangen, Germany) with the body 
coil of the system as the radiofrequency transmit coil and a spine and body-array 
coil for MR signal reception. Phase maps of a localizer image sequence (sagittal, 
coronal, and axial gradient echo images with an echo time of 10 ms) of a volunteer 
were made with and without the manipulator in correct position to ascertain that 
the MR compatible manipulator did not disturb the homogeneity of the magnetic 
field. None of the images in this study were corrected for distortions. 
Compressed air used in the pneumatic motors is generated in the controller 
unit and is transmitted through the plastic tubings (Fig. 1). Valves located in the 
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Figure 1: The robot shown from the side (A) and front (B). Most important parts are marked, 
with (1) needle guide, (2) safety mechanism with the suction cup, (3) pneumatic motors, (4) 
tubings to the motors, (5) ground plate for installation on MR table, (6) angulation rail to move 
the needle guide in the sagittal plane, (7) angulation rail to move the needle guide in the coronal 
plane, and the (8) tapping mechanism to introduce the needle guide.
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controller unit generate pressure waves to set the motors in motion. The graphical 
user interface (GUI) for motion control is connected to the controller unit. By 
selecting the desired motion control button in the GUI, the corresponding valve 
is opened and thereby generating a pressure wave to the corresponding motor, 
resulting in movement of the needle guide in the desired position/direction. No 
electricity is required inside the MR magnet room. 
The needle guide can be manipulated with five degrees of freedom (DOFs), 
which allows positioning of the end effector in the desired position. The angle of 
the needle guide with the main magnetic field could range from 30° to 55° in the 
sagittal plane and plus or minus 26° in the coronal plane. 
To assure patient safety and meet standard safety requirements for the use in 
a medical environment, the needle guide has a mechanical safety mechanism 
consisting of a suction cup (Fig. 1). When the force from the end effector applied 
to the patients rectal wall reaches a primary set value, this suction cup will 
automatically release, preventing the end effector from harming the patient. The 
suction cup consists of a seal, underpressure generated in the suction cup results 
in fixation of the needle guide to the manipulator. 
Patient safety
In a multidisciplinary group consisting of radiologists and (medical) physicists, a 
failure mode and effect analysis (FMEA) was performed. A FMEA is a systematic 
method to identify and prevent product and process problems before they can 
occur (20, 21). In this study a FMEA is performed to identify possible risks and 
hazards due the procedure or the manipulator itself, therefore ensuring that 
safety requirements are met. 
To assure patient safety, the mechanical safety mechanism is tested using a force 
dynamometer (Correx, Haag-Streit, 0-2000 g, Bern, Switzerland). In a previous 
study of the mechanical properties of the human gastrointestinal tract, it was 
found that a force of 60 N/cm2 can cause irregularities of the serosa and internal 
muscular layer of the human small bowel, whereas the mucosa, submucosa, and 
external muscular layer remained intact (22). The force needed to release the 
suction cup was determined at three different positions and directions on the 
needle guide (Figs. 2a-2c) Measurements of this force were repeated ten times. 
The results are presented as mean ± standard deviation. 
Depending on size and material, heating of metal wire or needle can occur due to 
deposited radio frequency (RF) power of the MR pulse sequence (23). To assure 
patient safety in future experiments, possible heating of the needle tip in the agar 
gel was studied with temperature mapping of the agar gel immediately after 
excessive RF power deposition. Temperature maps of the agar gel were made 
based on the difference in chemical shift of water with temperature, reflected in 
a phase shift of the water signal of a MR image between two experiments. After 
an initial gradient echo image (repetition time (ms); TR/echo time (ms); TE/flip 
angle (degrees); FA = 100/20/25; bandwidth 260 Hz/pixel; resolution 1.56 x 1.56 
x 5.0 mm; acquisition time 13 s) as a reference phase map, a multiple spin echo 
sequence with a continuous power of 148 W for 104 s was applied to a 1 kg agar 
phantom to heat the sample (TR/TE = 8000/107; bandwidth of 465 Hz/pixel). 
After heating with RF, the temperature map was constructed with the phase map 
difference of a second gradient echo image and the reference phase map.
Accuracy measurements
To evaluate the ability of sampling with the manipulator, a phantom made of agar 
was used. Small plastic beads located in the agar represented targets. All beads 
were imbedded in the agar at the same depth (3 cm) and distance (2-3 cm) 
between them. The beads were 2 mm in diameter. 
A schematic representation of the steps taken to perform a biopsy is illustrated in 
the flow chart in Figure 3. After the manipulator was connected to the controller 
unit, the phantom and manipulator were placed and secured on the table of the 
MR system (step 1). A body-array surface coil was used for MR signal reception 
(Fig. 4 - page 88).
Once the manipulator and phantom were fixed within the MR system, a T1-
weighted 3D volumetric gradient echo sequence was used to acquire an image 
set (step 2) (TR/TE/FA = 6.5/2.5/10; resolution of 0.72 x 0.72 x 0.72 mm; readout 
gradient direction H>>F; readout gradient strength = 6.5 mT/m; acquisition time 
of 2 min and 20 s). The acquired 3D volume was used to select the target (step 3) 
and as a reference to navigate on during positioning of the needle guide with real-
time MR imaging. After this initial target selection, a software package (interactive 
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Figure 2: Needle guide with the gadolinium-doped water reservoir (Invivo, Schwerin, Germany) 
to make the needle guide visible on MR images and the work channel (for needle insertion) are 
shown. The arrows A, B, and C represent the direction of the forces applied on the needle guide 
during the safety experiments.
Figure 3: Flow chart of the biopsy procedure showing the different steps during the biopsy 
procedure.
gadolinium-doped water work channel
30 mm
10 mm A
B C30 mm
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of the angle on the size of the artefact, different insertion angles relative to the 
static field were made, and the same 3D image sequence used to determine the 
accuracy was utilized to measure the artefact size.
Data evaluation
To determine the accuracy for needle positioning, the inplane error was 
determined because the out of plane error is less critical in the biopsy procedure 
due to the core sampling length of 17 mm of the biopsy needle (13). The in-plane 
error is defined as the distance between the centre of the target and the centre of 
the biopsy needle in the plane perpendicular to the needle. Therefore, the tip of 
the needle was injected approximately 10 mm beyond the target for hypothetical 
sampling of the target in the centre of the 17 mm biopsy sampling core. In other 
words, we inserted the needle deep enough to be sure the tip of the needle was 
beyond the target. The in-plane error, which was the distance between the centre 
of the target and centre of the needle, was calculated using the following formula:
The x, y, and z coordinates in the patient coordinate system were acquired from 
an image slice perpendicular to the needle guide, where both target and biopsy 
needle are visible (Fig. 5). The image slices perpendicular to the needle guide 
were reconstructed from the original 3D images. For this reason the coordinate 
system of the original image was still valid and, therefore, the distance needed 
to be calculated from all three dimensions. With the commercially available 
viewing program DYNACAD (Invivo, Schwerin, Germany), the three-dimensional 
coordinate positions of the centre of the needle and target were provided from 
the reconstructed 3D MR images. 
front end (IFE); work in-progress package; Siemens, Erlangen, Germany) was 
used to orient and direct the needle guide in the desired direction (step 4). The 
IFE software provides both 2D and 3D displays of real-time images. Manipulation 
of images and relevant controls can be performed in a single screen to simplify 
user interaction (24, 25). This software package uses a trufi sequence (Siemens, 
Erlangen, Germany) which supports interactive changes of imaging parameters 
during real-time imaging, such as image position/orientation. The sequence is 
especially designed to assist MR-guided interventional procedures which require 
interactive slice positioning for path planning and real-time monitoring of the 
acquired images. The sequence has the following parameters (TR/TE/FA = 
732/1.9/70; resolution of 1.65 x 1.65 x 5.0 mm; readout gradient strength = 15.4 
mT/m; three slices in different planes (sagittal, coronal, transverse plane); refresh 
rate = 2.2 s).
After correct positioning of the needle guide (step 5) according to the performing 
physician, the patient table with the manipulator and phantom is moved out of 
the magnet bore (step 6), and the biopsy was taken manually (step 7) with a 
standard biopsy gun (titanium 18-gauge, fully automatic, core-needle, double-
shot biopsy gun with needle length of 170 mm and tissue core sampling length of 
17 mm (Invivo, Schwerin, Germany)). The setup is returned to its original position 
in the magnet (step 8). Again a 3D volumetric gradient echo (TR/TE/FA = 4.6/ 
2.0/ 10; resolution of 0.72 x 0.72 x 0.72 mm; readout gradient direction H>>F; 
readout gradient strength = 25.5 mT/m; acquisition time of 2 min and 20 s) image 
was acquired with the needle inserted in the phantom (step 9) to evaluate the 
accuracy of sampling the target. 
The time needed for every step in the biopsy procedure was measured in order 
to evaluate the time needed for the procedure.
 The angle of the titanium needle with the static field (B0) of the MR scanner was 
of influence on the artefact size of the needle (26). To determine the influence 
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Figure 4: Measurement set up with the biopsy gun; (1) the needle is inserted in the phantom (4) 
through the needle guide (3). A body-array surface coil was used for MR signal reception (2). Plastic 
tubings connect the manipulator to the control room (5).
Figure 5: In the left panel (A) an image of the phantom is show where both needle and target are 
visible. The image slice is perpendicular to the needle. The white double arrow represents the in-
plane error. From this image it can be seen that the needle artefact is bigger than the real needle 
diameter (white circle). The influence of the angle with the static field of the MR scanner on the 
needle artefact is shown in the right panel (B).
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A 3D image set with isotropic voxels was chosen to be sure that the measured 
distance in every direction will have the same error due to the voxel size and to 
minimize this error in the reconstructed images, where voxels are not square 
anymore due to the angulation.
 
Results 
System
In total, 19 biopsies in phantoms were performed. No technical problems occurred 
during the procedure and all predefined targets could be reached. No artefacts 
from the manipulator were seen on the MR images. Phase maps in all orientations 
with and without the manipulator in place did not show any differences (data not 
shown), illustrating that the manipulator did not interfere with the magnetic field 
homogeneity in any way. The simple interface for manipulation, five DOFs, and 
fast manipulation speed of the end effector made it effortless to reach a target. 
Therefore, most of the manipulation time was spent on fine tuning of the final 
needle guide position, even when two predefined targets were far apart.
Patient safety
The FMEA risk analysis showed minor items for improvement. Most important failure 
modes observed were incorrect installation of the manipulator on the MR table 
and incorrect slice selection through the needle guide. Therefore, small technical 
adaptations were performed such as improved connection of the tubings on the 
MR table to prevent damage. Also the instructions for correct image slice selection 
were improved. Most important recommendation in this risk analysis was to test 
the mechanical safety mechanism. The mean (± standard deviation) forces required 
before the safety mechanism was activated during positioning of the needle guide 
were 5.5 ± 0.3, 8.1 ± 0.3, and 15.1 ± 0.9 N for position and directions A (needle guide 
tip), B, and C, respectively (Fig. 2). If we assume 20 N as the maximum force that 
can be applied on the needle guide (the mechanical safety tests show that this is 
in the direction of arrow C) before the safety mechanism will be activated, which 
includes a safety margin of 4.9 N, we can estimate the minimal contact surface 
needed to refrain from damaging the rectal wall. Taking 60 N/cm2 as the maximum 
allowed force per surface on the patient in order to prevent bowel wall damage (22), 
the minimal contact surface between the needle guide and rectal wall of 0.3 cm2 is 
allowed. Regarding these results, the flexibility of the rectal wall, and the estimated 
surface of the tip of the needle guide (1.8 cm2), we can conclude that the forces 
applied on the rectal wall by the manipulator cannot cause harm to the patient. 
The 1 kg agar phantom did heat up a few degrees due to the applied continuous 
power of 148 W for 104 s with the high-power multiple spin echo pulse sequence. 
Temperature mapping showed an inhomogeneous increase in temperature of the 
agar phantom, with more heat deposited at the bottom of the phantom than near 
the top. However, from the temperature map after RF heating (Fig. 6), it can be seen 
that there is no local heating around the needle tip in this phantom setup.
Accuracy measurements
The installation of the manipulator on the MR table and the connection to the 
controller unit was accomplished within 10 min (step1; Fig. 3). The average time 
needed for manipulation to place the needle guide in the desired position (step 
4) was 5 min (range 3-8 min). Total procedure time to perform a biopsy was less 
than 30 min for each sample (steps 1-10). To perform an additional biopsy (steps 
4-9), 11 min extra to total procedure time was needed on average. 
For needle placement the average in-plane error was 3.0 mm (range 0-5.6 mm; 
Fig. 7). In 3 out of 19 measurements, there was an exact hit of the needle and target. 
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Figure 6: Temperature map of a 1 kg agar phantom (A) after applying a continuous power of 
148 W for 104 s to a 1 kg phantom. The temperature map showed an inhomogeneous increase 
in temperature of the agar phantom. However, no local heating of the needle tip was seen. The 
colours indicate the relative temperature increase. Blue indicates an increase of 0.0°-1.0°, cyan 
of 1.0°-2.0°, yellow 2.0°-2.5°, and red 2.5°-3.0° with respect to the reference image made before 
applying a continuous power of 148 W for 104 s. An anatomical image of the set up is shown in 
the right panel (B).
Figure 7: Histogram of needle placement error (n=19), which is defined as the in-plane distance 
between the centre of the target and the centre of the needle. In three cases a direct hit of the 
target (error = 0 mm) resulted in movement of the plastic bead along with the needle tip in the 
agar phantom. In one case the bead probably bounced off the needle resulting in an error of 1.6 
mm (half the diameter of the needle plus half the diameter of the target).
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As a result the plastic bead moved with the needle in the agar phantom and was 
seen on the needle tip. In the other 16 biopsies the needle missed the target or 
bounced off on the plastic beads. 
An additional difficulty in assessing the accuracy of the procedure was the 
dependency of the apparent size of the needle in relation to the insertion angle 
of the needle with respect to the static magnetic field of the MR scanner. The size 
of the void in the images at the position of the needle increases with the angle 
between the needle and the static magnetic field (Fig. 5).
Discussion 
Our MR-compatible transrectal prostate biopsy manipulator demonstrated 
promising results with respect to the precision of needle positioning and short 
manipulation time. Furthermore, the manipulator prevented the need of moving 
the phantom in and out of the scanner bore for manipulation and imaging of the 
needle guide. This will be an enormous advantage when performing the biopsy 
procedure with the manipulator in patients.
Safety
Regarding the mechanical safety mechanism tests, we can conclude that the 
manipulator cannot harm the patient. However, it should be noted that the utilized 
20 N/cm2 as a measure for rectal wall damage are ex vivo laboratory results for 
damage in the small intestine. Therefore, extra safety margins were taken into 
account for the calculations. 
Local heating of the needle tip was not seen, in this experimental setup, after 
applying a continuous power of 148 W for 104 s to a 1 kg phantom. In patients 
in the 3T MR system, the amount of RF power that is allowed to be deposited in 
the body is the SAR limit of 4 W/kg averaged over a period of 6 min (this is only 
9% of the RF power deposited in the phantom). According to these results it is 
safe to perform in vivo accuracy studies in the future without causing heating 
damage with the currently used needles to the patient. Nevertheless, care should 
be taken into account when performing in vivo studies since these results are 
obtained from one experiment with a particular setup. In our experiment we 
neither investigated the influence of the surrounding medium of the needle nor 
differences in length, angle, and position of the needle with respect to the static 
magnetic field.
Accuracy measurements
We found an average in-plane error of 3.0 mm (range 0-5.6 mm) which is 
comparable to other devices used for prostate biopsies. Preliminary results of 
Fischer et al. (27) showed that their transperineal robot successfully punctured 
five out of five 10 mm targets. The transperineal robot described by Muntener et 
al. is able to perform biopsies with a median error of 2.02 mm (range 0.86-3.18 
mm) (7). These results suggest that these devices, including our manipulator, are 
able to puncture most clinically relevant tumours as 80% of the tumours with 
a volume of less than 0.5 mL (diameter = 1.0 cm) are unlikely to be important 
during the life of a patient (28). 
The average total procedure time was less than 30 min which is comparable 
with the time Muntener et al. (7) described in their study (30-35 min). When 
comparing with the MR-compatible biopsy device (Invivo, Schwerin, Germany) 
used in clinical practice, the procedure time found in this phantom study is 
shorter (18). However, it should be noted that it is difficult to compare phantom 
studies with patient studies since more precautions are taken when performing a 
biopsy on a patient. Our results with respect to the procedure time are promising, 
taking into account that the learning curve for using the manipulator is expected 
to optimize the procedure times even further. Most procedure time is spent in 
installation and removal of the manipulator and phantom from the MR table. 
The interface for manipulation of the needle guide is user friendly and does not 
need a lot of experience from the practitioner. This interface in combination with 
the IFE software, for interactive changes of imaging parameters during real-
time MR imaging, brings manipulation and orientation of the needle guide more 
together. Manipulation under real-time imaging enables monitoring of progress 
for the performing physician during intervention. 
The pneumatic robot that Fischer et al. (27) described also makes use of real-time 
imaging during needle guide positioning. However, the perineum is used as the 
entrance pathway which needs local anaesthesia to ease patient discomfort and 
has a longer distance to the prostate (which may result in a larger biopsy error) 
when compared to our manipulator using the transrectal entrance pathway.
Limitations and further improvements
By calculating the accuracy as the distance between the coordinates of the 
centre of the needle and the centre of the target rather than the edge of the 
needle and target, an error is introduced when the needle touches the target. 
The target is a plastic bead which can be displaced in the gel by a direct hit of 
the needle resulting in an error of 1.6 mm (half the diameter of the needle (0.6 
mm) plus half the diameter of the target (1 mm)). This may have occurred in one 
needle (error of 1.5-2 mm) (Fig. 7). 
The cannula of the needle guide is a fragment wider than the biopsy needle. This 
may result in an error in needle positioning due to the angle of insertion. This 
error increases with insertion depth.
The asymmetrical shape of the needle tip and tissue inhomogeneities may result 
in deflection of the needle (29, 30). Bosch et al. (17) used a tapping technique 
to minimize tissue deformation. Although deflection of the needle contributes to 
the measured error, we did not investigate this aspect of needle placement error 
since this is beyond the scope of this study. 
During manipulation under real-time imaging, the practitioner has to manually 
adjust the image slice direction within the IFE software to see whether the 
needle guide points in the correct direction. However, it should be noted that 
manipulation time is only 5 min and probably will become shorter taking into 
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account that the learning curve for using the manipulator is expected to optimize 
the procedure time even further. 
During manipulation of the pneumatically driven needle guide, some delay was 
seen resulting in overshoots of the needle guide toward the target. This delay 
is caused by the near-real-time imaging sequence (refresh rate of 2.2 s) and by 
the fact that the pneumatic motors not directly stop moving after release of the 
motion button in the GUI. 
The apparent size of the needle changes with the insertion angle and can be up 
to four times the actual needle size (5.3 mm). Although this is not of influence 
on positioning the needle guide with the manipulator (needle is not present yet), 
it could introduce a systematic bias in the calculated sampling error. The error 
is calculated from the centre of the needle position to the centre of the plastic 
bead. This may result in an error when the exact location of the needle within the 
signal void in the image is not known. 
In this study we did not investigate the required insertion depth of the needle. It is 
expected that the insertion depth will not be a problem since the sampling length 
of the biopsy needle is 17 mm. However, the insertion depth should be taken into 
account in future patient studies. 
The range of the manipulator is comparable with the manual device, used in 
clinical practice, which can range from 30° to 65° in the sagittal plane and plus 
or minus 20° in the coronal plane. It is therefore conceivable that the manipulator 
can cover the whole prostate. However, apical lesion may become a problem 
since the range of the manipulator in the sagittal plane is 30-50 which is 15° 
less compared to the range of the manual device (30°-65°). In a planning study 
for brachytherapy performed by van Gellekom et al. (31), they showed that it is 
feasible to cover the entire prostate with the divergent single needle method. 
They found that the limited space in the scanner bore and internal patient 
anatomy were the major limitations for possible needle trajectories. Using the 
transrectal pathway may overcome these limitations when compared with the 
transperineal pathway. 
The applied sequences have not been tested on patients since we optimized 
the sequences to obtain the best image contrast in the agar phantom. Before 
starting patient studies, these sequences have to be optimized to obtain the best 
image contrast in patients and minimize needle artefacts. 
In conclusion we can state that the new MR compatible manipulator is safe 
enough to do the first feasibility tests. It showed a high accuracy and short 
total procedure time, demonstrating great potential to improve the transrectal 
prostate biopsy procedure. The next step therefore is to establish the clinical 
feasibility of the system.
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Abstract
Objectives: To evaluate the accuracy and speed of a novel robotic technique as 
an aid to perform magnetic resonance (MR)-guided prostate biopsies on patients 
with cancer suspicious regions. 
Methods: A pneumatic controlled MR-compatible manipulator with 5 degrees 
of freedom was developed in-house to guide biopsies under real-time imaging. 
From 13 consecutive biopsy procedures, the targeting error, biopsy error and 
target displacement were calculated to evaluate the accuracy. The time was 
recorded to evaluate manipulation and procedure time. 
Results: The robotic and manual techniques demonstrated comparable results 
regarding mean targeting error (5.7 vs 5.8 mm, respectively) and mean target 
displacement (6.6 vs 6.0 mm, respectively). The mean biopsy error was larger 
(6.5 vs 4.4 mm) when using the robotic technique, although not significant. Mean 
procedure and manipulation time were 76 min and 6 min, respectively using the 
robotic technique and 61 and 8 min with the manual technique. 
Conclusions: Although comparable results regarding accuracy and speed 
were found, the extended technical effort of the robotic technique make the 
manual technique - currently - more suitable to perform MR-guided biopsies. 
Furthermore, this study provided a better insight in displacement of the target 
during in vivo biopsy procedures.
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Introduction
The detection rate of prostate cancer in men with elevated and/or rising prostate 
specific antigen (PSA) after negative transrectal ultrasound (TRUS)-guided biopsy 
sessions is poor. Hambrock et al. found a cancer detection rate of 59%, in men 
with an elevated PSA and multiple negative TRUS-guided biopsy (≥2) sessions, for 
magnetic resonance (MR)-guided biopsies. This is an improvement when compared 
to 8 to 12-core TRUS-guided biopsy schemes with a detection rate around 17% 
(TRUS-guided biopsy ≥1) (1-3). Nevertheless, MR-guided biopsy is unpleasant for 
the patient and time-consuming for the radiologist. For these reasons an in-house 
pneumatically actuated MR compatible robot was developed where needle-guide 
direction can be controlled in real-time inside the controller room (4). Consequently, 
the patient remains inside the scanner bore. This may decrease procedure time, 
enhance patient comfort and improve needle-guide positioning. 
Eighty-percent of the tumours with a volume larger than 0.5 cm3 (diameter=1.0 
cm) are likely to be clinically significant (5). Therefore, it is desirable to have a 
technique with a biopsy error smaller than 5 mm. Different factors, such as needle-
guide positioning, patient and prostate motion, and tissue deformation influence 
the accuracy of needle positioning (6-8). Consequently, the needle does not always 
reach the cancer suspicious lesion (CSL). 
In a phantom study the new robotic technique demonstrated a short manipulation 
time of 5 min (range 3-8 min) and a high accuracy of 3.0 mm (range 0-5.6 mm) 
for needle positioning (4). Yakar et al. demonstrated that it is technical feasible 
to perform transrectal prostate biopsies using the novel robotic technique (n=10) 
(Fig. 1) (9). To evaluate and optimize the biopsy procedure in the future, it is 
necessary to identify and quantify the cause of the biopsy error. Therefore, the 
purpose of this study was to evaluate the accuracy and speed of the novel robotic 
technique as an aid to perform MR-guided biopsy on patients with CSLs. 
Materials and methods
Patients 
This study was approved by the ethics review board and written informed 
consent was obtained from all patients who were biopsied with the robotic 
technique. From February to September 2010, 13 consecutive patients with 
an elevated PSA (>4 ng/mL) and at least one negative TRUS-guided biopsy 
session were included. Patient were included in the robotic patient population 
based on their willingness. The manual patient population was matched to the 
robotic population. Prior to the MR-guided, patients received a 3T (Magnetom 
TRIO, Siemens, Germany) multi-parametric MRI examination of the prostate for 
identification of possible CSLs. T2-weighted images in three orthogonal planes, 
transversal diffusion weighted images (DWI) and dynamic contrast-enhanced 
(DCE)-MR images (Table 1 - page 102) were obtained during and after injection of 
15 mL gadopentetate dimeglumine with a power injector (Guerbet, Gorinchem, 
Netherlands). To evaluate the CSL for clinical significance, the criteria for MR-
guided biopsy reported by Hambrock et al. were applied (3).
CSLs were determined in consensus by 2 readers with at least 6 years of 
experience in prostate MR reading. From each CSL the volume (in mL) was 
determined on the MR images, assuming that the lesions were ellipsoids.
MR-guided biopsy
MR-guided biopsy were performed within 12 weeks after the diagnostic multi-
parametric MR examination. Antibiotic prophylaxis was given with 500 mg 
ciprofloxacin in the morning and evening for three consecutive days, starting 
the day before biopsy. A schematic representation of the steps taken to perform 
a biopsy is illustrated in the flow chart (Fig. 2). 
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Figure 1: (a) the robot with (1) the needle guide, (2) safety mechanism with the suction cup, 
(3) tapping mechanism to introduce the needle guide, (4) pneumatic motor, (5) tubings 
to the motors, (6) ground plate for installation on the MR table, (7) angulation rail to move 
the needle guide in the coronal plane. (b) set-up of a patient with the robotic technique on 
the table of the MR system. The patient was positioned in prone position in the MR system. 
After the needle guide was inserted rectally it was attached to the robot
Figure 2: Flow chart of the biopsy procedure for both the robotic and manual techniques. 
Scan plane adjustments were only perfomed with the IFE software (step 4) when using the 
robotic technique
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A needle-guide filled with gadolinium-doped water was inserted in the rectum 
of the patient. Subsequently, the needle-guide was mounted to the robotic or 
manual device (Step 1). The MR imaging protocol (Step 2) for target selection 
and to navigate on during the biopsy procedure is shown in Table 1. 
Targets were selected (Step 3) on these images based on the CSLs found in the 
diagnostic MRI examination. Manipulation of the needle-guide was done using 
either the robotic or manual technique (Step 5). After correct alignment of the 
needle-guide the insertion depth of the needle was measured on a transversal 
true-FISP (TRUFI) image (Table 1). The patient was slid out the gantry to insert 
the biopsy needle manually (titanium 18-gauge, fully automatic, core-needle, 
double-shot biopsy gun with needle length of 175, sampling length of 17 mm 
(Invivo, Schwerin, Germany). 
A T2-weighted 3D volumetric gradient-echo (first two procedures with the 
robotic technique) or a T2-weighted 3D volumetric spin-echo image (all other 
patients) was acquired with the needle inserted (Step 7). This was the same 3D 
volumetric image (Table 1) as acquired in step 2. When the needle was in correct 
position, confirmed on the control images, another target could be targeted 
(Steps 3-8) or the patient was removed from the MR table (Step 9). 
Needle-guide positioning: robotic technique 
The robotic system has five degrees of freedom: translations in three directions 
(anterior-posterior, inferior-superior, lateral) and rotations in two directions 
(inferior-superior, lateral). The angle of the needle-guide with the main magnetic 
field could range from 30° to 55° in the inferior-superior direction and plus or 
minus 26° in the lateral direction (4). 
With a simple graphical user interface the direction of the needle-guide can 
be adjusted (9). A software package (Interactive Front End (IFE); Siemens 
Corporate Research, Baltimore (MD), USA) was used to orient and direct the 
needle-guide in the desired direction (Step 5) under real-time image guidance 
(Table 1). Manipulation of images and relevant controls can be performed during 
imaging which allows interactive slice positioning for path planning and real-time 
monitoring (10, 11). 
Needle-guide positioning: manual technique 
Transversal and sagittal TRUFI images (Table 1) through the needle-guide were 
acquired to determine needle-guide direction. The patient was withdrawn from 
the scanner bore and the radiologist manually adjusted the biopsy device to 
point the needle-guide towards the target. To confirm correct positioning of the 
needle guide sagittal and transversal TRUFI images were acquired through the 
needle-guide again. These actions were repeated until the needle-guide was in 
correct position (12). 
Total procedure time and manipulation time were recorded for both the robotic 
and manual techniques. 
Measurements 
Motion and deformation of the prostate may occur during the biopsy procedure. 
This will have effect on the position of the target. Since targeting of the CSL in 
both methods was done on the images acquired in Step 2, which do not take 
deformation and motion into account, it is important to distinguish between 
targeting and biopsy error (Fig. 3 - page 104). 
Targeting error (ε) The targeting error is defined as the normal (shortest) distance 
from the needle trajectory to the original target location (Fig. 3). This error does 
not take tissue deformation and patient motion into consideration. This error is a 
measure for needle-guide positioning towards the intended target. 
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Table 1: Imaging protocol with sequence specifications. Volumetric images were utilized to 
identify anatomical landmarks used to quantify target displacement. DWI = diffusion weighted 
imaging, TR = repitition time, TE = echo time, FA = flip angle, DCE = dynamic contrast 
enhanced, TRUFI = true-FISP
1 The initial two volumetric images (2/13) were gradient echo sequences (first 2 procedures 
using the robotic technique).
Sequence TR/TE/FA
ms/ms/degrees
Resolution
(mm)
Acquisition time
(minutes)
diagnostic multi-parametric image sequences
DWI, b-values: 50, 500, and 
800 s/mm²
2300-2500/61-
64
2.0 x 2.0 x 4.0 3:08
Transversal, sagittal and 
coronal T2-weighted turbo 
spin echo
4480-4950/103-
110/120
0.6 x 0.6 x 3.0 3:22-4:43
DCE-MRI 3D T1-w spoiled 
gradient-echo
32/1.47/10 1.8 x 1.8 x 4.0 2:43
Image sequences during biopsy procedure
DWI, b-values: 0, 100, 500 and 
800 s/mm²
2000/67 1.8 x 1.8 x 4.0 2:06
T2-weighted turbo spin echo 3620/103/120 0.8 x 0.8 x 4.0 3:26
Transversal and sagittal TRUFI 
image (manual technique)   
4.48/2.24/70 1.1 x 1.1 x 3.0 7.5 and 8.9 s
Transversal, sagittal and 
coronal TRUFI image  (robotic 
technique)
894/2.3/60 1.6 x 1.6 x 5.0 0.9 s/slice
T1-w 3D volumetric gradient 
echo1
4.5/2.2/43 1.0 x 1.0 x 1.0 2:20
T2-weighted 3D volumetric 
spin echo
1000/102/100 1.0 x 1.0 x 1.0 2:36
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Biopsy error (δ) The biopsy error is defined as the normal distance from the 
needle to the transformed target location (the actual target location after needle 
insertion). The coordinates of the transformed target are corrected for tissue 
deformation, as well as patient and prostate motion. The transformed target 
coordinates were calculated by adding the target displacement vector to the 
original target coordinates. 
Target displacement (φ) The target displacement vector is defined by the 
distance and angle between the original and transformed target location. The 
target displacement (φ) is the length of this vector. The 3D volumetric images 
made before (Step 2) and after needle insertion (Step 7) were used to determine 
the target displacement vector. In these images identical anatomical landmarks 
around the target (mean 13.7 mm; range 2.3-48.4 mm) were manually selected 
with the aid of an open source fusion package (13). Calcifications, benign prostate 
hyperplasia (BPH) nodules, the verumontanum and the urethra were used as 
anatomical landmarks. Coordinates of these anatomical landmarks (≥5) were 
used to create a 3D vector field. The arrows represent the direction and distance 
of displacement of anatomical landmarks (Fig. 4). The mean vector of this vector 
field is a quantitative measure for localized target displacement, since anatomical 
landmarks around the target were selected. 
To calculate the targeting and biopsy error the needle trajectory was determined 
by fitting a line through multiple points (≥8) within the needle artefact using linear 
regression in 3D-space. These points were obtained from the 3D volumetric MR 
images obtained in Step 7. 
Target coordinates (CSLs) were obtained from the T2-weighted and DW images 
acquired in Step 2. 
The angle between needle trajectory and target displacement direction was 
calculated in order to see whether the target moved along the needle trajectory 
or in a random direction (Fig. 5). 
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Figure 3: Representation of the needle inside the prostate, illustrating targeting error (ε), tar-
get displacement (φ) and biopsy error (δ). The targeting error, defined as the normal distance 
from needle to the original target coordinate (T), is shown. Target displacement, defined as 
the distance between original target (T) and transformed target (T’), is represented by φ. 
Furthermore, the biopsy error (δ) is shown, which is defined as the normal distance between 
transformed target (T’) and needle Figure 4: 3D vector field: The blue arrows represent the direction and displacement of the 
anatomical landmarks. The red arrow is the mean vector representing target displacement. 
Furthermore, the needle trajectory (black line), targeting error (ε), original target (T), biopsy 
error (δ) and transformed target (T’) are shown.
Figure 5: Transversal TRUFI image through the needle guide before (a) and after (b) needle 
insertion in the prostate
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Statistical analysis 
Two-tailed independent t-tests were performed to determine whether there 
were significant differences between the robotic and manual techniques for 
targeting error, biopsy error, target displacement, procedure and manipulation 
time. Differences were considered to be significant at p<0.05. Statistical analysis 
were performed with SPSS, version 16.0.01 (Chicago, Illinois). 
Results
In total, 13 patients with 32 needle positions were analyzed. Table 2 describes the 
patient characteristics and biopsy results for both techniques. 
Since the majority of previous negative TRUS-guided biopsy had been performed 
outside our institution, information on the number of cores was not available for 
most patients. 
Accuracy 
The mean targeting error for both the robotic and manual techniques was almost 
similar (5.7 vs 5.8 mm respectively, p=0.928) (Fig. 6). The mean biopsy error 
was less (4.4 vs 6.5 mm) with the manual technique compared to the robotic 
technique (p=0.054). Target displacement was larger with the robotic technique 
(6.6 vs 6.0 mm, p=0.439). 
Direction of target displacement 
The mean angle between needle trajectory and target displacement direction for 
the robotic and manual techniques was 36.7° (range 4.0-82.2°) and 37.6° (range 
7.7-73.3°), respectively. 
Time 
The mean time to perform a biopsy procedure using the robotic technique was 76 
min (range 60-100 min) and 61 min (range 52-64 min) with the manual technique. 
The total procedure time includes the extra time to acquire the 3D volumetric 
images (2:36 min each). The mean manipulation time to move from target to 
target was 6 min (range 3-11 min) with the robotic technique and 8 min (range 
5-11 min) with the manual technique. The differences in manipulation time and 
procedure time between both techniques were not significant. 
Discussion
The robotic and manual techniques demonstrated comparable results regarding 
targeting error and target displacement. The biopsy error was larger when using 
the robotic technique, however not statistically significant. The robotic technique 
prevented the need of moving the patient in and out of the scanner bore for 
manipulation and imaging of the needle-guide. Most of the target displacement 
found in our study was in the direction of the needle trajectory.
Several robots for transperineal seed delivery in brachytherapy have been 
described in literature (14-17). The robotic and manual techniques for transrectal 
biopsies demonstrated a larger targeting error (5.7 and 5 mm respectively) 
compared to other robotic techniques. Muntener et al. found a targeting error of 
2.02 mm (range 0.86-3.18 mm) with their robot in a canine model (16). Zangos 
et al. describe a transgluteal approach for prostate biopsy with a targeting error 
of 0.9 mm (range, 0.3-1.6 mm) (18). The targeting error, biopsy error and target 
displacement for a transrectal biopsy device were 2.2 mm (range 0.5-5.7 mm), 
5.1 mm (range 1.6-11.0 mm) and 5.4 mm (range 1.6-11.1 mm) respectively. Although 
the targeting error was less compared to our results, the biopsy error and target 
displacement were in concordance with our results (19). 
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Table 2: Patient characteristics and biopsy results for both the robotic and manual techniques. 
Patient characteristics Robotic Manual
Number of patients 8 5
Number of needle placements 19 13
Median needle positions per patient 1.5 (range 1-3) 2 (range 1-4)
Mean PSA (ng/mL) 15 (range 8-28) 14 (range 7-19)
Mean prostate volume (mL) 67 ( range 44-98) 72 (range 49-100) 
Median number of repeated negative  
TRUS-guided biopsy sessions
2 (range 1-4) 2 (range 1-4)
Median lesion volume on MR images (cc) 0.85 (0.38-1.61) 0.91 (0.6-3.19)
Histopathological findings (nr. of patients) non-malignant (3), 
prostatitis (3), 
cancer (2) 
non-malignant (2), 
prostatitis (2), 
cancer (1) 
Figure 6: Histogram showing the mean targeting error, biopsy error and target displacement 
for both the robotic and manual techniques. The error bars represent the standard deviation.
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MR-guided TRUS biopsy may be an alternative to MR-guided biopsy in the future 
because its availability and is probably less expensive. However, initial results 
show registration errors around three millimeter in phantoms and patients (20-
23). In addition to this error is the targeting error and tissue deformation which 
together determine the ability to sample a CSL. 
The anatomical landmarks chosen in the MR images to determine target 
displacement were selected manually. This may have introduced an error, since it 
is difficult to select exactly the same position. Automatic registration would be an 
alternative to diminish this error. However, automatic registration is difficult and 
introduces errors as well (15). Furthermore, the images that need to be registered 
are different in the area of the target, because of the presence of the needle, 
causing a line shape void in the area where best registration is needed. 
The biopsy procedures with the robotic and manual techniques were not 
performed by the same radiologist. To overcome the limitation of inter-variability, 
the performing physician of each procedure performed the biopsy session in 
consensus with the first author who attended all sessions. Despite the fact that 
patient selection for each technique was not randomly chosen, both groups had 
similar patient characteristics (Table 2). The number of cores taken during TRUS-
guided biopsy was not available for most patients in both groups. 
In the first patient a gradient-echo sequence was used to determine needle 
trajectory and target displacement. The needle artefact size was acceptable, 
varying from 3.5 mm to 4.5 mm. In the second patient, the angle of the needle 
with the static magnetic field was larger. As a result, the artefact size of the needle 
increased to 8.5 mm. Therefore, we decided to use a 3D spin-echo sequence in 
which the signal void around the needle was less influenced by distortions of the 
magnetic field. Needle artefact size now varied from 3.8 to 4.7 mm. 
The quantitative method described to determine target displacement cannot 
discriminate between patient motion, prostate motion and tissue deformation. 
However, our results demonstrated that most target displacement was in the 
direction of the needle trajectory suggesting that most of the target displacement 
was caused by needle insertion. 
Hambrock et al. found a median imaging time of 35 min for MR-guided biopsy 
(24). In our study, we reported the total procedure times (including patient 
preparation) for the robotic and manual techniques. Although manipulation time 
was shorter when using the robotic technique, the total procedure time was longer 
compared to the manual technique. Positioning of the patient was a precise and 
time-consuming process. In case of incorrect positioning the whole set-up did 
not fit inside the scanner bore, or the range of motion of the robotic technique 
was impaired. Furthermore, a connection with the IFE software was necessary for 
real-time image guidance. Even for small adjustments in needle-guide direction, a 
interaction with the IFE was necessary including manual selection of the correct 
slice direction through the needle guide. Furthermore, some actions were only 
possible from behind the MR-console (e.g. measurement tool); the operator had 
to switch constantly between MR console and IFE monitor during the procedure. 
Altogether this led to an extension of the procedure time. 
Image registration during the biopsy procedure can correct for target 
displacement and may attribute to reduce the biopsy error (25). Nevertheless, 
image registration is often a time consuming process. Furthermore, our results 
suggested that movement of the target was mainly caused by needle insertion. 
Image registration would not correct for prostate motion due to needle insertion. 
Deformation models of the prostate to predict tissue deformation due to needle 
insertion may help to overcome this problem (26). Other alternatives are different 
techniques for needle insertion, such as rotating needles and tapping devices 
(27-30). 
Promising treatment types in the MR-scanner such as focal cryosurgery (31) and 
laser ablation (32) are now under investigation. Major advantages of treatment in 
the MR scanner are the ability of soft tissue imaging and monitoring (for example 
temperature mapping) (33). Robotics will play an important role in the future 
during treatment in the MR since accurate needle placement is required.
In spite of the fact that the results are comparable regarding accuracy and speed, 
the larger biopsy error and the extended technical effort of the robotic technique 
make the manual technique - currently - more suitable to perform MR-guided 
biopsy. Furthermore, this study provided a better insight in displacement of the 
target during in-vivo biopsy procedures. 
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Abstract 
Purpose: To assess the feasibility of automatic needle-guide tracking by using a 
real-time phase-only cross correlation (POCC) algorithm-based sequence for 
transrectal 3T in bore magnetic resonance (MR)-guided prostate biopsies.
Materials and methods: This study was approved by the ethics review board, and 
written informed consent was obtained from all patients. Eleven patients with a 
prostate-specific antigen level of at least 4 ng/mL and at least one transrectal 
ultrasonography-guided biopsy session with negative findings were enrolled. Cancer 
suspicious lesions were identified on 3T multi-parametric MR images. During a 
subsequent MR-guided biopsy, the cancer suspicious lesions were reidentified and 
targeted by using the POCC-based tracking sequence. Besides testing a general 
technical feasibility of the biopsy procedure by using the POCC-based tracking 
sequence, the procedure times were measured, and a pathologic analysis of the 
biopsy cores was performed.
Results: Thirty-eight core samples were obtained from 25 cancer suspicious lesions. 
It was technically feasible to perform the POCC-based biopsies in all cancer 
suspicious lesions in each patient, with adequate biopsy samples obtained with 
each biopsy attempt. The median size of the cancer suspicious lesions was 8 mm 
(range, 4-13 mm). In each cancer suspicious lesion (median number per patient, 
two; range, 1-4), a median of one core sample per lesion was obtained (range, 1-3). 
The median time for guidance per target was 1.5 minutes (range, 0.7-5 minutes). 
Nineteen of 38 core biopsy samples contained cancer. 
Conclusion: This study shows that it is feasible to perform transrectal 3T MR-guided 
biopsies by using a POCC algorithm based real-time tracking sequence.
CHAPTER 8.0  
AuTOMATed ReAL-TIMe 
needLe-guIde TRAcKIng 
FOR FAST 3T MR-guIded 
TRAnSRecTAL PROSTATe 
bIOPSy: A FeASIbILITy STudy
Patrik Zamecnik, Martijn G. Schouten, Axel J. Krafft,  
Florian Maier, Heinz-Peter Schlemmer, Jelle O. Barentsz,  
Michael Bock, Jurgen J. Fütterer
Radiology 2014 Dec;273(3):879-86 8.0 
‹ bAcK TO TAbLe OF cOnTenTS
p 114 p 115MRI-guIded PROSTATe bIOPSy: whIch dIRecTIOn?
Introduction
Currently, a systematic transrectal ultrasonography (TRUS)-guided biopsy 
session with up to 10-12 biopsy cores is the reference standard for prostate cancer 
detection. However, the sensitivity for prostate cancer detection with TRUS is 
poor: In men clinically suspected of having this disease, detection rates of 30%-
40% have been reported (1,2). TRUS-guided prostate biopsies may have false-
negative rates of up to 23% (3). For a second TRUs-guided biopsy, the cancer 
detection rate was only in the range of 10%-17% (4-6). 
Multi-parametric magnetic resonance (MR) imaging is currently the preferred 
imaging modality for the prostate (7). On the basis of these results, MR-
compatible biopsy systems were developed to allow the use of MR imaging to 
guide prostate biopsies. Initial results with MR-guided prostate biopsies were very 
promising, showing high tumor detection rates (up to 59% in patients with repeat 
negative TRUS-guided biopsy findings) and reduced number of biopsy cores per 
patient (8-10). Unfortunately, the mean procedure time for an in-bore MR-guided 
biopsy is substantially longer than that with the TRUS-guided biopsy session 
(range, 39-76 minutes vs 15-20 minutes) (11,12), which considerably limits the 
clinical applicability of the procedure. Long procedure times in the MR imaging 
environment are primarily caused by the time required for manual alignment of 
the imaging planes with the biopsy needle trajectory. 
A fast real-time tracking sequence by using a phase-only cross correlation (POCC) 
algorithm was developed (13,14), which showed promising experimental results 
in animals (15). For this kind of real-time instrument or needle-guide tracking, a 
combination of the POCC algorithm and a common fast imaging sequence (for 
example, fast low-angle shot or balanced steady-state free precession) is used. 
The POCC algorithm-based tracking sequence is able to automatically recognize 
the position of the needle guide and align the imaging plane with the needle axis 
in nearly real time. Thus, imaging is linked to the device, and instrument handling 
becomes very similar to that in a TRUS-guided biopsy. In particular, the time-
consuming procedure steps during guidance (requiring the physician to walk in 
and out of the imaging room to adjust the needle guide during the procedure) 
are eliminated, which may result in a substantial reduction in procedure time. 
The POCC-based tracking sequence was previously evaluated for geometric 
accuracy and operational stability, with a mean target accuracy ± standard 
deviation of 1.5 mm ± 0.9, and it has been used successfully in MR interventions 
in animal experiments (15). 
The purpose of this study was to assess the feasibility of automatic needle-guide 
tracking by using a real-time POCC algorithm-based sequence for transrectal 3T 
in-bore MR-guided prostate biopsies.
Materials and methods
Patients
This study was approved by the ethics review board, and written informed consent 
was obtained from all patients. Eleven men with a prostate specific antigen (PSA) 
level of 4 ng/mL and higher and a history of at least one previous negative TRUS-
guided biopsy finding were enrolled in our study (the patients’ characteristics are 
summarized in Table 1). This study was performed during May and June 2011. All 
patients had cancer suspicious lesions (CSLs) identified in a diagnostic 3T multi-
parametric MR examination that consisted of T2-weighted, diffusion-weighted, 
and dynamic contrast material-enhanced imaging. In a subsequent MR-guided 
biopsy session, the CSLs were reidentified and targeted by using a real-time 
POCC-based automatic tracking sequence. Exclusion criteria for this study were 
general contraindications to MR imaging.
Multi-parametric MR imaging
Diagnostic MR imaging of the prostate was performed with a 3T MR system 
(Skyra; Siemens Healthcare, Erlangen, Germany) and a pelvic phased-array 
coil. Peristalsis was suppressed with an intramuscular administration of 20 
mg butylscopolamine bromide (Buscopan; Boehringer-Ingelheim, Ingelheim, 
Germany) and 1 mg glucagon (Glucagen; Nordisk, Gentofte, Denmark) 
approximately 5 minutes before imaging.
The multi-parametric MR imaging protocol included T2-weighted imaging in 
sagittal, coronal, and axial planes and axial diffusion-weighted imaging (DWI) 
from which maps of the apparent diffusion coefficient (ADC) were calculated 
automatically. By using intravenous administration of contrast agent (0.1 mmol/
kg body weight of gadoterate meglumine [Dotarem] administered with a 3 mL/
sec flow; Guerbet, Paris, France), dynamic contrast-enhanced (DCE) MR imaging 
was performed by using a three dimensional T1-weighted sequence with the 
same section orientation and image center as those with the transverse T2-
weighted sequence. The contrast agent was injected after 9 seconds (ie, after two 
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Table 1: Patient characteristics. PSA = prostate-specific antigen
Parameter Value
Number of patients 11
Median patient age (years) 64 (range: 59-71) 
Median PSA level (ng/mL) 13.9 (range: 5-36.6)
Median no. of negative TRUS-guided biopsy 
procedures per patient
2 (range: 1-4)
Mean prostate volume (mL) 72 (range 49-100) 
Median number of repeated negative TRUS-
guided biopsy sessions
2 (range 1-4)
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repetitions of T1-weighted image acquisitions) after the sequence was started. 
Detailed pulse sequence parameters are provided in Table 2. Before contrast 
agent injection, the same transverse three-dimensional T1-weighted gradient-
echo sequence was used (with the exception of repetition time msec/ echo 
time msec of 800/1.6 and a flip angle of 8°) to obtain proton-density images at 
identical section locations to allow calculation of the relative gadolinium chelate 
concentration curves (16).
Multi-parametric MR image interpretation
Images in all patients were interpreted together by two radiologists with 7 and 5 
years of experience in prostate MR imaging, and the final diagnosis was achieved 
in consensus. The interpretation of diagnostic MR images was performed by 
using the volume transfer constant pharmacokinetic parameter maps calculated 
from DCE MR imaging acquisitions based on the standard two-compartment 
model (17) with corrected curve fit algorithm (16) and DWI and ADC maps. Both 
the pharmacokinetic parameter and the ADC maps were overlaid as colour maps 
on the T2-weighted MR images. The CSLs were defined by using the Prostate 
Imaging Reporting and Data System, or PIRADS, classification, according to 
European Society of Urogenital Radiology prostate MR guidelines in 2012 (18). 
The CSLs were defined as lesions with final PIRADS scores of 4 and 5, where 
clinically significant cancer is likely or highly likely to be present.
MR-guided biopsy procedure
The biopsy was performed by one of the two evaluating radiologists. A manually 
adjustable MR-compatible biopsy instrument holder (DynaTrim; Invivo, Schwerin, 
Germany) was used as described previously to hold the MR compatible biopsy 
device (10,11,19). The holder contains a plastic cylinder (Invivo) filled with contrast 
agent solution (ratio of gadopentetate dimeglumine to water, 1:100), which serves 
as passive endorectal marker and needle guide. The spine and body array coils 
of the MR imaging system (Trio; Siemens Healthcare) were used for MR signal 
reception. After positioning of the patient in prone position, the passive marker 
(needle guide) was inserted into the patient’s rectum. To facilitate the insertion 
of the needle guide and for local anaesthesia, a topical anaesthetic gel was used. 
The needle guide was connected to the instrument holder, and the holder was 
fixed on the MR table. The biopsy MR protocol consisted of a short diagnostic 
part (reidentification of the CSLs) and the biopsy protocols. The diagnostic part 
included axial T2-weighted turbo spin-echo and DWI sequences to assess the 
position of the needle guide and to reidentify the CSLs within the prostate by 
means of comparison with the prior diagnostic multi-parametric MR images. A 
workstation that showed the prior diagnostic MR images was installed next to the 
MR console to facilitate the identification of the CSLs. 
After lesion identification, the needle guide was slowly moved inside the rectum 
and aligned with the CSLs by using the real-time POCC-based tracking sequence, 
providing T2-weighted images (balanced steady-state free precession or true fast 
imaging with steady-state precession sequence; 4.0/1.9; flip angle, 70°; resolution, 
1.2 x 1.2 x 4.0 mm; and temporal resolution, one image acquired per second). 
Then, the performing physician in the MR room reached into the imaging bore 
to manipulate the needle guide orientation. The sequence automatically aligned 
the imaging plane with the symmetry axis of the needle guide (Fig. 1 - page 118). 
The POCC algorithm-based tracking sequence worked as follows: As a start, two 
parallel so-called tracking sections (in our study, T1-weighted fast low-angle shot 
sequence; distance between these sections > 40 mm) are manually positioned 
perpendicular to the needle guide symmetry axis. The needle guide appears on 
these tracking sections as a ringlike structure. By using the POCC algorithm, the 
three dimensional positions of these ringlike structures are calculated (13,15). In 
this manner, the axis of the needle guide is defined, and the targeting image plane 
- which is then finally displayed to the performing physician - is automatically 
aligned with it. For the targeting image, a balanced steady state free precession 
sequence was used to provide contrast enhancement on T2-weighted images. 
The image plane could be changed manually (sagittal, axial, or coronal view) by 
the imaging operator to position the needle guide in three dimensions. For online 
guidance, the real-time images were projected directly into the MR room through 
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Table 2: sequence parameters used for multi-parametric MR imaging and POCC guidance. 
Sequence Repetition 
time/ Echo 
time (msec)
Slice 
thickness 
(mm)
Field of view 
(mm2)
Matrix Additional 
parameters
T2-weighted 
turbo spin 
echo
4010/107 3 180x180 320x320 Flip angle: 
120°
Diffusion 
weighted 
image
2300/61 3 256x256 128x128 b-values: 50, 
500, and 
800 s/mm2
Dynamic 
contract 
enhanced 
(3D- 
gradient 
echo)
32/1.47 3 230x230 128x128 35 measure-
ments within 
180 s
Flip angle: 
10°
Balanced 
steady-
state free 
precession 
(confirma- 
tion scan)
4.4/2.2 3 228x228 256x256 Flip angle: 
70°
Scan 
duration: 9s
Balanced 
steady-
state free 
precession 
(phase-
only cross 
correlation)
4/1.9 4 280x280 256x256 Temporal 
resolution: 
1/s
Flip angle: 
70°
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the MR-room window by using a video projector located outside the MR room 
(Fig. 2). When the calculated needle-guide axis (ie, the planned needle trajectory 
that was overlaid onto the real-time image as a green line) was aligned with the 
CSLs, the instrument holder was fixed, and the POCC sequence was stopped. 
Two additional confirmation acquisitions (in axial and sagittal planes) performed 
by using a standard balanced steady-state free precession sequence (duration, 
9 seconds each; for detailed parameters, see Table 2) were used to control the 
position of the needle guide before executing the biopsy. After the confirmation 
acquisitions, the MR table was moved out of the imager, and a biopsy sample 
was obtained by using an MR-compatible, 18-gauge fully automatic core-needle 
double-shot biopsy gun (Invivo) with a needle length of 175 mm and a tissue core 
sampling length of 17 mm. After the biopsy sample was obtained, the patient 
was placed back into the imager, while the needle was left in situ to verify the 
needle position in the target by using the balanced steady-state free precession 
sequence (the same as done for the confirmation acquisition; see Table 2) in 
two orientations, axial and sagittal. In the case of additional CSLs, the guidance 
process was continued. From small lesions (<7 mm in diameter), more additional 
biopsy samples were obtained to acquire enough biopsy material for pathologic 
evaluation. During the whole biopsy procedure, the patient remained in a prone 
position. The clinical status of the patient was monitored by the performing 
physician while performing the biopsy (in terms of pain or bleeding), as well as 
after the biopsy (in terms of infection). 
Procedure time assessment 
The procedure times were assessed by the retrospective evaluation of the Digital 
Imaging and Communications in Medicine (DICOM) header information of the 
acquired images. The following time parameters were assessed: guidance time 
(time needed for movement of the needle guide until the alignment of its axis 
with the CSLs or between two lesions) and sampling time (time needed for 
performing of the sampling and the confirmation acquisitions). The entire biopsy 
procedure time was defined as a sum of the guidance and sampling times. 
Evaluation of the biopsy targeting accuracy
For each of the CSLs, the geometric distance (d) between the biopsy needle 
axis and corresponding center point of the lesion was calculated to assess the 
targeting accuracy. The center points of the lesions were defined by conducting 
image analysis of the ADC images as the point with the lowest ADC value. Distance 
(d) was defined as the geometric distance between the needle axis and the center 
point of the lesions (Fig. 3). 
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Figure 2: Photographs demonstrate the interaction between the physician performing the 
real-time biopsy (left) and the imaging operator (right). The physician performing the biopsy 
is looking backward to the screen with the real-time images (the monitor is hanging on the 
cabin window) while moving the needle guide with his hand inside of the imager. The operator 
is controlling the POCC sequence, including the change of real-time imaging section orienta-
tion (on demand, for example from axial to sagittal orientation).
Figure 1: Images in a 64-year-old man with 
prostate cancer (Gleason score: 4+4=8) in 
the left anterior apical part of the transition 
zone (delineated with solid line) (A-F). Di-
agnostic axial T2-weighted turbo spin-echo 
image (A). Diagnostic axial ADC map (B). 
Axial (C) and sagittal (D) images used for 
needle guide positioning. The dotted line 
illustrates the axis of the endorectal marker 
(ie, the trajectory of the biopsy needle). 
Needle position confirmation acquisition 
shows the position of the biopsy needle in 
the cancer suspicious lesion (E,F).
Figure 3: Schematic illustrates the calcula-
tion of the distance d for quantification of the 
accuracy of the biopsy by using the POCC 
tracking sequence. x is the center point of a 
cancer suspicious lesion (CSL), defined as the 
lowest ADC value within the lesion.
A
c
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F
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Histopathologic analysis
All biopsy samples were analyzed by means of standard histopathologic 
examination to confirm the presence of prostate cancer or benign findings. 
Therefore, samples were routinely fixed in formalin, embedded in paraffin, and 
stained with hematoxylin-eosin with subsequent evaluation. For every sample 
that was positive for prostate cancer, a Gleason score and tumour volume 
percentage in the sample was determined. 
Results 
POCC guidance, CSLs, and samples
A total of 25 CSLs were identified in 11 patients, and 38 core biopsy samples 
were obtained. The median of the maximum diameter of CSLs on T2-weighted 
images was 8 mm (range, 4-13 mm). All detailed specifications of the CSLs are 
summarized in Table 3. All biopsy samples were obtained with the first attempt 
in each patient, and biopsy samples were obtained from all CSLs. 
In some cases it was uncomfortable for the performing physician to manipulate 
the needle guide, because it was located near the isocenter of the closed-
bore magnet (potentially a long distance from the gantry); however, the 
whole procedure was technically feasible. If the needle guide was manipulated 
during guidance by more than 50° in less than 1 second, the orientation - and, 
consequently, the guidance - was lost. In such cases, a manual restart of the 
sequence was needed, which took about 20-30 seconds. This occurred two times 
during our study, when the marker was rapidly repositioned to the contralateral 
side of the prostate. 
There were no complications during or after the biopsy in terms of severe pain 
(no pain relievers were needed), bleeding, or infection. A median of two CSLs 
(range, 1-4 lesions) per patient were targeted. A median of one core sample per 
lesion was obtained (range, 1-3 samples), and a median of three biopsy samples 
(range, 1-6 samples) per patient was obtained. 
Procedure time and targeting accuracy
The median time needed for the entire biopsy procedure (ie, time needed for 
guidance and biopsy sampling of all CSLs per patient) was 32 minutes (range, 14-
48 minutes). The median time for guidance per target (movement of the needle 
guide between two lesions) was 1.5 minutes (range, 0.7-5 minutes). The mean 
measured displacement from the target center (d) in all lesions was 1.7 mm ± 0.8.
Histopathologic findings
In seven of 11 patients, a diagnosis of prostate cancer was assigned on the basis of 
the biopsy samples obtained (detection rate of 64%). Nineteen of 38 core biopsy 
samples (50%) contained prostate cancer (Gleason scores: 3+3, 3+5, 3+4, and 
4+3). Eleven core biopsy samples contained prostatitis. In eight core samples, 
fibrotic or unspecific changes were found.
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Discussion
In this study, all CSLs could be identified during the targeting process by using 
the POCC approach, and biopsies were performed. While this study was not 
designed to prove the detection rate in patients with clinical suspicion of prostate 
cancer, our detection rate (64%, seven of 11 patients) was consistent and even 
higher than that reported in other studies of MR-guided prostate biopsies (8-11). 
The mean measured distance from the center of the target CSLs was 1.7 mm ± 
Table 3: characteristics of the cancer suspicious lesions (CSLs). PZ = peripheral zone, 
TZ = transition zone
Parameter Value 
Number of CSLs 25
Median maximum diameter of CSLs on T2-
weighted images (mm)
8 (range: 4-13)
Median maximum diameter of CSLs on DWI 
images (mm)
7 (range: 3-11)
number of cSLs localized in the right apex 
 Peripheral zone 3
 Transition zone 1
number of cSLs localized in the right mid prostate 
 Peripheral zone 6
 Transition zone 2
number of cSLs localized in the right basis
 Peripheral zone 1
 Transition zone 1
number of cSLs localized in the left apex
 Peripheral zone 3
 Transition zone 0
number of cSLs localized in the left mid prostate
 Peripheral zone 3
 Transition zone 1
number of cSLs localized in the left basis
 Peripheral zone 4
 Transition zone 0
Median distance of the CSLs from the 
anterior rectum wall (mm)
19 (range: 8-38)
Median distance of the CSLs from the 
midline left (mm)
14 (range: 5-26)
Median distance of the CSLs from the 
midline right (mm)
17 (range: 9-27)
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0.8. This is consistent with the result reported in our prior animal experiment with 
the POCC-based tracking sequence (1.5 mm ± 0.9) (15). Our current results show 
sufficient clinical accuracy comparable to that reported with other MR-guided 
prostate biopsy techniques (8,11,20). 
The automated POCC algorithm - based tracking sequence substantially 
accelerates and shortens the biopsy procedure time, since walking into the 
imaging room repeatedly to adjust the needle guide direction and the manual 
adjustments of the confirmation acquisitions is no longer necessary. In our study, 
however, we performed additional confirmation acquisitions directly before 
biopsy to confirm the orientation of the needle guide in relation to the CSL 
before needle insertion. In our study, there was no patient that needed additional 
readjustment of the needle after the additional confirmation acquisition. 
During our study, safe and precise guidance was demonstrated. The automatic 
section alignment of the POCC algorithm-based tracking sequence facilitated the 
targeting process and made handling very similar to that in ultrasound-guided 
procedures. The temporal resolution of the sequence during tracking of 1 second 
per section was fast enough to target the CSL in nearly real time. Compared 
with the published mean procedure times for MR-guided biopsies (range, 39-
76 minutes) (11,12), a considerable time improvement was achieved in this study. 
The entire biopsy procedure time needed was about 30 minutes (median, 32 
minutes). The median time for guidance per target (ie, movement of the needle 
guide between two CSLs) was only 1.5 minutes. However, these results need to 
be validated in future studies with larger numbers of patients. Even though our 
procedure time is still longer than that for TRUS-guided biopsies, reduction in 
procedure time may be achieved after more training of the personnel. 
One of the major factors hampering the availability of any new MR-based 
diagnostic or therapeutic technique is the need for additional, often specially 
designed and therefore costly MR-compatible hardware. In contrast, our study was 
performed by using standard, commercially available hardware only (instrument 
holder, needle guide, and biopsy needle), without any need for new hardware or 
hardware modifications of the closed-bore MR system. This fact could be very 
important for the potential availability of this technique in the future. Because 
of the versatility of the POCC algorithm-based tracking sequence, it can also 
be used to guide focal therapies (for example, cryoablation or laser-induced 
thermoablation) (21,22). 
First studies were conducted to evaluate the new prostate biopsy technique with 
MR imaging/TRUS fusion. This technique was developed to make the TRUS-
guided biopsies more accurate by using fused MR imaging and real-time TRUS 
images during the biopsy. The first published results are promising in terms of 
tumour detection (23,24), but there are no precise data concerning the procedure 
times. This technique also requires special MR imaging/TRUS-fusion software, 
which has to be evaluated in a larger number of patients. 
During our study, some minor issues arose. It was uncomfortable to reach into 
the magnet and to hold the needle guide by hand when it was located close to 
the isocenter of the magnet. Potentially, some performing physicians might not 
be able to reach the needle guide, particularly when MR systems with standard 
bore length and small bore diameters are used or when the patient’s legs are in 
the way, because of the possibly long distance from the gantry to the isocenter 
of the magnet. Accessibility might be further facilitated in future applications of 
the sequence, as modern MR systems with wider bore openings and shorter bore 
lengths become more available. 
The most important limitation of our study was that the demonstrated applicability 
of the POCC algorithm-based sequence for automatic tracking was limited to 
the transrectal prostate biopsy approach by using a specific commercial needle 
guide system.
In conclusion, it is feasible to use the POCC-based automatic tracking sequence 
to perform 3T MR-guided prostate biopsies. This technique has the potential to 
accelerate MR-guided prostate interventions.
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This thesis describes some aspects of the symbiosis between imaging and 
robotics in magnetic resonance (MR)-guided prostate biopsy. The need for 
MRI targeted biopsy in the detection of prostate cancer was demonstrated in 
chapter 2. We identified differences between MR image-guided and transrectal 
ultrasound (TRUS)-guided biopsy regarding cancer locations and aggressiveness 
in order to get insight in the diagnostic limitations of both techniques (chapters 3 
and 4). In chapter 5 we investigated the differences in apparent diffusion coefficient 
(ADC)-values derived from diffusion weighted imaging (DWI) in patients with 
either prostatitis and prostate cancer. We investigated the feasibility of an MR-
compatible robotic manipulator in a phantom and patients (chapter 6 and 7). In 
addition we addressed the feasibility of an automatic tracking sequence, which has 
the potential to improve the MR-guided biopsy procedure (chapter 8). 
Need for MR-guided biopsy
Chapter 2 reports on the detection rate of prostate cancer found with MR-guided 
prostate biopsy in a large patient population. In total 438 patients with a prostate 
specific antigen (PSA) level >4 ng/mL and at least one previous negative TRUS-
guided biopsy session were included. MR-guided prostate biopsy was performed 
in 265 of these patients. Prostate cancer detection rates were 25% for the entire 
study population (n=438) and 41% for the patients (n=265) who underwent MR-
guided prostate biopsy. Furthermore, predominantly clinical significant tumours 
(87%) were detected with MR-guided biopsy. 
In chapter 3 we identified the location of histopathologically proven prostate cancer 
detected with MR-guided. In this retrospective study 176 out of 872 patients met 
the inclusion criteria (elevated PSA level and at least one negative TRUS-guided 
biopsy session). Prostate cancer was detected in 78% (138/176) of the patients 
and 73% (202/277) of the cancer suspicious lesions seen on multi-parametric MRI. 
The majority of the patients had intermediate or high risk cancer (93%; 128/138). 
Anterior involvement was high (75%; 132/176) and peripheral zone cancers were 
found in 30% (52/176) of the patients. Cancers with a maximum cancer core length 
(MCCL) ≥6 mm were more likely to be located in the anterior part of the prostate 
than were cancers with a core length of less than 6 mm (66% vs 6% respectively). 
The location of significant prostate cancer lesions missed with MR- and TRUS-
guided biopsy in biopsy naïve men at risk is described in chapter 4. All subjects 
underwent multi-parametric MRI and 12-core systematic TRUS-guided biopsy. 
MR-guided biopsy was performed in all patients with a PI-RADS 3 to 5 lesion 
on multi-parametric MRI (n=142). In total 191 lesions were found in 108 patients 
with significant prostate cancer. From these lesions, 74% (141/191) were defined 
as significant prostate cancer on either MR- or TRUS-guided biopsy. MR-guided 
biopsy detected 74% (105/141) of these lesions and this was 61% (86/141) with 
TRUS-guided biopsy, respectively. TRUS-guided biopsy detected significantly 
more lesions compared to MR-guided biopsy (140 vs 109). However, these lesions 
were often low-risk/not significant (39%). 
CHAPTER 9.0  
SuMMARy And 
dIScuSSIOn 
9.0 
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Significant lesions missed with MR-guided had most often involvement of 
dorsolateral (58%) and apical (37%) segments and missed segments with TRUS-
guided biopsy were located anteriorly (79%), anterior mid prostate (50%) and 
anterior apex (23%).
The results from chapter 3 and 4 have clinical implications for both radiologists and 
urologists. For example to optimize biopsy scheme for TRUS-guided biopsy and 
systematic sampling with MRI targeted TRUS-biopsy. 
In chapter 5 we investigated whether it is possible to discriminate between prostatitis 
and prostate cancer based on ADC values using MR-guided biopsy as the standard 
of reference. The ADC values calculated from the diffusion weighted images (DWI) 
acquired during the biopsy procedure were correlated to the histopathology of 
the biopsy core. This was done by projecting bi-planar confirmation scans with the 
needle left in situ on the calculated ADC maps. By using this location, a region of 
interest was drawn manually with the size and extent of the most diffusion-restricted 
region on the ADC map, representing the biopsied cancer suspicious lesion. We 
concluded that DWI is a non invasive technique that demonstrated a significant 
difference in mean ADC of prostatitis (1.08 x 10-3 mm2/s, SD ± 0.18) and prostate 
cancer (0.88 x 10-3 mm2/s, SD ± 0.15). However, its usability in clinical practice is 
limited due to a high degree of overlap.
Robotic assisted MR-guided biopsy 
In chapter 6 the feasibility of an in-house developed pneumatically actuated MR-
compatible robotic manipulator was evaluated in a phantom study. With the robotic 
manipulator the needle guide direction can be controlled outside the magnet room 
under real-time MR image guidance. Consequently the patient does not need to be 
moved in and out of the magnet bore during needle guide manipulation. 
The failure mode and effect analysis (FMEA) and safety measurements of the robotic 
manipulator showed minor items for improvement. The average time needed for 
manipulation to place the needle guide in the desired position was 5 minutes. The 
average total procedure time (including set up) to perform a biopsy was less than 
30 minutes. For needle placement the average in-plane error was 3.0 mm (range 
0-5.6 mm). The manipulator prevented the need of moving the phantom in and 
out of the scanner bore for respectively imaging and manipulation of the needle 
guide. The results demonstrated great potential to improve the transrectal prostate 
biopsy procedure. The next step therefore was to establish the clinical feasibility of 
the system.
Chapter 7 evaluated the accuracy and speed of the novel robotic technique 
compared to the manual method in patients. The robotic and manual techniques 
demonstrated comparable results regarding mean targeting error (5.7 vs 5.8 mm, 
respectively) and mean target displacement (6.6 vs 6.0 mm, respectively). The mean 
biopsy error was larger (6.5 vs 4.4 mm) when using the robotic technique, although 
not significant. Mean procedure and manipulation times were 76 minutes and 6 
minutes, respectively using the robotic technique and 61 minutes and 8 minutes 
with the manual technique. Furthermore, it was observed that most of the target 
displacement was in the direction of the needle trajectory suggesting that most of 
the target displacement was caused by needle insertion. 
The robotic technique prevented the need of moving the patient in and out of the 
scanner bore for imaging and manipulation of the needle-guide. In spite of the 
fact that the results are comparable regarding accuracy and speed, the extended 
technical effort of the robotic technique makes the manual technique – currently – 
more suitable to perform MR-guided biopsy. 
The total procedure time with the robotic technique was longer compared to the 
results found in a phantom (chapter 6) and with the manual technique. Problems 
regarding patient positioning, limited range of motion and geometric constraints of 
the robotic technique have contributed to the limited gain in patients. Furthermore, 
the interaction with the real-time imaging software, robot controller and MR-console 
led to an extension of the procedure time. A real-time imaging sequence which has 
the potential to simplify these interactions was evaluated in the next chapter.
In chapter 8 the feasibility of a fast real-time tracking sequence was demonstrated in 
patients. The tracking sequence can determine the 3D-position of the passive needle 
guide during MR image acquisition and show the imaging plane corresponding to the 
axis of the needle guide in nearly real-time. The patient remains inside the scanner 
bore during needle guide positioning and imaging. The median time needed for the 
entire biopsy procedure was 32 minutes (range 14-48 minutes). The median time 
for guidance per target (movement of the endorectal marker between two cancer 
suspicious lesions) was 1.5 minutes (range 0.7-5 minutes). From this study we can 
conclude that it is feasible to use the automatic tracking sequence to perform MR-
guided prostate biopsies. This technique has the potential to accelerate MR-guided 
prostate interventions.
Suggestions for future research: which direction?
The ability of multi-parametric MRI to identify significant prostate cancer has made 
it possible to obtain targeted samples from lesions rather than systematically 
sampling the whole prostate with TRUS-guided biopsy (27). The introduction of 
the Prostate Imaging Reporting and Data System (PI-RADS) in 2012 was the first 
step in standardized and objective interpretation of multi-parametric MRI which is 
crucial to diminish the inter-observer variability in image interpretation (19). This 
system appears to have a good diagnostic accuracy in cancer detection, but no 
recommendation regarding the best threshold for biopsy can be provided (28). A 
newer version of the PI-RADS (version 2.0) classification was recently published 
and must be evaluated (29). Forthcoming from the results in chapter 4 it might be 
interesting to investigate a region dependent threshold for biopsy. This may improve 
cancer detection with multi-parametric MRI. For example, a threshold of PI-RADS 3 
for lesions in the apical and dorsolateral regions and a threshold of PI-RADS 4,5 for 
lesions elsewhere in the prostate. Another approach which should be investigated in 
future research is computer aided diagnosis where quantitative image parameters 
are used to determine the likelihood of malignancy for cancer suspicious lesions (30).
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In chapter 2 we found evidence that MR-guided biopsy has a high detection rate 
in patients with an elevated PSA and repeated negative TRUS-guided biopsy 
sessions. Later, it was found that also in biopsy naive men with elevated PSA, multi-
parametric MRI followed by MR-guided-biopsy reduces the detection of low-risk 
cancer compared with TRUS-guided biopsy, while improving the overall detection 
of intermediate/high-risk cancer (31, 32). These results are in concordance with a 
recently published systematic review which concluded that multi-parametric MRI 
is able to detect significant prostate cancer in biopsy-naïve males and men with 
prior negative biopsies (18). Moreover, multi-parametric MRI of the prostate is 
an excellent technology for diagnosis, patient selection, treatment planning and 
follow-up (24). However, it has to be kept in mind that significant tumours can still 
be missed. Insight into the diagnostic limitations of both modalities (chapters 3 
and 4) has clinical implications for both radiologists and urologists. For example to 
optimize biopsy sites for TRUS-guided biopsy and systematic sampling with MRI 
targeted TRUS-biopsy (33). 
MRI targeted TRUS-biopsy is a technique which combines previously obtained 
multi-parametric MR images and real-time TRUS images to direct the biopsy needle 
to a cancer suspicious lesion. Currently, multiple devices are available which can 
broadly be classified by the fusion process as either rigid or non-rigid (34). Rigid 
fusion does not correct for changes in shape and position of the prostate at the time 
of biopsy. Non-rigid fusion aims to compensate for prostate deformation at the time 
of biopsy which can be achieved with elastic registration or by statistical motion 
modelling. Reported target registration errors of 5.1 (rigid) and 2.4 mm (non-rigid) 
in the mid plane of the prostate are reported, which increase at the apex and base 
(35). Even though the fusion algorithm of MRI and TRUS images is an important 
limitation (36), the overall detection rate of MRI targeted TRUS biopsy was higher 
compared to standard TRUS-guided biopsy (51% vs 43%) (34). Furthermore, MRI 
targeted TRUS biopsy detects more clinically significant cancers (33% vs 24%) (34). 
However, some clinically significant cancers may be missed using this approach, 
and the necessity of obtaining systematic biopsies in addition should be taken in 
consideration (33, 37).
Initial research in the field of MRI targeted biopsy has been performed in patients 
with clinical suspicion for prostate cancer with repeated negative TRUS-guided 
biopsy sessions. Currently, considerable research has been performed in biopsy 
naïve patients which found evidence that multi-parametric MRI is capable to mainly 
detect significant prostate cancer with a high negative predictive value in these 
patients (38). These results are promising in the field of prostate cancer screening 
and may contribute to a paradigm shift (39). However, it should be kept in mind 
that the current research is limited by the lack of a reliable and reasonable gold 
standard to compare with. Whole mount prostatectomy would be the most reliable 
tool for histopathologic evaluation but is ethically impossible in patients with no 
proven cancer on biopsy. An alternative approach is to use 5 mm transperineal 
template prostate mapping (40). The need for general anaesthesia and increased 
complication rate makes this a highly invasive technique and presents challenges 
in recruiting patients for clinical trials when less invasive alternatives are available 
(40, 41). Furthermore, a universally accepted definition for significant cancer 
should be introduced and validated since the variability in definitions in the current 
research makes it difficult to compare and combine results for generalization to 
clinical practice. 
The next step is to investigate which MRI targeted biopsy technique is the most 
suitable option for each specific patient. Variables such as number of previous 
negative TRUS-guided biopsy sessions, costs, lesions size and location on multi-
parametric MRI may help to select patients and should be investigated in future 
research. 
Besides tailored patient selection it is important to further evolve MRI targeted 
biopsy techniques. Most important limitation of the current MR-guided biopsy 
method is the procedure time on MRI which makes this technique not readily 
available in routine clinical practice yet. The robotic manipulator described in this 
thesis has the potential to shorten procedure time (chapter 6). However, due to 
the limited research performed in patients with the robotic manipulator (chapter 
7), the current clinical value of this technique is unclear. Therefore, more clinical 
research needs to be done to investigate whether the implementation of robotics 
will improve MR-guided biopsy. Before further research is done in patients, some 
important aspects to improve the robotic manipulator are required. Most essential 
are size reduction, broader range of motion and integration of imaging, intervention 
planning and robotic manipulation within one user interface. A novel robotic 
manipulator, which incorporated these suggestions for improvement, is now being 
tested in our clinical practice. 
The automatic needle guide tracking sequence described in chapter 8 integrates 
imaging and intervention planning. This sequence has the potential to further 
incorporate imaging and robotic targeting. The next step is therefore to apply this 
tracking sequence during the robotic intervention. 
Another interesting aspect, that needs further investigation to improve MR-guided 
biopsy accuracy, came forth of the results presented in chapter 7. It was found 
that movement of the target was mainly caused by needle insertion. Special 
techniques for needle insertion, such as rotating needles and tapping devices have 
been investigated to minimize target displacement (42-44). When these insertion 
techniques can be performed inside the scanner bore under real-time imaging, 
needle insertion will no longer be a blind process, as it is at the moment, and biopsy 
accuracy may be improved. Alternatively, deformation models of the prostate 
to predict tissue deformation due to needle insertion may help to overcome this 
problem (45).
The combination of tumour identification with imaging and accurate needle 
placement has not only changed the diagnostic process but also the concept of 
prostate cancer treatment. Minimally invasive therapies are increasingly applied for 
treatment of localized prostate cancer (14, 15). Major advantages of treatment in 
the MR scanner are the ability of soft tissue imaging for treatment guidance and 
monitoring (for example temperature mapping) (24). Likewise biopsy, accurate 
needle placement is required during treatment. 
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Conclusions
The following overall conclusions can be drawn:
1. MR-guided biopsy of 3T multi-parametric MRI detected 
cancer suspicious lesions has a high detection rate of 41% for 
predominantly clinically significant prostate cancer (87%) in 
patients with an elevated PSA and at least one previous negative 
TRUS-guided prostate biopsy session (chapter 2).
2. Most cancers (75%) detected with MR-guided biopsy in patients 
with an elevated PSA and at least one negative TRUS-guided 
biopsy session, are located in the anterior part of the prostate 
(chapter 3). 
3. MR- and TRUS-guided biopsy both have difficulties in detecting 
apical lesions in biopsy naive men at risk (chapter 4).
4. In biopsy naive patients at risk MR-guided biopsy most often 
missed cancer with involvement of the dorsolateral part (58%) 
and TRUS-guided biopsy with involvement of the anterior part 
(79%) (chapter 4).
5. Diffusion weighted imaging is a non invasive technique that 
demonstrated a significant difference in mean ADC values 
between prostatitis (1.08 x 10-3 mm2/s) and prostate cancer 
(0.88 x 10-3 mm2/s). However, its usability in clinical practice is 
limited due to a high degree of overlap (chapter 5). 
6. The MR compatible robotic manipulator allows a high accuracy 
and short total procedure time in a phantom (chapter 6).
7. It is feasible to perform transrectal prostate biopsy with real-time 
3T MR imaging guidance with the aid of a remote-controlled, 
pneumatically actuated MR-compatible robotic manipulator in 
patients (chapter 7).
8. Although comparable results regarding accuracy and speed 
were found, the extended technical effort of the robotic 
manipulator makes the manual technique – currently – more 
suitable to perform MR-guided biopsies (chapter 7). 
9. During MR-guided biopsy most target displacement is in the 
direction of the needle trajectory suggesting that most of the 
target displacement is caused by needle insertion (chapter 7). 
10. It is feasible to use an automatic needle guide tracking sequence 
to perform 3T MR-guided prostate biopsies (chapter 8).
With multi-parametric MR imaging it has become possible to identify significant 
prostate cancer suspicious lesions with reduced detection of insignificant 
disease. Successively, MR-guided biopsy is a suitable technique for prostate 
cancer diagnosis. Robotic assisted MR-guided biopsy has the potential to 
reduce procedure time and increase accuracy, which currently limits the clinical 
availability. Furthermore, minimally invasive therapies are increasingly applied for 
treatment of localized prostate cancer. Consequently, the symbiosis of robotics 
and multi-parametric MRI will play an important role in the future during diagnosis 
and focal treatment of prostate cancer.
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Dit proefschrift beschrijft enkele aspecten van de symbiose tussen beeldvorming 
en robotica bij magnetische resonantie (MR)-geleide prostaatbiopsie. De noodzaak 
van MR-geleide biopsie wordt aangetoond in hoofdstuk 2. Verschillen in locatie en 
agressiviteit tussen MR-geleide biopsie en transrectale echografie (TRUS)-geleide 
biopsie worden in hoofdstukken 3 en 4 beschreven teneinde inzicht te krijgen in de 
tekortkomingen van beide technieken. In hoofdstuk 5 beschrijven we de verschillen in 
‘apparent diffusion coeffcient’ (ADC)-waarden verkregen tijdens ‘diffusion weighted 
imaging’ (DWI) teneinde onderscheid te kunnen maken tussen prostatitis en prostaat 
kanker. De toepasbaarheid van een MR-compatibele robot wordt aangetoond in een 
fantoom- en patiëntenstudie (hoofdstuk 6 en 7). Daarnaast is de bruikbaarheid van een 
automatische ‘tracking’ sequentie aangetoond, die de MR-geleide biopsieprocedure 
mogelijk kan verbeteren (hoofdstuk 8).
Noodzaak van MR-geleide biopsie
Hoofdstuk 2 rapporteert over de detectieratio van prostaatkanker, gevonden met 
MR-geleide prostaatbiopsie, in een grote patiëntenpopulatie. In totaal werden 438 
patiënten geïncludeerd, die zowel een prostaatspecifiek antigeen (PSA) > 4 ng/mL 
hadden, als tenminste 1 eerdere negatieve transrectale ultrageluid (TRUS)-geleide 
biopsiesessie hadden ondergaan. MR-geleide prostaatbiopsie werd uitgevoerd 
bij 265 van deze patiënten. De detectieratio van prostaatkanker voor de gehele 
onderzoekspopulatie (n=438) was 25% en respectievelijk 41% voor de patiënten 
(n=265) die de MR-geleide prostaatbiopsie ondergingen. Bovendien zijn de tumoren, 
die met MR-geleide biopsie werden gediagnosticeerd, hoofdzakelijk klinisch significant 
(87%). De resultaten van deze studie tonen aan dat, bij patiënten met een verhoogd 
PSA en 1 of meer negatieve TRUS-geleide biopsiesessies, MR-geleide biopsie een 
hogere prostaatkanker detectieratio heeft dan herhaalde TRUS-geleide biopsie. 
Tevens detecteert MR-geleide biopsie meer klinisch significante prostaattumoren.
Hoofdstuk 3 beschrijft de locatie van prostaatkanker, gediagnosticeerd met 3 tesla 
(3T) MR-geleide biopsie in patiënten met een verhoogd PSA en tenminste 1 negatieve 
TRUS-geleide biopsiesessie. Retrospectief werden 176 patiënten geïncludeerd. 
Prostaatkanker is vastgesteld bij 78% (138/176) van de patiënten en bij 73% (202/277) 
van de laesies gezien op de multi-parametrische MRI. Bij het grootste deel van de 
patiënten is een klinisch significante tumor (93%; 128/138) gediagnosticeerd. In 75% 
(132/176) van de patiënten is kanker gevonden in het ventrale deel van de prostaat 
en in 30% (52/176) van de patiënten zijn periferezone tumoren gevonden. Tumoren 
met een maximale kanker core lengte (MCCL) ≥6 mm zijn voornamelijk (66%) in het 
ventrale deel van de prostaat gevonden. 
In hoofdstuk 4 zijn de locaties van significante prostaatkankerlaesies, die worden 
gemist met MR- of TRUS-geleide biopsie, onderzocht. Bij alle (n=223) mannen, met 
een klinische verdenking op prostaatkanker die niet eerder een prostaatbiopsie 
hadden ondergaan, werd een multi-parametrische MRI gemaakt en een 12-core 
systematische prostaat biopsie verricht. Bij alle patiënten met een PI-RADS 3 - 5 
laesie op de multi-parametrische MRI (n=142) werd een MR-geleide biopsie verricht. 
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Bij 108 van de 142 patiënten werd de diagnose significante prostaatkanker gesteld. 
In deze patiëntengroep zijn 191 verschillende tumoren gevonden. Van deze tumoren 
is 74% (141/191) gedefinieerd als significante prostaatkanker. Bij MR-geleide biopsie 
is 74% (105/141) van deze tumoren significant en bij TRUS-geleide biopsie is dit 61% 
(86/141). TRUS-geleide biopsie detecteerde weliswaar meer tumoren dan MR-geleide 
biopsie (140 vs 109) maar een groot deel van deze tumoren zijn niet significant 
(39%). Significante tumoren, gemist met MR-geleide biopsie, zijn vaak gelegen in 
de dorsolaterale en apicale segmenten van de prostaat. Met TRUS-geleide biopsie 
werden vooral significante tumoren gemist in het ventrale (79%) deel van de prostaat. 
Met name in de ventrale mid prostaat (50%) en het ventrale deel van de apex (23%). 
De resultaten van de hoofdstukken 3 en 4 hebben klinische implicaties voor zowel 
de uroloog als de radioloog. Bijvoorbeeld voor het optimaliseren van het biopsie 
schema, gebruikt bij TRUS-geleide biopsie en MRI-gerichte TRUS-biopsie.
In hoofdstuk 5 is onderzocht of het mogelijk is om onderscheid te maken tussen 
prostatitis en prostaatkanker op basis van ADC-waarden, verkregen tijdens MR-
geleide biopsie. De ADC-waarden, berekend uit de diffusie gewogen beelden 
(DWI) van de MR-geleide biopsie, werden gecorreleerd aan de histopathologie 
van het biopsiemonster. Dit werd gedaan door de controle MRI-scan (in twee 
richtingen), met de naald in situ, op de berekende ADC-afbeelding te projecteren. 
De biopsielocatie werd gebruikt om handmatig een regio met grootte en omvang 
van de diffusierestrictie in te tekenen op de ADC-afbeelding die de kankerverdachte 
laesie weergeeft. DWI is een niet-invasieve techniek, die een significant verschil laat 
zien tussen gemiddelde ADC-waarden van prostatitis (1,08 x 10-3 mm2/s, SD ± 0,18) en 
prostaatkanker (0,88 x 10-3 mm2/s, SD ± 0,15). Echter, de bruikbaarheid in de klinische 
praktijk wordt beperkt door een hoge mate van overlap van de ADC-waarden. 
Robot geassisteerde MR-geleide biopsie
In hoofdstuk 6 is de toepasbaarheid van een pneumatisch aangedreven MR-
compatibele robot bepaald in een fantoom. Vanuit de controlekamer kan met de 
robot de richting van een naaldgeleider onder real-time MRI worden aangepast. 
Het is daarbij niet meer nodig om het fantoom uit de MR-tunnel te schuiven om de 
naaldgeleider te verplaatsten. 
Uit de analyse naar potentiële gevaren (FMEA) en de veiligheidsmetingen van de 
robot kwamen enkele verbeter punten naar voren. Uit de proef in het fantoom blijkt 
dat de gemiddelde tijd die nodig was om de naaldgeleider in de gewenste positie 
te brengen 5 minuten is; De gemiddelde totale proceduretijd (inclusief opbouwen) 
om een biopsie uit te voeren was minder dan 30 minuten; De nauwkeurigheid (in-
plane error) voor het plaatsen van de naald was gemiddeld 3,0 mm (range 0-5,6 
mm). De robot voorkomt de noodzaak om een patiënt in en uit de scanner te 
schuiven voor respectievelijk beeldvorming en manipulatie van de naaldgeleider. 
Deze resultaten bewezen de potentie om de transrectale prostaatbiopsieprocedure 
te verbeteren. De volgende stap is derhalve de klinische toepasbaarheid van dit 
systeem te onderzoeken. 
Hoofdstuk 7 vergelijkt de nauwkeurigheid en snelheid van de nieuwe robottechniek 
met de handmatige methode in patiënten. De robotmethode en de handmatige 
methode toonden vergelijkbare resultaten met betrekking tot de gemiddelde 
fout (respectievelijk 5,7 vs 5,8 mm) voor de positionering van de naaldgeleider en 
gemiddelde doelwit verplaatsing (respectievelijk 6,6 vs 6,0 mm). De gemiddelde 
biopsiefout was groter (6,5 vs 4,4 mm) bij gebruik van de robot, echter niet 
significant. De mediaan van de proceduretijd en manipulatietijd waren respectievelijk 
76 minuten en 6 minuten met behulp van de robot en 61 minuten en 8 minuten met de 
manuele methode. Verder werd waargenomen dat de meeste doelwit verplaatsing in 
de richting van het naaldtraject was. Dit suggereert dat de meeste verplaatsing werd 
veroorzaakt door het inbrengen van de naald.
De robot voorkomt de noodzaak om de patiënt in en uit de scanner te schuiven 
voor respectievelijk beeldvorming en manipulatie van de naaldgeleider. Ondanks 
vergelijkbare resultaten met betrekking tot de nauwkeurigheid en snelheid prefereert 
op dit moment de manuele techniek voor MR-geleide biopsieën. De extra technische 
handelingen maken het gebruik van de robotminder geschikt. 
De totale proceduretijd met de robot bij patiënten is langer dan bij de fantoomstudie 
(hoofdstuk 6). Problemen met betrekking tot positionering van de patiënt, beperkte 
bewegingsmogelijkheid en ruimtelijke beperkingen van de robot zijn hieraan debet. 
De interactie tussen de real-time imaging software, de robotcontroller en de MR-
console veroorzaakt een verlenging van de proceduretijd. Een real-time imaging 
sequentie, die deze interacties vereenvoudigt wordt geëvalueerd in het volgende 
hoofdstuk.
Hoofdstuk 8 toont de toepasbaarheid van een snelle real-time ‘tracking’ sequentie 
aan in een patiëntenonderzoek. De ‘tracking’-sequentie berekent tijdens de MR-
beeldacquisitie de 3D-positie van de passieve naaldgeleider en geeft bijna real-
time het beeldvlak weer dat overeenkomt met de richting van de naaldgeleider. 
De patiënt blijft in de MR-tunnel tijdens het positioneren van de naaldgeleider en 
de beeldvorming. De mediane tijd, die nodig is voor de gehele biopsieprocedure 
was 32 minuten (range 14-48 minuten). De mediane tijd voor manipulatie per laesie 
(manipulatie van de endorectale marker tussen twee kankerverdachte laesies) 
was 1,5 minuten (range 0,7-5 minuten). Uit deze studie kunnen we concluderen 
dat het mogelijk is om met de automatisch ‘tracking’ sequentie MR-geleide 
prostaatbiopsieën uit te voeren. Deze techniek heeft potentie om MR-geleide 
prostaatinterventies te verbeteren. 
9.0 
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Met multi-parametrische MRI is het mogelijk om kankerverdachte laesies te 
identificeren. MR-geleide biopsie is een geschikte techniek om deze verdachte 
gebieden te biopteren. De klinische beschikbaarheid van MR-geleide biopsie 
is momenteel beperkt vanwege de lange proceduretijd en nauwkeurigheid. 
Robotgeassisteerde MR-geleide biopsie is mogelijk en heeft de potentie deze 
beperkingen te verbeteren. Daarnaast worden minimaalinvasieve therapieën steeds 
meer toegepast in de behandeling van prostaatkanker. Derhalve zal de symbiose 
van robotica en multi-parametrische MRI in de toekomst mogelijk een belangrijke rol 
spelen bij zowel de diagnose als de focale behandeling van prostaat kanker. 
9.0 
Conclusies
De volgende algemene conclusies kunnen worden getrokken:
1. MR-geleide biopsie van 3T multi-parametrische MRI-gedetecteerde 
kankerverdachte laesies heeft een detectieratio van 41% voor 
overwegend klinisch significante prostaatkanker (87%) bij patiënten 
met een verhoogd PSA en ten minste 1 eerdere negatieve TRUS-
geleide prostaatbiopsiesessie (hoofdstuk 2).
2. De meeste prostaatkankers (75%) gedetecteerd met MR-geleide 
biopsie bij patiënten met een verhoogd PSA en ten minste 1 negatieve 
TRUS-geleide biopsiesessie, bevinden zich in het ventrale deel van 
de prostaat (hoofdstuk 3).
3. Zowel MR- als TRUS-geleide biopsie missen apicale tumoren in 
patiënten met een klinische verdenking op prostaat kanker, die nog 
niet eerder een prostaat biopsie hebben ondergaan (hoofdstuk 4).
4. In patiënten die niet eerder een prostaatbiopsie hebben ondergaan 
worden met MR-geleide biopsie vooral tumoren gemist die in het 
dorsolaterale deel van de prostaat (58%) zijn gelegen. Met TRUS-
geleide biopsie zijn de gemiste tumoren vooral gelegen in het 
ventrale deel van de prostaat (79%) (hoofdstuk 4).
5. Diffusiegewogen beeldvorming is een niet-invasieve techniek, die een 
significant verschil in gemiddelde ADC-waarden tussen prostatitis 
(1,08 x 10-3 mm2/s) en prostaatkanker (0,88 x 10-3 mm2/s) laat zien. 
Echter, de bruikbaarheid in de klinische praktijk wordt beperkt door 
een hoge mate van overlap in ADC-waarden (hoofdstuk 5).
6. De MR-compatibele robot zorgt voor een hoge nauwkeurigheid en 
korte totale proceduretijd in een fantoom (hoofdstuk 6).
7. Het is mogelijk om transrectale prostaatbiopsie met real-time 3T 
MR-beeldvorming uit te voeren in patiënten met behulp van een 
op afstand bedienbare, pneumatisch aangedreven MR-compatible 
robot (hoofdstuk 7). 
8. Hoewel vergelijkbare resultaten met betrekking tot de 
nauwkeurigheid en snelheid werden gevonden, maken de extra 
technische handelingen voor het gebruik van de robot de manuele 
techniek op dit moment meer geschikt voor MR-geleide biopsieën 
(hoofdstuk 7).
9. Tijdens MR-geleide biopsie werd de meeste verplaatsing van de 
laesie in de richting van het naaldtraject gevonden, wat suggereert 
dat de meeste verplaatsing wordt veroorzaakt door het inbrengen 
van de naald (hoofdstuk 7).
10. Het is mogelijk om met een automatische ‘tracking’ sequentie 3T 
MR-geleide prostaatbiopsieën uit te voeren (hoofdstuk 8). 
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